netFormulary
 Report : A-Z of formulary items 21/09/2018 15:39:53
[Back]
 
Section Name Details
07.04.02 Desmopressin Noqdirna®

*Oral lyophilisates: 25microgram, 50 microgram


*Only to be used in line with NICE guidance (NG 171, NG 97)

15.02 Levobupivacaine with Fentanyl 

unlicensedunlicensed Infusion bag: Levobupivacaine 0.1% with fentanyl 2 micrograms, 500 mL CD

05.03.01 Abacavir Ziagen®

Tablets: 300mg
Oral solution: 20mg/ml

05.03.01 Abacavir and Lamivudine Kivexa®

Tablets: 600mg/300mg

05.03.01 Abacavir,Lamivudine and Zidovudine Trizivir®

Tablets: 150/300/300mg

10.01.03 Abatacept 

IV infusion: 250 mg
Injection (pre-filled syringe): 125 mg (for rheumatoid arthritis only)

Note: 4th line with MTX on failure after 6 months of 3rd line

02.09 Abciximab  Vial: 10mg/5ml
08.03.04.02 Abiraterone 

Tablets: 250mg

08.01.05 Abraxane® Paclitaxel

Powder for suspension for infusion: 5mg - restricted for use within its current license for metastatic breast cancer patients who cannot tolerate standard taxanes.

04.10.01 Acamprosate  Tablets: 333mg
06.01.02.03 Acarbose  Tablets: 50mg*
*For existing patients only, no new patients. Unless for reactive hypoglycaemia on advice of specialist
11.06 Acetazolamide 

Tablets: 250 mg
MR Capsules: 250 mg

11.06 Acetazolamide 

Injection: 500 mg vial

12.01.01 Acetic Acid (glacial) (1st line for mild otitis externa) Earcalm ®

Ear spray: 2%

11.08.01 Acetylcysteine  

Eye drops: acetylcysteine 5%, hypromellose 0.35% (Ilube®)
unlicensed unlicensed Eye drops (preservative-free): 5%,

23.01 Acetylcysteine  

Injection: 2 g/10 mL ampoules


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

05.03.02.01 Aciclovir  Tablets: 200mg, 400mg, 800mg
Dispersible tablets: 200mg, 400mg, 800mg
Oral suspension (sugar-free available): 200mg/5ml, 400mg/5ml
05.03.02.01 Aciclovir  Injection (for IV infusion): 250mg, 500mg
11.03.03 Aciclovir 

Eye ointment: 3%

03.01.02 Aclidinium Eklira Genuair®

Eklira Genuair® breath actuated DPI: 375mcg/puff (equivalent to 322mcg aclidinium)

 

This is one of the Sunderland COPD guideline preferred options for LAMA.

03.01.04 Aclidinium and formoterol inhaler Duaklir Genuair ®

Duaklir Genuair® breath actuated DPI: 340/12mcg/puff

01.05.03 Adalimumab 
10.01.03 Adalimumab Humira®

Pre-filled syringe or pen: 40 mg
Injection (vial): 40 mg/0.8 mL

Note: Subcutaneous first choice with MTX

02.03.02 Adenosine  Vials: 6mg/2ml
02.07.03 Adrenaline / Epinephrine  Ampoules: 1mg/1ml (1 in 1,000), 1mg/10ml (1 in 10,000)
Pre-filled syringe: 1mg/10ml (1 in 10,000)
03.04.03 Adrenaline / epinephrine EpiPen® & Jext®

Auto-injector: 150 micrograms, 300 micrograms

Use either Jext® or Epipen® but do not interchange

03.04.03 Adrenaline / epinephrine Emerade®

Autoinjector: 500 micrograms (Emerade®)

03.04.03 Adrenaline / epinephrine 1 in 1,000  Injection: 500 micrograms/0.5ml, 1mg/1ml
22 Adult resuscitation trolley drug list 

RedAdrenaline 1 mg/1 mL (1:1000) ampoules 
RedAdrenaline 1 mg/10 mL (1:10,000) prefilled syringe
RedAmiodarone 300 mg/10 mL prefilled syringe
RedAtropine 3 mg/10 mL prefilled syringe 
RedCalcium chloride 1000 mg/10 mL (10%) prefilled syringe
RedNaloxone 400 micrograms/1 mL ampoules
RedSodium bicarbonate 8.4%, 200 mL 
RedSodium chloride 0.9% flush, 10 mL prefilled syringe 
RedSodium chloride 0.9% solution, 1000 mL


*These medications are red in the context of the adult resuscitation trolley. Please see other chapters for formulary status when used for other indications

12.03.05 Aequasyal 

By initiation of head and neck specialist only (2nd or 3rd line for patients undergoing radiotherapy)

08.01.05 Afatinib 

Film coated tablets: 20mg, 30mg, 40mg, 50mg

08.01.05 Aflibercept Zaltrap®

Vials: 100mg/4ml, 40mg/1ml

11.08.02 Aflibercept 

Intravitreal injection: 4 mg/ 0.1mL (dose 2mg/0.05ml)

04.03.04 Agomelatine  Tablets: 25mg
- NETAG approved for the treatment of depression only following an adequate trial of at least three alternative antidepressant drugs at maximally tolerated doses (as described by NICE and as stated in the BNF). Prescribing and monitoring should be initiated by specialist mental health physicians. After a minimum of 12 weeks, prescribing may be transferred to primary care.
23.01 Alcohol (ethanol) 

Injection: 2 mL ampoules


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

08.02.03 Alemtuzumab 

Concentrate for IV infusion: 30mg in 1ml
- for use in lymphocytic leukaemia & prevention of graft vs. host disease on bone marrow transplant patients
-approved for use in high-risk kidney and pancreas transplantation


Concentrate for IV infusion 12mg in 1.2ml
-approved as an option for treating adults with active relapsing– remitting multiple sclerosis in line with NICE (subject to NHS ENGLAND funding)


 

06.06.02 Alendronic Acid  Tablets: 10mg, 70mg
06.06.02 Alendronic Acid Binosto

Effervescent tablets: 70mg

09.06.04 Alfacalcidol 

Capsules: 0.25 micrograms, 0.5 micrograms, 1 microgram
Oral drops (sugar-free): 2 micrograms/1 mL
Injection: 1 microgram/0.5 mL, 2 micrograms/1 mL

04.07.02 Alfentanil 

Injection: 500 micrograms/1 mL, 5 mg/1 mL

Specialist initiation only - consult pain team or palliative care before use.

15.01.04.03 Alfentanil 

Injection (amps): 1 mg/2 mL, 5 mg /1 mL

07.04.01 Alfuzosin Hydrochloride 

M/R tablets: 10mg

03.04.01 Alimemazine  Tablets*: 10mg
Syrup*: 7.5mg/5ml, 30mg/5ml
*Hospital use only as pre-medication in paediatric patients
02.12 Alirocumab Praluent®

Solution for injection (pre-filled pen): 75mg/ml, 150mg/ml

To be used in line with NICE TA393
N.B. Supply currently only available via secondary care. No prescribing in primary care.

02.05.05.03 Aliskiren  Tablets: 150mg, 300mg
10.01.04 Allopurinol  Tablets: 100 mg, 300 mg
10.01.04 Allopurinol 

Tablets: 100mg, 300mg

12.01.03 Almond Oil 

Ear drops

06.01.02.03 Alogliptin 

Tablets: 6.25mg, 12.5mg, 25mg

09.06.05 Alpha Tocopheryl Acetate 

Suspension:  500 mg/5 mL
Capsules: 200units (for use in children with cystic fibrosis)

09.06.05 Alpha Tocopheryl Acetate 

unlicensed unlicensed Injection: 100mg/2ml 

07.04.05 Alprostadil 

Dual chamber injections: 10microgram, 20 microgram
Injections: 10microgram, 20 microgram, 40microgram (Caverject®)
Starter pack and dual chamber injections: 10microgram, 20micrograms, 40microgram (Viridal Duo®)
Cream: 3mg/g (Vitaros®)

02.10.02 Alteplase  Vials: 10mg, 20mg, 50mg
04.09.01 Amantadine  Capsules: 100mg
Syrup: 50mg/5ml
05.01.04 Amikacin 

Injection: 100mg/2ml, 500mg/2ml

02.02.03 Amiloride Hydrochloride  Tablets: 5mg
Liquid: 5mg/5ml
03.01.03 Aminophylline Phyllocontin®

SR tablets: 225mg

Prescribe by brand name.

03.01.03 Aminophylline IV  Injection: 250mg/10ml
02.03.02 Amiodarone  Tablets: 100mg, 200mg
02.03.02 Amiodarone  Infusion: 150mg/3ml
04.02.01 Amisulpride  Tablets: 50mg, 200mg
Oral solution: 100mg/1ml
04.03.01 Amitriptyline  Tablets: 10 mg, 25 mg, 50 mg
Sugar-free oral solution: 25 mg/5 mL
04.07.03 Amitriptyline   Tablets: 10 mg, 25 mg, 50 mg
Oral solution: 25 mg/5 mL, 50 mg/5 mL
04.07.04.02 Amitriptyline  Tablets: 10 mg, 25 mg, 50 mg
Liquid: 25 mg/5 mL, 50 mg/5 mL
06.01.05 Amitriptyline  See section 4.3 for preparations
02.06.02 Amlodipine  Tablets: 5mg, 10mg
05.01.01.03 Amoxicillin  Capsules: 250mg, 500mg
Oral suspension (sugar-free available): 125mg/5ml, 250mg/5ml
Oral sachets (sugar-free): 3g/sachet
05.01.01.03 Amoxicillin  Injection: 250mg, 500mg, 1g
05.02 Amphotericin  Injection (for IV infusion): 50mg
Liposomal injection (for IV infusion) (AmBisome®): 50mg
11.03.02 Amphotericin 

unlicensed unlicensed Eye drops: 0.15%

08.01.05 Amsacrine 

Injection: 75mg in 15ml

09.01.04 Anagrelide Xagrid®

2nd line for ITP and patients at risk of essential thrombocythaemia
Capsules: 500micrograms

10.01.04 Anakinra  unlicensedunlicensed

Solution for injection (pre-filled syringe): 100mg/0.67mL

Note: for the indication of acute gout in hospital setting only
08.03.04.01 Anastrozole 

Tablets: 1mg

12.03.01 Antacid with Oxetacaine 

unlicensedunlicensed Suspension


Used to relieve symptoms in patients who have had radiotherapy and may be of value in some patients with acute oesophagitis. Not for routine use as an antacid

08.02.02 Antithymocyte immunoglobulin (horse)  

unlicensedunlicensed Injection: 250mg in 5ml -NETAG approved for aplastic anaemia in adults

08.02.02 Antithymocyte immunoglobulin (rabbit)  

Injection: 25mg injection
– used in the management of transplant rejection

01.07.01 Anusol®  Cream
Suppositories
01.07.02 Anusol-HC  Suppositories
Ointment
02.08.02 Apixaban  Tablets: 2.5mg, 5mg
04.09.01 Apomorphine  Injection: 20 mg/2 mL, 50 mg/5 mL
Pre-filled multiple dose pen injection device: 30 mg/3 mL
Pre-filled syringe: 50 mg/10 mL
11.08.02 Apraclonidine 

Eye drops: 0.5%
Unit dose eye drops: 1%

11.06 Apraclonidine hydrochloride 

Eye drops: 0.5% Single use (preservative free): 1%

10.01.03 Apremilast 

Tablets: 30mg

04.06 Aprepitant 

Capsules: 80mg, 125mg

01.06.03 Arachis Oil  Enema
02.08.01 Argatroban monohydrate 

Infusion vial: 250mg/2.5 mL 

04.02.01 Aripiprazole  Tablets: 5mg, 10mg, 15mg, 30mg

Orodispersible tablets: 10mg, 15mg
- for doses over 5 mg for those patients who have difficulty swallowing

Oral solutions: 1mg/1ml
- only for doses of 5 mg or less, or when titrating patients on doses of increments of less than 5 mg, in patients who have difficulty swallowing tablets
04.02.01 Aripiprazole  IM Injection: 7.5mg/ml
- approved for use in rapid tranquilisation in patients with acute psychosis. NTW use only
04.02.02 Aripiprazole  Injection: 400mg long acting injection
-NTAG approved for the treatment of schizophrenia as per its licensed indication and as outlined in the Guidance on the Use of Antipsychotic Long-Acting Injections in the North of England
08.01.05 Arsenic Trioxide 

Ampoule: 10mg in 10ml
-NECDAG approved relapsed or refractory acute promyelocytic leukaemia (APL)

05.04.01 Artesunate Malacef 60

Injection: 60mg

09.06.03 Ascorbic Acid 

Tablets: 50 mg, 100 mg, 200 mg, 500 mg

02.09 Aspirin  

Dispersible tablets: 75mg, 300mg (loading dose)

02.09 Aspirin  

Suppository: 150mg, 300mg
For use in patients following stroke

04.07.04.01 Aspirin  Soluble Tablets: 300 mg
07.01.04 Aspirin 

Dispersible tablets: 75mg

05.03.01 Atazanavir Reyataz®

Capsules: 150mg, 200mg, 300mg

05.03.01 Atazanavir sulfate and cobicistat Evotaz®

Tablets: 300mg/150mg

02.04 Atenolol  Tablets: 25mg, 50mg, 100mg
Sugar-free syrup: 25mg/5ml
08.01.05 Atezolizumab 

Atezolizumab is recommended for use within the Cancer Drugs Fund as an option for untreated locally advanced or metastatic urothelial carcinoma in adults, for whom cisplatin-based chemotherapy is unsuitable, only if the conditions of the managed access agreement for atezolizumab are followed

04.04 Atomoxetine  Capsules: 10mg, 18mg, 25mg, 40mg, 60mg, 80mg
02.12 Atorvastatin  Tablets: 10mg, 20mg, 40mg, 80mg
Chewable tablets: 10mg, 20mg - to be used when solid dosage forms cannot be used
07.01.03 Atosiban 

Injection: 6.75mg in 0.9ml
Concentrate for IV infusion: 37.5mg in 5ml (7.5mg/ml)

15.01.05 Atracurium Besilate 

Injection (amps): 25 mg/2.5 mL, 50 mg/5 mL

11.05 Atropine 

Eye drops: 0.5%
Minims® (preservative free): 1%
unlicensed unlicensed Eye drops (preservative free): 1%
unlicensed unlicensed Eye ointment: 1%

15.01.03 Atropine  

Injection (amps): 600 micrograms/1 mL 

23.01 Atropine sulphate  

Injection: 600 micrograms/1 mL ampoules


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

07.04.05 Avanafil 

Tablets: 50mg, 100mg, 200mg

08.01.05 Avelumab  Bavencio ®

20mg/ml concentrate for infusion.

08.01.05 Axitinib 

Film coated tablets: 1mg, 3mg, 5mg and 7mg

08.01.03 Azacitidine Vidaza®

Vial: 100mg

01.05.03 Azathioprine  Tablets: 25mg, 50mg

Maximum dose for TPMT- deficient patients 5mg
08.02.01 Azathioprine 

Tablets: 25mg & 50mg
unlicensedunlicensed Suspension: 50mg in 5ml
Injection: 50mg

10.01.03 Azathioprine  Tablets: 25 mg, 50 mg
12.02.01 Azelastine Hydrochloride 

Nasal spray: 140 micrograms (0.14 mL)/spray

05.01.05 Azithromycin  Tablets: 250mg, 500mg
Capsules: 250mg
Oral suspension: 200mg/5ml

The tablets have a lower acquisition cost than the capsules

N.B. Green+ for use in COPD
11.03.01 Azithromycin Azyter®

Eye drops: 1.5% (single use)

05.01.02.03 Aztreonam  Injection: 1g, 2g
Powder for inhalation: 75mg

Approved in line with NHS England specialised commissioning criteria for the treatment of chronic pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Only to be prescribed by secondary care from April 2016 in line with NHS England Clinical Commissioning Policy
10.02.02 Baclofen  Tablets: 10 mg
Oral solution (sugar-free available): 5 mg/5 mL
01.05.01 Balsalazide Sodium Colazide® Capsules: 750mg
10.01.03 Baricitinib Olumiant

Film coated tablets: 2mg, 4mg

17 Barium sulfate  E-Z-HD®

For oral use: 98.45%

17 Barium sulfate  Polibar®

For rectal use: 94.015%

08.02.02 Basiliximab Simulect®

Vial for preparing IV infusion: 20mg


-approved for limited use in adult renal translplant patients with high risk of acute organ rejection


-approved for severe graft versus host disease post haematopoietic stem cell transplantation


 

08.02.04 BCG Connaught 

Vial: 81mg for bladder instillation

14.04 BCG vaccine 

Bacillus Calmette-Guérin Vaccine (BCG Vaccine, Dried/Tub/BCG)  
unlicensed unlicensed Injection: 1 mL multidose ampoules containing freeze dried powder for preparing intradermal injections (InterVax). 


 


Tuberculin Purified Protein Derivative (Tuberculin PPD)
unlicensed unlicensed Vial (1.5 mL): 20 units/mL (2 units/0.1 mL dose) (for routine use); 100 units/mL (10 units/0.1 mL dose) (Statens Serum Institut). 

03.02 Beclometasone Clenil Modulite® Beclometasone is the first line corticosteroid; Clenil is first choice for asthma

Clenil Modulite® CFC-free MDI: 50mcg, 100mcg, 200mcg, 250mcg per puff

N.B. CFC-free beclometasone must be prescribed by brand name
03.02 Beclometasone Qvar® Beclometasone is the first line corticosteroid

QVAR® CFC-free MDI: 50mcg, 100mcg per puff
QVAR® breath-actuated MDI: 50mcg, 100mcg per puff
Extra-fine particle inhaler

N.B. CFC-free beclometasone must be prescribed by brand name.

50mcg QVAR is equivalent to 100mcg for a conventional beclometasone inhaler and 100mcg is equivalent to 250mcg conventional beclometasone.
03.02 Beclometasone and formoterol Fostair®

Fostair ® CFC-free MDI: 100/6mcg per puff 
Fostair ® CFC-free MDI: 200/6mcg/puff

N.B. Extra fine-particle aerosol - 100mcg of beclomethasone in Fostair ® is equivalent to a 250mcg dose in a conventional beclomethasone metered dose inhaler

Fostair ® NEXThaler (breath actuated DPI): 100/6mcg, 200/6mcg per puff

The 100/6mcg inhalers are first choice ICS/LABA combination inhalers in the Sunderland COPD guideline.

12.02.01 Beclometasone Dipropionate 

Nasal spray: 50 micrograms/ spray

03.01.04 Beclomethasone/Formoterol/Glycopyrronium 87/5/9 Trimbow®

Trimbow®   87/5/9mcg MDI

Triple therapy inhaler -ICS/LABA/LAMA for COPD.

If spacer required, manufacturer recommends AeroChamberPlus.

Formulary approved for use in COPD only.

 

10.01.03 Belimumab Benlysta®

Vial for intravenous infusion: 120mg

08.01.01 Bendamustine 

Injections: 25mg & 100mg


-approved for the first line treatment of CLL (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate in line with NICE


-NECDAG approved for use in combination with rituximab for patients with CLL not fit for FCR chemotherapy and not fit for alemtuzumab.


-approved for Low Grade Non-Hodgkins Lymphoma in line with NICE -not recommended for (low grade) non-Hodgkin's lymphoma that is refractory to rituximab or a rituximab-containing regimen NICE

02.02.01 Bendroflumethiazide  Tablets: 2.5mg
05.01.01.01 Benzathine penicillin 

unlicensed unlicensed Injection: 2.4MU vial

10.01.04 Benzbromarone 

Tablets: 100mg

12.03.01 Benzydamine 

Mouthwash: 0.15%
Spray: 0.15% 

05.01.01.01 Benzylpenicillin  Injection: 600mg, 1.2g
11.03.01 Benzylpenicillin 

unlicensed Eye drops: 100,000 units/mL

04.06 Betahistine Dihydrochloride  Tablets: 8mg, 16mg
07.01.04 Betamethasone 

Injection: 4mg/ml

11.04.01 Betamethasone 

Eye/Ear/Nose drops: 0.1%
Eye ointment: 0.1%

12.01.01 Betamethasone Betnovate Scalp application

unlicensedunlicensed Solution (as ear drops for eczema): 0.1% (Betnovate Scalp Application)

12.03.01 Betamethasone 

Tablets (soluble): 500 micrograms (Betnesol®)
Used as mouth gargle

12.01.01 Betamethasone sodium phosphate 

Ear/eye/nose drops: 0.1%

12.02.01 Betamethasone Sodium Phosphate 

Eye/ear/nose drops: 0.1%

11.04.01 Betamethasone with Neomycin  

Eye drops: betamethasone 0.1%, neomycin sulfate 0.5%

12.01.01 Betamethasone with Neomycin  Betnesol N®

Ear drops: 0.1% with neomycin sulfate 0.5%

08.01.05 Bevacizumab Avastin®

Vial: 100mg/4ml
Syringe: 5mg/0.2ml
Solution for infusion: 25mg/1ml


*Avastin is available as a treatment option for wet AMD in situations where ophthalmologists feel, in discussion with their patients, that the licensed options are unsuitable

08.01 Bicalutamide  Tablets: 50mg, 150mg
08.03.04.02 Bicalutamide 

Tablets: 50mg, 150mg 
-initiated with specialist advice

11.06 Bimatoprost 

Eye drops: 100 micrograms/1 mL, 300 micrograms/1 mL
Unit dose eye drops (preservative-free): 300 micrograms/1 mL

11.06 Bimatoprost with Timolol 

Eye drops: bimatoprost 300 micrograms/1 mL, timolol 5 mg/1 mL (Ganfort®)

01.05.03 Biosimilar Infliximab Inflectra®

Vial (powder for reconstitution): 100mg

12.03.05 Biotene Oralbalance® 

Gel

12.03.05 BioXtra® 

Gel: 40 mL
Spray: 50 mL
Mouth rinse: 250 mL      

06.01.01.02 Biphasic Insulin Aspart NovoMix® 30 Cartridge: 3ml for NovoPen® Novopen penmate

Prefilled pen: 3ml FlexPen®
06.01.01.02 Biphasic Insulin Lispro Humalog® Mix Cartridge: 3ml for HumaPen® Savvio or Autopen® Classic

Prefilled pen: 3ml KwikPen®

Hospital note - Minimal stock levels of cartridges held
Humalog Mix 50®: KwikPen® pre-loaded pen – not stocked but available on request
06.01.01.02 Biphasic Isophane Insulin Humulin® M3 Cartridge: 3ml for HumaPen® Savvio or Autopen® Classic

Prefilled pen: 3 ml KwikPen®

Vial: 10ml

01.06.02 Bisacodyl  Tablets: 5mg
Suppositories: 5mg*, 10mg
*5mg suppository for use in paediatrics only
12.02.03 Bismuth and Iodoform Paste (BIPP) 

Impregnated gauze: 1.25cm x 100cm and 2.5cm x 100cm

02.04 Bisoprolol  Tablets: 1.25mg, 2.5mg, 3.75mg, 5mg, 7.5mg, 10mg
The 5mg and 10mg tablets should be used where possible due to lower cost.
02.08.01 Bivalirudin  Injection: 250 mg
08.01.02 Bleomycin 

Injection: 15,000 units (strength formerly expressed as 15mg)
-unlicensedunlicensed also approved for use in intralesional sclerotherapy in the treatment of low-flow vascular lesions – unlicensed indication

08.02 Blinatumomab Blincyto®

Vials: 38.5microgram

05.03.03.02 Boceprevir  Capsules: 200mg
12.01.01 Boric acid (insufflation) 

Powder: 10g

08.01.05 Bortezomib 

Injection: 3.5mg

02.05.01 Bosentan  Tablets: 62.5mg
08.01.05 Bosutinib 

Film coated tablets: 100mg, 500mg

04.09.03 Botulinum Toxin Type A 

Botox®: 50 units, 100 units, 200 units
Dysport®: 300 units, 500 units
Xeomin ®: 50units, 100 units, 200 units

 

N.B. Botox® is also licensed for the prophylaxis of headache in adults with chronic migraine (NICE TA260)

08.01.05 Brentuximab vedotin Adcetris®

Vial: 50mg

07.03.01 Brevinor® 

Tablets: ethinylestradiol 35 microgram/norethisterone 500 microgram

11.06 Brimonidine Tartrate 

Eye drops: 0.2%

11.06 Brimonidine Tartrate with timolol 

Eye drops: brimonidine 0.2%, timolol 0.5% (Combigan®)

11.06 Brinzolamide 

Eye drops: 1% (10 mg/1 mL)

11.06 Brinzolamide and brimonidine Simbrinza®

Eye drops: brinzolamide 10mg/ml, brimonidine tartrate 2 mg/mL

11.06 Brinzolamide with timolol 

Eye drops: brinzolamide 10 mg/1 mL, timolol 5 mg/1 mL (Azarga®)

04.08.01 Brivaracetam  Tablets: 25mg, 50mg
Oral solution: 10mg/ml
Solution for injection/infusion: 10mg/ml
08.02.04 Brodalumab Kyntheum ®

210mg solution for infusion

Brodalumab for treating moderate to severe plaque psoriasis (TA511) 21.3.18

06.07.01 Bromocriptine  Tablets: 1mg, 2.5mg
01.05.02 Budenoside Budenofalk

Rectal foam: 2mg/dose

01.05.02 Budesonide Budenofalk® Entocort ®

CR capsules: 3mg (Entocort)

Capsules:3mg (Budenofalk)

03.02 Budesonide  Alternative corticosteroid

Breath actuated DPI (Turbohaler®): 100mcg, 200mcg, 400mcg per puff
Respules®: 250mcg/1ml, 500mcg/1ml, 500mcg/2ml
03.02 Budesonide and formoterol DuoResp Spiromax®

DuoResp Spiromax ® 

160/4.5: Budesonide with formoterol 160/4.5mcg per puff
320/9: Budesonide with formoterol 320/9mcg per puff

DuoResp Spiromax 320/9 inhaler is included as an option on the Sunderland COPD guideline for patients that need ICS/LABA.

03.02 Budesonide and formoterol Symbicort®

Symbicort Turbohaler® 
100/6: Budesonide with formoterol 100/6mcg per puff
200/6: Budesonide with formoterol 200/6mcg per puff
400/12: Budesonide with formoterol 400/12 mcg per puff

 

Not a first-line choice on the Sunderland COPD guideline for newly diagnosed COPD patients. May be continued in existing patients if guideline alternatives are unsuitable.

02.02.02 Bumetanide  Tablets: 1mg, 5mg
Liquid: 1mg/5ml
15.02 Bupivacaine Hydrochloride 

Injection: 0.5% (100 mg/4 mL), in glucose 8%, 4 mL ampoules (Marcain Heavy®)

04.07.02 Buprenorphine 

Transdermal patches: 5mcg, 10mcg, 15mcg, 20mcg/hour over 7 days*
Transdermal patches: Transtec® 35mcg, 52.5mcg, 70mcg/hour over 96 hours

*Sevodyne preferred brand in primary care

 

 

Red Sublingual tablets: 200micrograms

* For treatment of post-operative pain only*

04.10.03 Buprenorphine  Sublingual Tablets: 400 micrograms, 2 mg, 8 mg
04.10.03 Buprenorphine and Naloxone Suboxone® Sublingual tablets: 8mg/2mg*
*Following initiation by, or on the recommendation of addiction services only
04.10.02 Bupropion Hydrochloride 

MR Tablets: 150 mg

08.03.04.02 Buserelin 

Injection: 5mg in 5ml
Metered dose nasal sprays 150 microgram

04.01.02 Buspirone Hydrochloride  Tablets: 5mg
08.01.01 Busulfan 

Tablets: 2mg
Injection: 60mg in 10ml
unlicensedunlicensed Capsules: 25mg

03.04.03 C1 Esterase Inhibitor Berinert®

Injection: powder for reconstitution, 500 unit vial and 1,500 unit vial (Berinert®)

Treatment of hereditary angioedema (HAE) and pre-procedure prevention

08.01.05 Cabazitaxel 

Concentrate for IV infusion: 40mg/1ml

06.07.01 Cabergoline  Tablets: 500micrograms
09.06.04 Calcitriol 

Capsules: 0.25 micrograms, 0.5 micrograms

09.05.02.02 Calcium Acetate 

Tablets: 1 g (Phosex)
Tablets: 475mg, 950mg (Renacet)

09.05.02.02 Calcium carbonate 

Tablets: 1.5 g (Adcal)


Please note preferred brands may vary between primary and secondary care

09.05.01.01 Calcium Chloride 

Injection:10% equivalent to calcium 6.8 mmol/10 mL

23.01 Calcium chloride 

Injection: 10 mmol/10 mL ampoules


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

08.01 Calcium Folinate (Folinic acid) 

Tablets: 15mg
Injection: 3mg, 15mg, 30mg and 300mg
An unlicensed 1mg per 1ml mouthwash can be prepared if needed unlicensedunlicensed 

09.05.01.01 Calcium Gluconate 

Injection: 10%, equivalent to calcium 2.25 mmol/10 mL

23.01 Calcium gluconate 

Injection: 10 % (1 g/10 mL) ampoules
Gel: 25 g tube


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

09.05.01.01 Calcium Salts 

Chewable tablets (as carbonate 1.5 g): equivalent to calcium 600 mg, 15 mmol (Adcal®)


Effervescent tablets: equivalent to calcium 1 g, 25 mmol (Sandocal 1000®)


Syrup (per 5 mL): equivalent to calcium 102 mg, 2.55 mmol (Alliance Calcium Syrup)

09.05.02.02 Calcium/Magnesium Salts 

Tablets: Calcium acetate 435 mg and Magnesium carbonate 235 mg (Osvaren)

06.01.02.03 Canagliflozin  Tablets: 100mg, 300mg
02.05.05.02 Candesartan  Tablets: 2mg, 4mg, 8mg, 16mg, 32mg
08.01.03 Capecitabine 

Tablets: 150mg & 500mg

12.03.01 Caphosol® 

Oral rinse: 30 doses

04.07.03 Capsaicin Axsain® Cream: 0.075%
10.03.02 Capsaicin  Cream: 0.025% (Zacin®)
For osteoarthritis
04.02.03 Carbamazepine  Tablets: 100mg, 200mg, 400mg
Sugar-free liquid: 100mg/5mL
- see section 4.8 for other formulations

04.07.03 Carbamazepine  Tablets: 100 mg, 200 mg, 400 mg
SR Tablets: 200 mg, 400 mg
Liquid: 100 mg/5 mL

Indicated in trigeminal neuralgia and compression neuralgia
04.08.01 Carbamazepine  Tablets: 100 mg, 200 mg, 400 mg
SR Tablets: 200 mg, 400 mg
Liquid: 100 mg/5 mL
Suppositories: 125 mg, 250 mg

CHM advise brand specific prescribing
17 Carbex® granules   Containing: citric acid, sodium bicarbonate, simeticone
06.02.02 Carbimazole  Tablets: 5mg, 20mg
03.07 Carbocisteine  Capsules: 375mg
Oral liquid: 125mg/5ml, 250mg/5ml
11.08.01 Carbomer 980 

Eye drops (liquid gel): 0.2%
Also available as single dose units (preservative-free)

15.01.02 Carbon dioxide 
08.01.05 Carboplatin 

Injections: 50mg in 5ml, 450mg in 45ml

07.01.01 Carboprost 

Injection 250 micrograms in 1ml

08.01.05 Carfilzomib Kyprolis®

Vial: 60mg

11.08.01 Carmellose 

Eye drops: 0.5%,
Single dose units (preservative-free): 0.5%, 1% (Celluvisc®)

08.01.01 Carmustine BiCNU®

Implants: 7.7mg

02.04 Carvedilol  Tablets: 3.125mg, 6.25mg, 12.5mg, 25mg
05.02.04 Caspofungin  Injection: 50mg, 70mg
05.01.02.01 Cefalexin  Capsules: 250mg, 500mg
Oral suspension: 125mg/5ml, 250mg/5ml
05.01.02.01 Cefixime  Tablets: 200mg
Oral solution: 100mg/5ml
05.01.02.01 Cefotaxime  Injection: 500mg, 1g, 2g
05.01.02.01 Ceftazidime  Injection: 500mg, 1g, 2g, 3g
05.01.02 Ceftolozane & tazobactam Zerbaxa®

Solution for infusion: 1g/0.5g

05.01.02.01 Ceftriaxone  Injection: 250mg, 1g, 2g
05.01.02.01 Cefuroxime  Injection: 250mg, 750mg, 1.5g
10.01.01 Celecoxib  Capsules: 100mg, 200mg
08.01.05 Ceritinib 

Capsule: 150mg

10.01.03 Certolizumab Pegol 

Pre-filled syringe: 200 mg


Note: Option if anti-TNF withdrawn during 1st 6 months due to adverse effects

Also approved for:
-Adults with severe active Ankylosing Spondylitis who have had an inadequate response to, or are intolerant to NSAIDs
-In combination with MTX, is indicated for the treatment of active psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate

03.04.01 Cetirizine  Tablets: 10mg
Oral solution: 5mg/5ml
08.01.05 Cetuximab 

Vials for IV infusion: 100mg in 20ml & 500mg in 100ml

23.01 Charcoal (activated) 

Oral suspension: 50 gm/250 mL


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

04.01.01 Chloral Hydrate  Elixir*: 143.3mg/5ml
*Use in paediatrics only
04.01.01 Chloral Hydrate  Mixture: 500mg/5ml
08.01.01 Chlorambucil 

Tablets: 2mg

05.01.07 Chloramphenicol  Capsules: 250mg
05.01.07 Chloramphenicol  Injection (for IV infusion): 1g
11.03.01 Chloramphenicol 

Eye drops: 0.5%
Eye ointment: 1%
Minims® single use, preservative free: 0.5%

12.01.01 Chloramphenicol 

Ear drops: 5%

04.01.02 Chlordiazepoxide  Capsules: 5mg, 10mg
07.04.04 Chlorhexidine 

100ml sachets: 0.02% (1 in 5,000) solution

11.03.02 Chlorhexidine 

unlicensed unlicensed Eye drops: 0.02%

12.03.02 Chlorhexidine 

Mouthwash: 0.2% (contains alcohol)
Mouthwash (alcohol free): 0.2%
Spray: 0.2% – contains alcohol
Gel: 1%

12.02.03 Chlorhexidine Hydrochloride and Neomycin Suphate  

Naseptin®
Cream: chlorhexidine hydrochloride 0.1%, neomycin sulfate 0.5%
Contains peanut oil

03.04.01 Chlorphenamine  Tablets: 4mg
Syrup: 2mg/5ml
Injection: 10mg/1ml
04.02.01 Chlorpromazine  Tablets: 10mg, 25mg, 50mg, 100mg
Oral solution: 25mg/5ml, 100mg/5ml
Injection: 50mg/2ml
07.05.03 Choriogonadotrophin alfa Ovitrelle®

Prefilled syringe: 250microgram/0.5ml

06.05.01 Choriogonadotropin Alfa Ovitrelle® Injection (pre-filled syringe): 6,500 units/0.5mL (250 micrograms/0.5mL) (Ovitrelle®)
06.05.01 Chorionic Gonadotrophin Pregnyl® Injection: 1,500 units, 5,000 units (Pregnyl®)
01.05.03 Ciclosporin 

Capsules: 10mg, 25mg, 50mg, 100mg
Oral solution: 100mg/ml
Prescribe by brand name.

Brands include Capimune, Capsorin, Deximune, Neoral, Sandimmun, Vanquoral

08.02.02 Ciclosporin Sandimmun®

IV Infusion: 50mg in 1ml & 250mg in 5ml concentrate (oily)

08.02.02 Ciclosporin Neoral®

Capsules: 10mg, 25mg, 50mg & 100mg
Sugar free oral solution (oily): 100mg in 1ml

08.02.02 Ciclosporin Sandimmun®

Original oral formulations Sandimmun supplied on request for patients who cannot take Neoral
unlicensedunlicensed Capsules: 25mg & 100mg
Sugar-free oral solution (oily): 100mg in 1ml

10.01.03 Ciclosporin Neoral® Capsules: 10 mg, 50 mg, 100 mg
Oral solution (sugar-free): 100 mg/1 mL
11.04.02 Ciclosporin  

unlicensed unlicensed P/F unit dose eye drops: 0.05%

11.04.02 Ciclosporin  

Eye drops: 0.1%

07.03.01 Cilest® 

Tablets: Ethinylestradiol 35 mcg / norgestimate 250 mcg

07.03.01 Cilique® 

Tablets: Ethinylestradiol 35 mcg / norgestimate 250 mcg

09.05.01.02 Cinacalcet Mimpara®

Please note the RAG status of cinacelet is dependent on indication


Amber Cinacalcet for the treatment of primary hyperparathyrodism


Red Cinacalcet for the treatment of secondary hyperparahyrodism


Tablets: 30 mg, 60 mg, 90 mg

04.06 Cinnarizine  Tablets: 15mg
05.01.12 Ciprofloxacin  Tablets: 100mg, 250mg, 500mg, 750mg
Oral suspension: 250mg/5ml
05.01.12 Ciprofloxacin  IV infusion: 2mg/ml
11.03.01 Ciprofloxacin 

Eye drops: 0.3%
Eye ointment (preservative-free): 0.3%

12.01.01 Ciprofloxacin 

unlicensedunlicensed Eye drops: 0.3%


(Off-licence use)

08.01.05 Cisplatin 

Injection: 50mg

04.03.03 Citalopram  Tablets: 10 mg, 20 mg, 40 mg
Oral drops (sugar-free): 40 mg/1 mL
4 drops (8mg) is therapeutically equivalent to a 10 mg tablet
08.01.03 Cladribine 

Solution for preparing infusions: 10mg in 10ml
Subcutaneous injection: 2mg in 1ml
- approved for Hairy Cell Leukemia only

05.01.05 Clarithromycin  Tablets: 250mg, 500mg
Oral suspension: 125/5ml, 250mg/5ml
05.01.05 Clarithromycin  Injection (for IV infusion): 500mg
05.01.06 Clindamycin   Capsules: 75mg, 150mg
Suspension: 75mg/5ml
05.01.06 Clindamycin   Injection: 300mg/2ml, 600mg/4ml
07.02.02 Clindamycin 

Vaginal cream: 2%

04.08.01 Clobazam  Tablets: 10 mg
Oral Suspension: 5mg/5 mL - licensed product, Tapclob®, now available
Should only be prescribed on the NHS to patients for the treatment of epilepsy under SLS regulations. Prescriptions should be endorsed “SLS”.
04.01.01 Clomethiazole  Capsules: 192mg
Oral solution: 157.5mg/5ml

Chlordiazepoxide is preferred in the management of alcohol withdrawal.
Heminevrin syrup has been discontinued.
06.05.01 Clomifene Citrate  Tablets: 50mg
07.05.01.01 Clomiphene 

Tablets: 50mg

04.03.01 Clomipramine  Capsules: 10 mg, 25 mg, 50 mg
04.08.01 Clonazepam  Tablets: 500 micrograms, 2 mg
Oral solution (contains alcohol): 500 micrograms/5 mL, 2 mg/5 mL
Oral solution contains 100mg ethanol per 5mL (Rosemont Pharmaceuticals)
02.05.02 Clonidine hydrochloride  Tablets: 25 micrograms, 100 micrograms
02.05.02 Clonidine hydrochloride  Ampoules: 150 micrograms/1ml
04.07.04.02 Clonidine Hydrochloride  Suspension*: 50mcg/5ml
*Hospital use only
02.09 Clopidogrel  Tablets: 75mg, 300mg (loading dose)
07.02.02 Clotrimazole 

Cream: 1%
Thrush cream: 2%
Vaginal cream: 10%
Pessaries: 100mg, 200mg & 500mg
Cream with hydrocortisone: 1%/1%

12.01.01 Clotrimazole 

Solution (as ear drops): 1%

04.02.01 Clozapine  Tablets: 25mg, 100mg
First choice in patients with treatment-resistant schizophrenia
Contact NTW pharmacy department for continued supplies of clozapine during admission and on discharge
05.01.01.03 Co-Amoxiclav (amoxicillin with clavulanic acid)  Tablets: 250/125, 500/125
Oral suspension (sugar-free available): 125/31, 250/62, 400/57

(Quantities are indicated in the form of x/y where x = mg amoxicillin and y = mg clavulanic acid)
05.01.01.03 Co-Amoxiclav (amoxicillin with clavulanic acid)  Injection: 500/100 (600mg), 1000/200 (1.2g)

(Quantities are indicated in the form of x/y where x = mg amoxicillin and y = mg clavulanic acid)
04.09.01 Co-Beneldopa  Capsules: 12.5/50, 25/100, 50/200
Dispersible Tablets: 12.5/50, 25/100
CR capsules: 25/100
05.03.01 Cobicistat Tybost®

Tablets: 150mg

11.99.99.99 Cocaine 

unlicensed unlicensed P/F eye drops: 4%

12.02.03 Cocaine 

unlicensedunlicensed Drops: 4%

04.09.01 Co-Careldopa  Tablets: 12.5/50, 10/100, 25/100, 25/250
MR Tablets: 25/100, 50/200
04.09.01 Co-Careldopa and Entacapone  Stalevo® 50 mg/12.5 mg/200 mg Tablets: levodopa 50 mg, carbidopa 12.5 mg, entacapone 200 mg
Stalevo® 75 mg/18.75 mg/200 mg Tablets: levodopa 75 mg, carbidopa 18.75 mg, entacapone 200 mg
Stalevo® 100 mg/25 mg/200 mg Tablets: levodopa 100 mg, carbidopa 25 mg, entacapone 200 mg
Stalevo® 125 mg/31.25 mg/200 mg Tablets: levodopa 125 mg, carbidopa 31.25 mg, entacapone 200 mg
Stalevo® 150 mg/37.5 mg/200 mg Tablets: levodopa 150 mg, carbidopa 37.5 mg, entacapone 200 mg
Stalevo® 175 mg/43.75 mg/200 mg Tablets: levodopa 175 mg, carbidopa 43.75 mg, entacapone 200 mg
Stalevo® 200 mg/50 mg/200 mg Tablets: levodopa 200 mg, carbidopa 50 mg, entacapone 200 mg
07.03.01.02 Co-cyprindiol 2000/35 

Tablets: Ethinyllestradiol 35 micrograms/ cyprioterone 2mg

04.07.02 Codeine 

Codeine phosphate
Tablets: 15 mg, 30 mg, 60 mg
Syrup: 25 mg/5 mL

Injection 60mg/ml - hospital only

03.09.01 Codeine Linctus BP  15mg/5ml
10.01.04 Colchicine  Tablets: 500 micrograms
Note: When treating acute gout, max. 6 mg per course; course not to be repeated within 3 days
09.06.04 Colecalciferol  

Capsules: 800 units, 20,000 units
Tablets: 800units, 1000units, 25,000 units


Liquid: Secondary care: contact pharmacy for advice regarding available brands. Primary care: use most clinically and cost effective option


Note,Green +  for bariatric indications

09.06.04 Colecalciferol and Calcium Carbonate  

Please note, the following preparations are listed generically. Please be aware that the branded products issued by primary and secondary care, and patients may be changed onto an equivalent preparation depending on which products are most cost-effective.


Tablets: 1.5g Calcium Carbonate (600mg Calcium) and 400 units (10mcg) Colecalciferol
Chewable tablets: 1.5g Calcium Carbonate (600mg Calcium) and 400 units (10mcg) Colecalciferol
Eff Tablets: 1.5g Calcium Carbonate (600mg Calcium) and 400 units (10mcg)
Caplets: 750mg calcium carbonate (300mg Calcium) an 200units (5mcg) – used by secondary care, review use in primary care as more cost-effective options are available.             



Secondary care: contact pharmacy for advice regarding available brands. Primary care: use most clinically and cost effective option

01.09.02 Colesevelam  Tablets: 625mg
For second line use (after colestyramine)for the treatment of bile malabsorption that results in diarrhoea (unlicensed indication)
01.09.02 Colestyramine  Sachets: 4g
05.01.07 Colistimethate inhaler Colobreathe® Dry powder for inhalation: 1.66 million units per capsule (Colobreathe®)

Approved in line with NHS England specialised commissioning criteria for the treatment of chronic pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Only to be prescribed by secondary care from April 2016 in line with NHS England Clinical Commissioning Policy.
05.01.07 Colistimethate sodium  Injection: 1,000,000 units, 2,000,000 units
Powder for nebulised solution: 1,000,000 units
10.03.01 Collagenase (Clostridium histolyticum) Xiapex® Vial: 900 micrograms

Clinicians must be trained and registered with the company before supply can be made
01.01.01 Co-magaldrox Maalox® Sugar-free suspension

Prescribers should choose the product with the lowest acquisition cost. In the community - Mucogel is cheaper.
01.01.01 Co-magaldrox Mucogel® Sugar-free suspension

Prescribers should choose the product with the lowest acquisition cost. In the community - Mucogel is cheaper.
06.04.01.01 Combined continuous HRT patch Evorel® Conti Evorel® Conti
Patches: Pack containing 8 patches releasing 50mcg estradiol/24 hours and 170mcg noresthisterone acetate/24 hours
06.04.01.01 Combined continuous HRT tablet - high dose Kliofem® Kliofem®
Tablets: 2mg estradiol and 1mg norethisterone acetate


06.04.01.01 Combined continuous HRT tablet - low dose Premique low-dose® Premique low-dose®
Tablets: 0.3mg conjugated oestrogen + medroxyprogesterone acetate 1.5mg
06.04.01.01 Combined continuous HRT tablet - standard dose Kliovance® Kliovance®
Tablets: 1mg estradiol and 500mcg norethisterone acetate

06.04.01.01 Combined cyclical HRT patch Evorel® Sequi Evorel Sequi®
Patches: Pack containing 4 patches releasing 50mcg estradiol/24 hours and 4 patches releasing 50mcg estradiol and 170mcg norethisterone acetate/24 hours
06.04.01.01 Combined cyclical HRT tablet Elleste Duet® Elleste Duet®
Tablets: Pack of 16 x 1mg estradiol tablets + 12 x 1mg estradiol and 1mg norethisterone tablets
06.04.01.01 Combined cyclical HRT tablet Prempak-C® Prempak-C®
Tablets: 0.625 (pack of 28 x 625mcg conjugated oestrogen tablets + 12 norgestrel 150mcg tablets)

Tablets: 1.25 (pack of 28 x 1.25mg conjugated oestrogen tablets + 12 norgestrel 150mcg tablets)

06.04.01.01 Combined cyclical HRT tablet Femoston® 2/10 Femoston® 2/10
Tablets: Pack of 14 x 2mg estradiol tablets + 14 tablets containing estradiol 2mg and dydrogesterone 10mg

06.04.01.01 Combined cyclical HRT tablet Femoston® 1/10 Femoston® 1/10
Tablets: Pack of 14 x 1mg estradiol tablets + 14 tablets containing estradiol 1mg and dydrogesterone 10mg

05.01.08 Co-trimoxazole  480mg in 5ml ampoules for IV infusion
05.01.08 Co-trimoxazole  Tablets: 480mg, 960mg
Suspension: 480mg/5ml
08.01.05 Crizotinib 

Capsules: 200mg, 250mg

04.06 Cyclizine  Tablets: 50 mg
Injection: 50 mg/1 mL
Suspension*: 50mg/5ml
*For paediatric use only
11.05 Cyclopentolate  

Eye drops: 0.5%, 1%
Minims® (preservative free): 0.5%, 1%

11.05 Cyclopentolate with phenylephrine 

unlicensed unlicensed Eye drops (preservative free): 1%

08.01.01 Cyclophosphamide 

Tablets: 50mg 
Injection: 1g

23.01 Cyproheptadine hydrochloride 

Tablets: 4 mg


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

07.05.05 Cyproterone 

Tablets: 50mg

08.03.04.02 Cyproterone 

Tablets: 50mg & 100mg

06.04 Cyproterone Acetate  Tablets: 50mg & 100mg
06.04.02 Cyproterone Acetate  Tablets: 50mg
08.01.03 Cytarabine 

Injections: 100mg in 5ml, 1g in 10ml
Vial: 50mg (cytarabine encapsulated in liposomes)

02.08.02 Dabigatran  Capsules: 75mg, 110mg, 150mg
08.01.05 Dabrafenib Tafinlar®

Capsules: 50mg and 75mg

08.01.05 Dacarbazine 

Injection: 500mg

05.03.03.02 Daclatasvir   Tablets: 30mg, 60mg
08.01.02 Dactinomycin 

Injection: 500 microgram

02.08.01 Dalteparin  Injection: (pre-filled syringe): 2,500 units/0.2ml, 5,000 units/0.2ml, 7,500 units/0.3ml, 10,000/0.4ml, 12,500 units/0.5ml, 15,000 units/0.6ml, 18,000 units/0.72ml
02.08.01 Danaparoid sodium  Injection (ampoule): 750 units/0.6ml
06.07.02 Danazol  Capsules: 100mg, 200mg
10.02.02 Dantrolene  Capsules: 25 mg, 100 mg
15.01.08 Dantrolene Sodium Dantrium Intravenous®

Injection (vials): 20 mg

23.01 Dantrolene sodium  

Injection: 20 mg vials


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

06.01.02.03 Dapagliflozin  Tablets: 5mg, 10mg
05.01.10 Dapsone  Tablets: 50mg, 100mg

Used for the treatment of leprosy and some skin conditions (e.g. dermatitis herpetiformis, pemphigoid on the advice of dermatologists)
05.01.07 Daptomycin  Injection (for IV infusion): 350mg, 500mg
08.01.05 Daratumumab Darzalex ®

20mg/ml concentrate for infusion

09.01.03 Darbepoetin Alfa Aranesp®

Prefilled syringes: 10, 15, 20,30, 40, 50, 60, 80, 100, 150, 300 micrograms
Sureclick pens: 20,40,60,80, 100, 150, 300micrograms

05.03.01 Darunavir Prezista®

Tablets: 75mg, 150mg, 400mg, 600mg, 800mg
Oral suspension: 100mg/ml

05.03.01 Darunavir and cobicistat Rezolsta®

Tablets: 800mg/150mg

08.01.05 Dasatinib 

Tablets: 20mg, 50mg

08.01.02 Daunorubicin 

Injection: 20mg
Prefilled syringes: 10mg, 15mg, 35mg & 40mg

10.03.02 Deep heat  Rub: 35gram
Hospital use only
09.01.03 Deferasirox Exjade®

Tablets:  90mg, 180mg, 360mg

08.03.04.02 Degarelix Firmagon®

Green+ Traffic Light OR Amber Traffic Light


Dependent on patient disease state


Vials (with diluent): 80mg & 120mg

06.05.02 Demeclocycline  Capsules: 150mg
06.06.02 Denosumab 

Injection (pre-filled syringe): 60mg/1mL
Vials: 120mg/1.7ml

To be used in line with NICE TA204

 

Note: Recommendation that denosumab is reclassified from Amber to Green Plus at JFC meeting May 2018. Green Plus leaflet discussed at June MOGG meeting - required changes and deferred to August 2018 meeting.

 

09.01.03 Desferrioxamine Mesilate 

Injection: 500mg, 2g

23.01 Desferrioxamine mesilate 

Injection: 500 mg, 2 g vials


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

15.01.02 Desflurane Suprane®

240ml

06.05.02 Desmopressin  Metered nasal spray: 10 micrograms/spray
Tablets: 100 micrograms, 200 micrograms
Oral lyophilisate: 60 micrograms, 120 micrograms, 240 micrograms
*Oral lyophilisate (Noqdirna): 25mcg, 50mcg
Intranasal solution: 100 micrograms/1mL

*Only to be used in line with NICE guidance CG171 and CG97
06.05.02 Desmopressin  Injection: 4 micrograms/1mL, 15 micrograms/1mL
Metered nasal spray: 150 micrograms/spray (Unlicensed)
07.04.02 Desmopressin 

Tablets: 100 microgram, 200 microgram
Sublingual tablets: 120 microgram

07.03.02 Desogestrel 

Tablets: 75 microgram


(Brands: Cerelle®(preferred) , Cerazette®, Zellata®

06.03.02 Dexamethasone  Tablets: 500 micrograms, 2mg
Oral solution (sugar-free): 2 mg/5mL
Soluble tablets: 2mg,4mg, 8mg

N.B. Sodium content of soluble tablets:
2mg tablet - 14.96 mg sodium
4 mg tablet - 29.95 mg sodium
8 mg tablet - 60.50 mg sodium
06.03.02 Dexamethasone  Injection: (as sodium phosphate) 3.3mg/1mL, 6.6mg/2mL
11.04.01 Dexamethasone 

Eye drops: 0.1%
Minims® (preservative free): 0.1%

10.01.02.02 Dexamethasone (as sodium phosphate)  Injection: 3.3 mg/1 mL, 4 mg/1 mL, 6.6 mg/2 mL, 8 mg/2 mL
11.04.01 Dexamethasone intravitreal implant 

Intravitreal implant: 700 micrograms

11.04.01 Dexamethasone with framycetin and gramicidin Sofradex®

Eye/Ear drops

12.01.01 Dexamethasone with framycetin sulfate and gramicidin Sofradex®

Ear drops: 0.05% with framycetin sulfate 0.5% and gramicidin 0.005% (Sofradex®)

12.01.01 Dexamethasone with Neomycin Otomize®

Ear spray: 0.1% with neomycin sulfate 3250 units/1 mL and glacial acetic acid 2% (Otomize®)

11.04.01 Dexamethasone with Neomycin and Polymyxin B sulphate Maxitrol®

Eye drops: 0.1%
Eye ointment: 0.1%

04.04 Dexamfetamine 

Tablets: 5mg

ADHD in children and adults : AMBER -  see shared care guideline.

Narcolepsy: Doses up to 30mg GREEN +, doses over 30mg RED

15.01.04.04 Dexmedetomidine  

Injection (vials): 1 mg/10 mL

08.01 Dexrazoxane Savene®

Vials: 500mg (with diluent)
- for use in line with NECN extravasation

06.01.04 Dextro Energy® Tablets  Tablets: (47g) – glucose 80%
24.01 Diagnostic Agents used at City Hospitals Sunderland  

Accu-chek Inform II® Test Strip
Combur 9® Strips
RedEdrophonium Injection
Glucose Powder 75 g
Redunlicensed unlicensed Indigocarmin 0.4% (20 mg/5 mL) injection ampoules
RedIndocyanine Green 25 mg Vial
Ketostix® Test Strip
Redunlicensed unlicensed Patent Blue V® 2 mL vial
Redunlicensed unlicensed Adenosine injection 1 mg/1 mL, 100 mL, 120 mL, 130 mL
Redunlicensed unlicensed Ajmaline injection 50 mg/10 mL ampoules

10.02.01 Diaminopyridine  Tablets: 20mg
04.07.02 Diamorphine 

Injection: 5 mg, 10 mg, 30 mg, 100 mg, 500 mg
N.B. 10mg strength also used in maternity

Specialist initiation only - consult pain team or palliative care before use.

04.01.02 Diazepam  Tablets: 2mg, 5mg
2mg tablets are the preferred strength in primary care. 10mg diazepam tablets should no longer be used

Oral solution: 2mg/5ml
Injection: 10mg/2ml - for use in epilepsy
Rectal tubes: 2.5mg/1.25ml, 5mg/2.5ml, 10mg/2.5ml
04.08.02 Diazepam  Injection: 5 mg/1 mL
Rectal solution: 2.5 mg, 5 mg, 10 mg
10.02.02 Diazepam 

Tablets: 2 mg, 5 mg
Oral solution (sugar-free available): 2 mg/5 mL

23.01 Diazepam (emulsion) 

Injection: 10 mg/2 mL ampoules


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

06.01.04 Diazoxide  Suspension: 5mg/5ml*
*Hospital use only - for insulin resistance in paediatrics
11.08.02 Diclofenac 

Eye drops: 0.1%
Unit dose eye drops (preservative-free): 0.1%

10.01.01 Diclofenac sodium  Tablets: 25mg, 50mg
10.01.01 Diclofenac Sodium 

Injection: 75 mg/3 ml
To be used in secondary care only

23.01 Dicobalt edetate  

Injection: 300 mg/20 mL ampoules


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

05.03.01 Didanosine Videx®

Chewable tablets: 25mg
E/C capsules: 125mg, 200mg, 250mg, 400mg

08.03.01 Diethylstilbestrol 

Tablets: 1mg

02.01.01 Digoxin  Tablets: 62.5 micrograms, 125 micrograms, 250 micrograms
Liquid: 50 micrograms/1ml
Injection: 500 micrograms/2ml
23.01 Digoxin specific antibody fragments (Digifab®)  

Injection: 40 mg vial


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

04.07.02 Dihydrocodeine 

SR Tablets: 60mg, 90mg, 120mg
SR formulation only to be used on advice of pain specialists

Not recommended for regular use. Codeine is the first line weak opioid.

04.07.02 Dihydrocodeine 

Tablets: 30mg

 

Not recommended for regular use. Codeine is the first line weak opioid.

02.06.02 Diltiazem  Tablets: 60mg
SR preparation (twice daily): 60mg, 90mg, 120mg, 180mg
XL preparation (once daily): 120mg, 180mg, 200mg, 240mg, 300mg, 360mg

Must be prescribed by brand
01.07.04 Diltiazem Cream 2%  Cream: 2%
For use in patients with anal fissures who do not respond to or cannot tolerate topical glyceryl trinitrate. This is an unlicensed product.
08.02.04 Dimethyl fumarate 

Capsules: 120mg, 240mg

07.01.01 Dinoprostone 

Injection: 0.75mg in 0.75ml
Vaginal tablets: 3mg
Vaginal gel: 1mg/2.5ml, 2mg/2.5ml

14.04 Diphtheria vaccines for Children Under 10 years 

Diphtheria, Tetanus, Pertussis (acellular, 3-component), polio,Haemophilus influenzae type b (Hib) and hepatitis B vaccine (DTaP/IPV/Hib/HepB)
Vial with solvent in a pre-filled syringe 0.5 mL (Infanrix hexa®)
May contain traces of formaldehyde, neomycin and polymyxin B


 


Diphtheria, Tetanus, Pertussis (acellular, 3-component) and Poliomyelitis (inactivated) vaccine (DTaP/IPV)
Prefilled syringe: 0.5 mL (Infanrix-IPV®)
May contain traces of formaldehyde, neomycin and polymyxin B


 


Diphtheria (low dose), Tetanus, Pertussis (acellular, 5-component) and Poliomyelitis (inactivated) vaccine (dTaP/IPV)
Prefilled syringe: 0.5 mL (REPEVAX®, Boostrix-IPV®)
REPEVAX® may contain traces of formaldehyde, glutaraldehyde, streptomycin, neomycin, polymyxin B and bovine serum albumin
Boostrix-IPV® may contain traces of neomycin and polymyxin B


 


Diphtheria, Tetanus, Pertussis (acellular, 5-component), Poliomyelitis (inactivated) and Haemophilus influenzae type b vaccine (DTaP/IPV/Hib)
Prefilled syringe: 0.5mL (Pediacel®)

14.04 Diphtheria vaccines for over 10 years and adults 

Diphtheria (low dose), Tetanus and Poliomyelitis (Inactivated) vaccine (Td/IPV)
Prefilled syringe: 0.5 mL (Revaxis®)
May contain traces of streptomycin, neomycin and polymyxin B

02.09 Dipyridamole  SR capsules: 200mg
Sugar-free suspension: 50mg/5ml
14.05.02 Disease-specific immunoglobulins 

Preparations stocked by pharmacy:


Tetanus immunoglobulin (HTIG): 250 units


 


Other immunoglobulins


The following immunoglobulins are kept at the Pharmacy Distribution Centre, Royal Victoria Infirmary, Newcastle upon Tyne, and can be obtained via the Clinical Virology Team at Newcastle Hospitals:



  • Hepatitis B immunoglobulin (HBIG): contact on-call virologist (24/7)

  • Rabies immunoglobulin (HRIG) and also vaccine: contact first on-call for Health Protection at Public Health England NE (24/7)

  • Varicella-zoster immunoglobulin (VZIG): contact virologist (office hours, or 24/7 if close to end of window period - 10 days in pregnancy, 7 days in immunosuppressed)

  • Human Normal Immunoglobulin (HNIG) for HAV and measles post-exposure prophylaxis: contact on-call virologist 24/7


From blood bank


Anti D (Rh0) immunoglobulin

11.03.01 Disodium Edetate 

unlicensed Eye drops: 0.37%

06.06.02 Disodium Pamidronate  IV infusion: 15mg/1mL, 15 mg/5mL, 30 mg/2mL, 30 mg/10mL, 60 mg/4mL, 60 mg/10mL, 90 mg/6mL, 90 mg/10mL
Injection: 15mg, 30mg, 90mg
09.05.01.02 Disodium pamidronate 

Injection: 30mg

02.03.02 Disopyramide  Capsules: 100mg, 150mg
02.03.02 Disopyramide  Injection: 50mg/5ml
04.10.01 Disulfiram  Tablets: 200 mg
02.07.01 Dobutamine  Injection: 250mg/20ml and 250mg/50ml; pre-filled syringe in 5% dextrose
08.01.05 Docetaxel 

Injections: 20mg, 80mg

01.06.02 Docusate Sodium  Capsules: 100mg
Liquid: 12.5mg/5ml*, 50mg/5ml
* for use in paediatrics only
05.03.01 Dolutegravir Tivicay®

Tablets: 10mg, 25mg, 50mg

05.03.01 Dolutegravir, abacavir and lamivudine Triumeq®

Tablets: 50mg/600mg/300mg

01.02 Domperidone  Tablets: 10mg
Liquid: 5mg/5ml
04.06 Domperidone  Tablets: 10 mg
Liquid: 5 mg/5 mL
Suppository: 30 mg
04.11 Donepezil  Tablets: 5 mg, 10 mg
Orodispersible tablets: 5mg, 10mg
02.07.01 Dopamine  Injection: 200mg/5ml ampoule and prefilled syringe in 5% dextrose
02.07.01 Dopexamine 

Injection for infusion: 50mg/5ml (Dopacard)


Used in critical care at City Hospitals Sunderland

03.07 Dornase Alfa Pulmozyme® Vial: 2.5mg (2500 units)/2.5ml

Only to be prescribed by secondary care from April 2016 in line with NHS England Clinical Commissioning Policy
11.06 Dorzolomide 

Eye drops: 2%
Eye drops PF: 2% (Brands include Eydelto PF)
P/F unit dose eye drops: 2%

11.06 Dorzolomide with Timolol 

Eye drops: dorzolamide 2%, timolol 0.5% (Cosopt®) (Eylamdo PF)
Single use (preservative free): dorzolamide 2%, timolol 0.5% (Cosopt®)

04.03.01 Dosulepin  Capsules*: 25mg
Tablets*: 75mg
*For existing patients only - no new patients
03.05.01 Doxapram Dopram® Injection: 100mg/5ml
Infusion: 2mg/1ml in 5% glucose (500ml)
15.01.07 Doxapram 

Injection: 100 mg in 5 mL ampoules
Infusion: 2 mg/ mL, 500 mL intravenous infusion in glucose 5%

02.05.04 Doxazosin  Tablets: 1mg, 2mg and 4mg
N.B. 4mg M/R and 8mg M/R are not included in this formulary - plain tablets are less expensive
07.04.01 Doxazosin 

*Tablets: 1mg, 2mg, 4mg
*Legacy patients only

08.01.02 Doxorubicin Hydrochloride 

Injection: 50mg
- includes use with DC Beads for use in transcatheter arterial chemoembolisation (TACE) therapy in patients with hepatocellular cancer

Pegylated liposomal injection: 20mg & 50mg
-approved for the treatment of recurrent ovarian cancer in line with NICE

05.01.03 Doxycycline  Capsules: 50mg, 100mg
Dispersible tablets: 100mg
05.01.03 Doxycycline  Injection: 100mg
02.03.02 Dronedarone  Tablets: 400mg
03.01.05 Drug Delivery Device Volumatic® Available with or without paediatric mask
03.01.05 Drug Delivery Device AeroChamber Plus® Infant (orange with mask)
Child (yellow with mask)
Adult (blue with or without mask)
06.01.02.03 Dulaglutide  Injection (pre-filled pen): 0.75mg/0.5ml, 1.5mg/0.5ml
04.03.04 Duloxetine  Capsules: 30mg, 60mg
- For use on advice of psychiatrists as a 3rd line antidepressant but only for use in patients who cannot tolerate high dose (>150mg daily) venlafaxine, or patients with hypertension, established CHD or other cardiovascular risk factors which would make the use of high dose venlafaxine undesirable.
04.07.03 Duloxetine  Capsules: 30mg, 60mg
06.01.05 Duloxetine  Capsules: 30mg, 60mg
07.04.02 Duloxetine 

*Capsules: 20mg, 40mg
(*Moderate to severe stress incontinence in combination with supervised pelvic floor excercises only)

06.04.02 Dutasteride  Capsules: 500 micrograms
07.04.01.02 Dutasteride 

Capsules: 500micrograms

09.01.03 Eculizumab 

Solution for infusion: 300mg

02.08.02 Edoxaban 

Tablets: 15mg, 30mg, 60mg

10.02.01 Edrophonium Chloride 

Injection: 10 mg/1 mL
Hospital use only. This is only used as a diagnostic test in some suspected cases of MG. It has a brief effect to improve the symptoms.

05.03.01 Efavirenz Sustiva®

Tablets: 600mg
Capsules: 50mg, 100mg 200mg

07.05.05 Eflornithine  Vaniqa®

Cream: 11.5%

09.01.04 Eltrombopag Revolade®

3rd line for severe, refractory ITP – choice according to patient preference
Tablets: 25mg, 50mg

01.04.02 Eluxadoline Truberzi

Tablets: 75mg, 100mg

05.03.01 Elvitegravir Vitekta

Tablets: 85mg, 150mg

11.04.02 Emedastine 

Eye drops: 0.05%

06.01.02.03 Empagliflozin 

Tablets: 10mg, 25mg

05.03.01 Emtricitabine Emtriva®

Capsules: 200mg
Oral solution: 10mg/ml

05.03.01 Emtricitabine and tenofovir Descovey®

Tablets: 200mg/10mg
Tablets: 200mg/25mg 

05.03.01 Emtricitabine rilpivirine and tenofovir Eviplera®

Tablets: 200mg/25mg/245mg

05.03.01 Emtricitabine, rilpivirine and tenofovir Odefsey®

Tablets: 200mg/25mg/25mg

02.05.05.01 Enalapril   Tablets*: 2.5mg, 5mg, 10mg, 20mg
*For existing patients only, no new patients to be started on enalapril
05.03.01 Enfuvirtide Fuzeon®

Powder and solvent for solution for injection vials: 108mg

02.08.01 Enoxaparin  Injection (pre-filled syringe): 20mg/0.2ml, 40mg/0.4ml, 60mg/0.6ml, 80mg/0.8ml, 100mg/1ml, 300mg/3ml, 120mg/0.8ml, 150mg/1ml
04.09.01 Entacapone  Tablets: 200 mg
05.03.03.01 Entecavir  Tablets: 500 micrograms (white), 1mg (pink)
Oral solution: 250 micrograms/5ml
15.01.02 Entonox® 
08.03.04.02 Enzalutamide 

Capsules: 40mg

02.07.02 Ephedrine 

Injection:30mg/1ml amps
Prefilled syringe: 30mg/10ml


Used in critical care at City Hospitals Sunderland

08.01.02 Epirubicin hydrochloride 

Injections: 50mg
unlicensedunlicensed Injection: 100mg  

02.02.03 Eplerenone  Tablets: 25mg, 50mg
09.01.03 Epoetin alfa Eprex®

Injection (pre-filled syringe): 1000, 2000, 3000, 4000, 5000, 6000, 8000, 10000, 20000, 30000, 40000units

09.01.03 Epoetin beta NeoRecormon®

Injection (pre-filled syringe): 500 units, 2,000 units, 3,000 units, 4,000 units, 5,000 units, 6,000 units, 10,000 units, 20,000 units, 30,000 units

09.01.03 Epoetin Zeta 

Injection (pre-filled syringe): 1000 units, 2000 units, 3000 units, 4000 units, 5000 units, 6000 units, 8000 units, 10000 units, 20000 units, 30000 units, 40000 units

02.08.01 Epoprostenol 

Infusion vial: 500 micrograms

09.06.04 Ergocalciferol 

Injection: 300,000 units/1 mL, 600,000 units/2 mL

07.01.01 Ergometrine 

Injection: 500 micrograms in 1ml

07.01.01 Ergometrine Maleate and Oxytocin Syntometrine®

Injection: ergometrine maleate 500micrograms and oxytocin 5 units

08.01.05 Eribulin Halaven®

Vial: 0.88mg/2ml
Vial: 1.32mg/3ml

08.01.05 Erlotinib Tarceva®

Tablets: 25mg, 100mg & 150mg

05.01.02.02 Ertapenem  Injection: 1g
05.01.05 Erythromycin  Tablets: 250mg, 500mg
Oral suspension (sugar-free available): 125mg/5ml, 250mg/5ml, 500mg/5ml
05.01.05 Erythromycin 

Injection for infusion: 1g vial*


*For use as a prokinetic

02.04 Esmolol  Injection: 100mg/10ml
Infusion: 2.5g/250ml
06.04 Estradiol  Patches: Twice weekly matrix patches releasing approximately 50, 75 & 100 microgram/24 hours
Gel: 0.1% gel (Sandrena®)
Gel: 0.06% gel (Oestrogel®)
07.02.01 Estradiol 

Vaginal tablets: 10 microgram (Oestradiol)


 

06.04 Estradiol (Oestradiol)  Tablets: 1mg & 2mg
08.01.01 Estramustine 

Capsules: 140mg

07.02.01 Estriol 

Cream: 0.01% (Gynest) 80g - preferred choice
Cream: 0.1% (Ovestin)

10.01.03 Etanercept 

Injection (pre-filled syringe) (Enbrel®): 25 mg, 50 mg
Solution for injection (pre-filled syringe, pre-filled pen) (Benepali®): 50mg
Injection (vial) (Enbrel®): 25 mg
Injection (paediatric) (Enbrel®): 10 mg, 25 mg

Note: subcutaneous 1st line with MTX

09.05.01.02 Etelcalcitide 

Vials: 2.5mg in 0.5ml, 5mg in 1ml, 10mg in 1ml

05.01.09 Ethambutol  

Tablets: 100mg, 400mg
Suspension: 400mg/5ml. This is the nationally recommended standard strength.

Standardising strengths of high risk, unlicensed oral liquids formulations for anti-TB medicines.

11.03.01 Ethanol  

unlicensed P/F Eye Drops: 18%

04.08.01 Ethosuximide  Capsules: 250 mg
Liquid: 250 mg/5 mL
15.02 Ethyl Chloride 

Spray: 100 mL

10.01.01 Etodolac  Capsules: 300mg
MR tablets: 600mg
15.01.01 Etomidate Hypnomidate®

Injection: 20 mg/10 mL ampoules
Injection (emulsion): 20 mg/10 mL ampoules (Lipuro®)

07.03.02.02 Etonorgestrel Nexplanon®

Implant: 68mg

08.01.04 Etoposide 

Capsules: 50mg & 100mg
Injections: 100mg in 5ml & 500mg in 25ml

10.01.01 Etoricoxib 

Tablets: 30mg, 60mg, 90mg, 120mg


Indications:
Long-term for ankylosing spondylitis

10.01.04 Etoricoxib 

Tablets: 120 mg

Note: Maximum of 8 days treatment for gout

05.03.01 Etravirine Intelence®

Tablets: 25mg, 100mg, 200mg

08.01.05 Everolimus Votubia®

Capsules: 2.5mg, 5mg, 10mg


-Approved for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in accordnace line with NHS England Commissioning Policy
-a
pproved for the treatment of angiomyolipomas associated with tuberous sclerosis in line with NHS England Commissioning Policy


Tablets: 5mg and 10mg


- Clinical Commissioning Policy: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex
- Approved, in combination with exemestane, for the treatment of advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer in postmenopausal women in accordance with NICE
- Approved for the treatment of advanced breast cancer after endocrine therapy in line with NICE.
-Approved for the treatment of advanced renal cell carcinoma after previous treatment in line with NICE


 

02.12 Evolocumab Repatha®

Solution for injection (pre-filled syringe): 140mg/ml
Solution for injection (pre-filled pen): 140mg/ml

To be used in line with NICE TA394
N.B. Supply currently only available via secondary care. No prescribing in primary care.

07.03.01.05 Evra® 

*Self adhesive patches releasing approximately 20 micrograms ethinylestradiol and 150 micrograms norelgestromin /24hours


 


*For use in a small number of women with gastrointestinal absorption problems or with compliance issues

08.03.04.01 Exemestane 

Tablets: 25mg

06.01.02.03 Exenatide  Injection (250 microgram/1ml pre-filled pens): 5 microgram/dose, 10 microgram/dose

MR Pen: 2mg pen
02.12 Ezetimibe  Tablets: 10mg
10.01.04 Febuxostat 

Tablets: 80 mg, 120 mg

02.06.02 Felodipine  M/R tablets: 2.5mg, 5mg, 10mg
07.03.01 Femodene® 

Tablets: Ethinylestradiol 30mcg / gestodene 75 mcg

07.03.01 Femodene® ED 

Tablets: Ethinylestradiol 30mcg / gestodene 75 mcg

07.03.01.04 Femodette® 

Tablets: Ethinylestradiol 20mcg / gestodene 75 mcg

07.03.02 Femulen® 

Tablets: 500microgram (Ethynodiol)

02.12 Fenofibrate  Capsules: 67mg, 200mg, 267mg
Tablets: 160mg
04.07.02 Fentanyl  Transdermal patches: 12, 25, 50, 75 and 100 micrograms/hour
15.01.04.03 Fentanyl 

Injection: 100 micrograms/2 mL, 500 micrograms/10 mL ampoules
With levobupivacaine
unlicensedunlicensed Levobupivacaine 0.1% with fentanyl 2 micrograms, 500 mL infusion bag

04.07.02 Fentanyl Lozenges 

Lozenges*: 200mcg, 400mcg

*Existing chronic or palliative care patients only

04.07.02 Fentanyl Nasal Spray PecFent®

Nasal spray (PecFent): 100 micrograms/metered spray, 400 micrograms/metered spray

N.B. For short term use in palliative care only.

Specialist initiation only - consult pain team or palliative care before use.

04.07.02 Fentanyl sublingual tablets Abstral®

Sublingual tablets (Abstral): 100 micrograms, 200 micrograms, 300 micrograms, 400 micrograms, 600 micrograms, 800 micrograms

N.B. For short term use in palliative care only.

Specialist initiation only - consult pain team or palliative care before use.

09.01.01.02 Ferric Carboxymaltose Ferinject®

Solution for injection: 100mg/2ml, 500mg/10ml

09.01.01.01 Ferric maltol Feraccru

Capsules: 30mg

09.01.01.01 Ferrous Fumarate Fersaday®

Tablets: 210mg (68mg iron)
Syrup 140mg/5ml

09.01.01.01 Ferrous Sulphate 

Tablets: 200mg (65mg elemental iron)

07.04.02 Fesoterodine 

MR tablets: 4mg, 8mg

03.04.01 Fexofenadine  Tablets: 120mg, 180mg

Only after trialling other options
05.01.07 Fidaxomicin 

Tablets: 200mg

09.01.06 Filgrastim Neupogen®

(1st line) Injection (Nivestim® - biosimilar): 12 million units (120 micrograms)/0.2mL, 30 million units (300 micrograms)/0.5mL, 48 million units (480 micrograms)/0.5mL


Injection (Neupogen®): 30 million units (300 micrograms)/mL


Injection (pre-filled pen, Neupogen® Singleject®): 30 million units (300 micrograms)/0.5mL, 48 million units (480 micrograms)/0.5 mL

06.04 Finasteride  Tablets: 5mg
06.04.02 Finasteride  Tablets: 5mg
07.04.01.02 Finasteride 

Tablets: 5mg

07.05.05 Finasteride 

Tablets: 1mg

08.02.04 Fingolimod 

Capsules: 500microgram - - approved for the treatment of highly active relapsing–remitting multiple sclerosis in line with NICE - approved for patients who have progressed on glatiramer acetate and for those patients who are at high risk of progressive multifocal leukoencephalopathy (PML) in line withNHS EnglandClinical Commissioning Policy

02.03.02 Flecainide  Tablets: 50mg, 100mg
02.03.02 Flecainide  Injection: 150ml/15ml
05.01.01.02 Flucloxacillin  Capsules: 250mg, 500mg
Oral solution (sugar-free available): 125mg/5ml, 250mg/5ml
05.01.01.02 Flucloxacillin  Injection: 250mg, 500mg, 1g
05.02 Fluconazole  Capsules: 50mg, 150mg, 200mg
Oral solution: 50mg/5ml, 200mg/5ml
05.02 Fluconazole  IV infusion: 50mg/25ml, 200mg/100ml
12.03.02 Fluconazole 

Capsules: 50 mg, 150 mg, 200 mg Oral solution: 50 mg/5mL, 200 mg/5mL

08.01.03 Fludarabine 

Tablets: 10mg
Injection: 50mg

06.03.01 Fludrocortisone  Tablets: 100 micrograms
15.01.07 Flumazenil Anexate®

Injection (amps): 500 micrograms/5 mL

23.01 Flumazenil 

Injection: 500 micrograms/5 mL ampoules


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

12.01.01 Flumetasone with Clioquinol  Locorten-Vioform®

Ear drops: flumetasone (as pivalate) 0.02% and clioquinol 1% ear drops

11.04.01 Fluocinolone intravitreal implant 

Intravitreal implant: 190 micrograms

11.08.02 Fluorescein Sodium 

Minims® (preservative free): 1%, 2%

11.04.01 Fluorometholone FML®

Eye drops: 0.1% with polyvinyl alcohol 1.4%

08.01.03 Fluorouracil 

Injections: 2.5g in 50ml & 2.5g in 100ml
unlicensedunlicensed Subconjunctival injection: 10mg in 0.4ml
(FOLFIRINOX is approved for the management of selected patients with inoperable pancreatic cancer in patients with performance status 0-1).

04.03.03 Fluoxetine  Fluoxetine
Capsules: 20 mg
Dispersible tablets: 20mg - 1st choice in patients unable to use the capsules
Liquid: 20 mg/5 mL
04.02.01 Flupentixol  Tablets: 500 microgram, 1mg, 3mg
04.02.02 Flupentixol Decanoate  Injection: 20mg/1ml, 40mg/2ml, 50mg/0.5ml, 100mg/1ml, 200mg/1ml
10.01.01 Flurbiprofen  Tablets: 50mg, 100mg
For use in Sunderland eye infirmary only
08.03.04.02 Flutamide 

Tablets:  250mg

12.02.01 Fluticasone furoate 

Nasal spray: 27.5 micrograms/spray

03.02 Fluticasone furoate & vilanterol Relvar Ellipta®

Revlar Ellipta Dry Powder Inhaler

92/22: Fluticasone 92mcg & Vilanterol 22mcg per dose inhaler

184/22: Fluticsone184 mcg & Vilanterol 22mcg per dose inhaler

 

Formulary approved for use in the treatment of ASTHMA only.

03.01.04 Fluticasone Furoate/Umeclidinium bromide/Vilanterol 92/55/22mcg Trelegy Ellipta®

Trelegy Ellipta ® 92/55/22 mcg Dry Powder Inhaler

Triple therapy ICS/LAMA/LABA inhaler for COPD.

Formulary approved for use in COPD only.

 

03.02 Fluticasone propionate  Alternative corticosteroid

CFC-free MDI: 50mcg, 125mcg, 250mcg per puff
12.02.01 Fluticasone Propionate 

Nasal spray: 50 micrograms/spray
Nasal drops: 400 micrograms/unit dose

03.02 Fluticasone propionate and formoterol Flutiform®

Flutiform® MDI


50/5mcg per puff
125/5mcg per puff
250/10mcg per puff

03.02 Fluticasone propionate and salmeterol Seretide®

Seretide Evohaler ® - For the treatment of asthma only
50/25 mcg, 125/25mcg and 250/25mcg

Seretide Accuhaler ®
100/50mcg (for paediatric use only)
250/50mcg (for use in asthma only)
500/50mcg (for use in asthma only)

Not a first line choice on the Sunderland COPD guideline for new patients. Can be continued in existing patients if guideline options are unsuitable.

09.01.02 Folic Acid 

Tablets: 400micrograms, 5mg
Oral solution: 2.5mg/5ml (sugar-free available)
unlicensed unlicensed Injection: 15mg/1ml

23.01 Folinic acid (calcium folinate) 

Injection: 30 mg/10 mL, 300 mg/30 mL ampoules


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

07.05.01.02 Follitrophin alfa Gonal F®

Prefilled pens: 300 units

23.01 Fomepizole (4-methylpyrazole)  

Injection: 100 mg/20 mL, 1.5 g/1.5 mL ampoules


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

02.08.01 Fondaparinux  Injection (pre-filled syringe): 2.5mg/0.5ml
03.01.01.01 Formoterol   Breath actuated DPI: 6mcg/puff, 12mcg/puff
05.03.01 Fosamprenavir Telzir®

Tablets: 700mg
Oral suspension: 50mg/ml

05.01.07 Fosfomycin Monuril Sachets: 3g
02.02.02 Furosemide  Tablets: 20mg, 40mg, 500mg
Liquid: 1mg/1ml, 20mg/5ml, 40mg/5ml
Injection: 20mg/2ml, 50mg/5ml, 250mg/25ml
11.03.01 Fusidic Acid Fucithalmic®

Eye drops in gel basis (liquifies on contact with eye: 1%)

04.07.03 Gabapentin  Capsules: 100mg, 300mg, 400mg
Tablets: 600mg, 800mg
Oral solution: 250mg/5ml
04.08.01 Gabapentin  Capsules: 100 mg, 300 mg, 400 mg
Tablets: 600 mg, 800 mg
Oral solution: 50mg/mL
06.01.05 Gabapentin  See section 4.8 for preparations
17 Gadobutrol Gadovist® 1mmol/mL as 7.5 mL
17 Gadoxetate Primovist®

0.25 mmol/mL as a 10 mL pre-filled syringe

04.11 Galantamine 

Tablets: 8 mg, 12 mg
MR capsules: 8mg, 16mg, 24mg
Oral solution (sugar-free): 4 mg/1 mL
(preferred brand in primary care is Luventa XL)

05.03.02.02 Ganciclovir  IV infusion: 500mg
11.03.03 Ganciclovir 

Eye gel: 0.15%

17 Gastrografin® 

100 mL Contains sodium amidotrizoate, meglumine amidotrizoate

01.01.02 Gaviscon Advance  Sugar-free suspension (sodium alginate 500 mg, potassium bicarbonate 100 mg/5 mL. Contains 2.3 mmol Na+/5mL)

Tablets (sodium alginate 500 mg, potassium bicarbonate 100 mg. Contains 2.25 mmol Na+/tablet)
01.01.02 Gaviscon Infant  Oral powder, sugar-free
07.03.01.04 Gedarel 20/150 ® 

Tablets: Ethinylestradiol 20mcg / desogestrel 150mcg

07.03.01 Gedarel 30/150 ® 

Tablets: Ethinylestradiol 30mcg / desogestrel 150mcg

08.01.05 Gefitinib Iressa®

Tablets: 250mg

09.02.02.02 Gelatin Gelofusine®

Isoplex Intravenous Infusion: 500 mL
Volplex Intravenous Infusion: 500 mL
Gelofusine Intravenous Infusion: 500 mL

12.03.01 Gelclair® 

Oral gel sachets: 15 mL

08.01.03 Gemcitabine 

Injection: 200mg, 1g, 2g

07.01.01 Gemeprost 

Pessaries: 1mg

05.01.04 Gentamicin  Injection: 20mg/2ml, 40mg/1ml, 80mg/2ml
11.03.01 Gentamicin Genticin®

Eye drops: 0.3%

11.03.01 Gentamicin 

unlicensed unlicensed Eye drops: 1.5%
unlicensed unlicensed Eye drops (preservative free)1.5%

12.01.01 Gentamicin  

Eye/ear drops: 0.3%

12.01.01 Gentamicin with hydrocortisone 

Ear drops: hydrocortisone 1% with gentamicin 0.3% (as sulfate) (Gentisone HC®)

12.03.05 Glandosane® 

Spray

08.02.04 Glatiramer Acetate 

Prefilled syringe injection: 20mg

05.03.03.02 Glencaprevir-pibrentasvir Maviret

Tablets: 300mg/120mg

06.01.02.01 Gliclazide  Tablets: 40mg, 80mg
MR tablets: 30mg

N.B. the MR tablets should not be used 1st line
06.01.02.01 Glimepiride  Tablets: 1 mg, 2 mg, 3 mg, 4 mg
06.01.04 Glucagon  Injection: 1mg
23.01 Glucagon  

Injection: 1 mg syringe


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

08.01 Glucarpidase 

unlicensedunlicensed Vials: 1000units -approved for the urgent treatment of methotrexate-induced renal dysfunction (subject to NHS England funding)

06.01.04 GlucoGel®  Glucose 40% (3 x 25g tubes), each tube is equivalent to 10g carbohydrate

09.02.02.01 Glucose Intravenous 

IV infusion: 5% 100ml, 250ml, 500ml & 1000ml
IV infusion: 10% 500ml & 1000ml
IV infusion: 20% 500ml
IV infusion: 40% 500ml
IV infusion: 50% 500ml
Injection: 50% 50ml

01.06.02 Glycerol (Glycerin)  Suppositories: 1g*, 2g*, 4g
* For use in paediatrics only
02.06.01 Glyceryl Trinitrate  Spray: 400 micrograms/spray
02.06.01 Glyceryl Trinitrate 

Ampoules: 5mg/5ml, 10mg/10ml, 50mg/50ml
Injection for infusion: 25 mg/5 mL amps
Patches*: 5mg, 10mg
*Hospital use only e.g. vascular access, tendonitis

07.01.04 Glyceryl trinitrate 

Spray: 400micrograms/dose

23.01 Glyceryl trinitrate  

Injection: 10 mg/10 mL ampoules


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

01.07.04 Glyceryl Trinitrate 0.4% Rectogesic® Ointment: 0.4% (Rectogesic®)
07.04.04 Glycine 

1.5% solutions (up to 3 litres)

03.01.04 Glycopyrrolate/ indacaterol inhaler Ultibro Breezhaler®

Ultibro breezhaler: device and capsules containing powder for inhalation

Each dose delivers indacaterol 85 micrograms/glycopyrronium 43 micrograms

03.01.02 Glycopyrronium Seebri breezhaler®

Seebri Breezhaler® breath actuated DPI: 50mcg/puff (equivalent to 44mcg glycopyrronium)

 

This is one of the Sunderland COPD guidelines preferred options for LAMA.

15.01.03 Glycopyrronium 

Injection: 200 micrograms/1 mL, 600 micrograms/3 mL ampoules


With neostigmine
Injection: glycopyrronium 500 microgram & neostigmine 2.5mg in 1ml ampoules

04.06 Glycopyrronium 2mg/5ml SF suspension 

Suspension*: 2mg/5ml
*Only for use in patients with excessive secretions

01.05.03 Golimumab 
10.01.03 Golimumab  Injection (pre-filled pen, pre-filled syringe): 50 mg

Note: Option if anti-TNF withdrawn during 1st 6 months due to adverse effects
06.05.01 Gonadorelin  Injection: 100 micrograms
06.04 Goserelin  Injection: 3.6mg
08.03.04.02 Goserelin 


Green+ Traffic Light OR Amber Traffic Light


Dependent on patient disease state


Implants: 3.6mg & 10.8mg

06.07.02 Goserelin (as acetate)  Implant: 3.6mg, 10.8mg
03.04.02 Grass pollen extract Grazax®

Oral lyophilisate containing grass pollen extract 75,000 units

04.04 Guanfacine Intuniv® Prolonged release tablets: 1mg, 2mg, 3mg, 4mg
01.03.05 H Pylori eradication  First line: Amoxicillin (1g BD) + Clarithromycin (500mg BD) + Omeprazole (20mg BD)
Second line: Amoxicillin (1g BD) + Metronidazole (400mg BD) + Omeprazole (20mg BD)
Penicillin allergic - first line: Clarithromycin (500mg BD) + Metronidazole (400mg BD) + Omeprazole (20mg BD)

Biopsy for culture and sensitivity after first line treatment failure
14.04 Haemophilus influenzae type B 

Use combined vaccines

04.02.01 Haloperidol  Capsules: 500 microgram
Tablets: 1.5mg, 5mg, 10mg
Oral liquid: 1mg/1ml, 2mg/1ml
Injection: 5mg/1ml, 20mg/2ml
04.02.02 Haloperidol decanoate  Injection: 50mg/1ml, 100mg/1ml
09.02.02.01 Hartmann's solution (compound sodium lactate) 

Infusion: 500ml, 1000ml

15.01.02 Heliox 21  
02.08.01 Heparin 

unlicensed unlicensed Heparin 500 Units in sodium chloride 0.9% 500 mL infusion bag

02.08.01 Heparin  Injection (ampoule); 1,000 units/1ml, 5,000 units/5ml, 10,000 units/10ml, 20,000 units/20ml
02.08.01 Heparin (for flushing)  Injection: 50 units/5ml, 200 units/2ml
14.04 Hepatitis A vaccine 

Hepatitis A (inactivated, adsorbed) vaccine (HAV)
Prefilled syringe: 1 mL (Havrix Monodose®, VAQTA® Adult)
Prefilled syringe: 0.5 mL (AVAXIM®)
Prefilled syringe: 0.5 mL (Havrix Junior Monodose®, VAQTA® Paediatric)
May contain traces of neomycin
VAQTA® Adult and Paediatric may contain traces of formaldehyde, glutaraldehyde, streptomycin, neomycin, polymyxin B and bovine serum albumin


 


With typhoid vaccine


Hepatitis A (inactivated) and Typhoid Polysaccharide vaccine (adsorbed).
Prefilled syringe: 1 mL (Hepatyrix®)


 


Hepatitis A (inactivated, adsorbed) and Typhoid polysaccharide vaccine
Prefilled syringe: 1 mL (ViATIM®)
May contain traces of neomycin

14.04 Hepatitis A vaccine with Hepatitis B vaccine  Twinrix®

Hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed).
Prefilled syringe: 1 mL (Twinrix® Adult); 0.5 mL (Twinrix® Paediatric)
May contain traces of neomycin
Prefilled syringe: 1 mL (Ambirix®)

14.04 Hepatitis B vaccine 

Prefilled syringe: 10 micrograms, 1 mL; 5 micrograms, 0.5 mL (HBVAXPRO®)
Vial: 40 micrograms, 1 mL, (HBVAXPRO®)
May contain traces of formaldehyde and potassium thiocyanate
Prefilled syringe: 10 micrograms, 0.5 mL; 20 micrograms, 1 mL, (Engerix®)
Prefilled syringe: 20 micrograms, 0.5 mL, (Fendrix®)

11.03.01 Hexamidine 

unlicensed unlicensed Eye drops: 0.1%

09.02.02.02 Human Albumin Solution 

Solution 4.5%: 50ml, 100ml, 500ml
Solution 20%: 50ml, 100ml


(Obtain via blood bank)

14.04 Human papilloma virus vaccine 

Human Papillomavirus 9-valent (Recombinant, adsorbed) vaccine (HPV).
Prefilled syringe: 0.5 mL (Gardasil 9®)

10.03.01 Hyaluronidase  Ampoules: 1,500units
02.05.01 Hydralazine  Tablets: 25mg, 50mg
02.05.01 Hydralazine  Ampoules: 20mg
01.05 Hydrocortisone  Injection: 100mg
Suspension: 1mg/1ml (unlicensed)

Both for hospital use only
01.05.02 Hydrocortisone Colifoam® Foam: 10% (Colifoam®)
06.03.01 Hydrocortisone  Tablets: 10mg, 20mg
06.03.02 Hydrocortisone 

MR tablets: 5mg, 20mg

06.03.02 Hydrocortisone 

Injection (as sodium succinate): 100mg
Injection (as sodium phosphate) amps: 100mg/1ml*

 

*Used for home self-administration in an emergency

06.03.02 Hydrocortisone  Tablets: 10mg, 20mg
12.03.01 Hydrocortisone 

Mucoadhesive buccal tablets: 2.5mg

10.01.02.02 Hydrocortisone acetate Hydrocortistab® Injection: 25mg/1ml (Hydrocortistab)
12.03.04 Hydrogen Peroxide 

Mouthwash: 1.5%, 6% (BP)

04.07.02 Hydromorphone 

IR capsules 1.3 mg, 2.6 mg
SR capsules : 2 mg, 4 mg, 8 mg, 16 mg, 24 mg

Specialist initiation only - consult pain team or palliative care before use.

04.07.02 Hydromorphone  Ampoules*: 10mg/ml

*For palliative care use only
09.01.02 Hydroxocobalamin 

Injection: 1mg/1ml

23.01 Hydroxocobalamin 

Injection: 5000 mg vial (Cyanokit®)


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

08.01.05 Hydroxycarbamide 

Capsules: 500mg
unlicensedunlicensed Suspension: 500mg in 5ml

10.01.03 Hydroxychloroquine sulfate  Tablets: 200 mg
03.04.01 Hydroxyzine  Tablets: 10mg, 25mg
Syrup: 10mg/5ml
01.02 Hyoscine Butylbromide Buscopan® Tablets: 10mg
Injection: 20mg/1ml
04.06 Hyoscine Hydrobromide  Tablets: 300mcg
Transdermal patch: 1mg/72hrs
04.06 Hyoscine Hydrobromide  Tablets: 150mcg*
Ampoules: 400mcg/1ml**
*For paediatric use only
**For palliative care use only
15.01.03 Hyoscine Hydrobromide 

Injection (amps): 400 micrograms/1 mL

11.08.01 Hypromellose 

Eye drops: 0.3%, 0.5%, 1%
Eye drops (preservative-free): 0.3%
unlicensed unlicensed Eye drops (preservative-free): 0.5%, 1%, 2%

06.06.02 Ibandronic Acid  Tablets: 50mg

Pre-filled syringe*: 3mg/3mL

*Only for use where oral bisphosphonates are not appropriate (not tolerated, contra-indicated because of upper gastro-intestinal problems or insufficiently effective).
08.01.05 Ibrutinib Imbruvica®

Capsules: 140mg

04.07.04.01 Ibuprofen  Tablets: 200 mg, 400 mg
Suspension: 100 mg/5 mL
10.01.01 Ibuprofen  Tablets: 200mg, 400mg, 600mg
Suspension (sugar-free available): 100mg/5mL
10.03.02 Ibuprofen  Gel: 5%, 10%
03.04.03 Icatibant Firazyr® Pre-filled syringe: 30mg/3ml (Firazyr®)
Symptomatic treatment of acute episodes of hereditary angioedema (HAE)
12.01.01 Ichthammol glycerine 

Solution

08.01.02 Idarubicin Hydrochloride 

Capsules: 5mg & 10mg
Injection: 10mg

02.08 Idarucizumab Praxbind® 2.5g/50ml solution for injection/infusion

Limited to haematology use and kept under the control of haematology (location = ED)
08.01.05 Idelalisib 

Film coated tablets: 100mg, 150mg

08.01.01 Ifosfamide 

Injection: 2g

02.05.01 Iloprost injection  

Injection for infusion 50micrograms/0.5ml amps


Used in critical care at City Hospitals Sunderland

08.01.05 Imatinib 

Capsules: 100mg & 400mg

04.03.01 Imipramine  Tablets: 10 mg, 25 mg
Syrup: 25 mg/5 mL

03.01.01.01 Indacaterol  Breezhaler® breath actuated DPI: 150mcg, 300mcg
02.02.01 Indapamide  Tablets: 2.5mg
MR Tablets: 1.5mg
05.03.01 Indinavir Crixivan®

Capsules: 200mg

10.01.01 Indometacin  Capsules: 25 mg, 50 mg
SR Capsules: 75 mg
Suppositories: 100 mg
01.05.03 Infliximab See 10.01.03 for preparations
10.01.03 Infliximab  Solution for infusion: 100mg

Note: Intravenous 2nd line with MTX
14.04 Influenza vaccine  

Public Health England (PHE) information for vaccine ordering for 2018-19 influenza season can be found here: https://www.england.nhs.uk/wp-content/uploads/2018/02/vaccine-ordering-18-19-influenza-season-gp-pharm.pdf


Inactivated influenza vaccine (split virion) BP


Adjuvanted trivalent influenza vaccine (aTIV) for 65 years and over (Fluad®)


Quadrivalent influenza vaccine (QIV) for at risk adults under 65 years of age (including pregnant women and health care workers).


For the children’s vaccination programme


Influenza vaccine (live attenuated, nasal)
Nasal applicator: 0.2 mL (Fluenz Tetra®)

06.01.01.01 Insulin - Actrapid 100 units/ml 

Vial: 10ml

Hospital note - Humulin S® will be listed on EP to allow patients to use own supplies. Message “This is not available – use alternative” Patients who do not have their own supply can be given Actrapid® vials and syringes in the short term.

06.01.01.01 Insulin - Humulin S 100 units/ml 

Cartridge: 3ml – for Autopen® Classic or HumaPen®

Vial: 10ml

06.01.01.01 Insulin - Insuman Rapid 100 units/ml 

Cartridge: 3ml – for ClikSTAR® and Autopen® 24

Hospital note - Fast acting soluble human insulin – NOT a rapid acting insulin analogue. NOT SUITABLE FOR IV INFUSION

06.01.01.01 Insulin Aspart - NovoRapid 100 units/ml 

Cartridge:3ml for Novopen /Novopen penmate® and 1.6ml PumpCart®

Prefilled pen:3ml FlexPen®,3mlFlexTouch®

Vial: 10ml


Hospital note – preloaded pen not stocked but available on request. Minimal stock of vials.

06.01.01.02 Insulin degludec - Tresiba 100 units/ml  

ONLY THE 100 UNITS/ML STRENGTH IS ON THE FORMULARY.

THE 200 UNITS/ML STRENGTH MUST NOT BE PRESCRIBED IN PRIMARY CARE.


Cartridge: 3ml

Prefilled pen: 3ml FlexTouch

Evaluation of response after 3 months is required. If there has been no significant improvement in the key parameter after 3 months then insulin degludec should be stopped.

06.01.01.02 Insulin Detemir - Levemir 100units/ml 

Cartridge: 3ml for NovoPen® Novopen PenMate®

Prefilled pen:3ml Flexpen® and 3ml Levemir Innolet®

Vial: 10ml

Hospital note – minimal stock of vials held.
Levemir InnoLet Pen – not stocked but available on request.

06.01.01.02 Insulin Glargine - Lantus 100 units/ml 

Cartridge: 3ml for ClikSTAR® or Autopen® 24

Prefilled pen: 3ml SoloStar®

Vial: 10ml

Hospital note – minimal stock of vials held

06.01.01.02 Insulin Glargine - Toujeo 300 units/ml 

**HIGH STRENGTH INSULIN 300 units/ml**

For specialist initiation only - can be continued in primary care. See information leaflet link below.

 

Solostar prefilled pen: 300units/ml 

06.01.01.01 Insulin Glulisine - Apidra 100 units/ml 

Cartridge: 3ml – for ClikSTAR® and Autopen® 24

Prefilled pen:3ml SoloStar®

Vial: 10ml

06.01.01.01 Insulin Lispro - Humalog 100 units/ml 

note ONLY THE 100 UNITS/ML STRENGTH IS ON THE FORMULARY.

THE 200 UNITS/ML STRENGTH IS NOT TO BE PRESCRIBED IN PRIMARY CARE.

Cartridge:3ml for Autopen® Classic or HumaPen® Savvio

Prefilled pen:3ml Kwikpen®

Vial: 10ml

Hospital note – minimal stock of vials

08.02.04 Interferon alfa-2b 

Multidose pen injections: 10 mega units, 30 mega units

08.02.04 Interferon beta-1a 

Prefilled pen (Avonex): 30 micrograms (6 million units)
Prefilled pen (Rebif): 22 microgram (6 million units) & 44 microgram (12 million units)
Cartridge for use in rebismart device: 22 microgram per 0.5ml and 44 microgram per 0.5ml
Prefilled pen: 44 microgram per 0.5ml (Rebidose)
-approved for use when the cartridges and prefilled syringes are unsuitable.

08.02.04 Interferon beta-1b 

Vials for preparing 750 microgram in 3ml injection (Betaferon)
Vials for preparing 250 microgram in 1ml injection (Extavia)

23.01 Intralipid® 

Injection: 20% infusion 500 mL


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

06.02.02 Iodine Lugol’s Iodine® Total iodine 130mg/1 mL
17 Iohexol Omnipaque®

140 mg/mL as 50ml, 200ml
300mg/ml as 50ml, 75ml, 100ml, 200ml
350mg/ml as 50ml, 100ml, 500ml

17 Iopamidol Gastromiro®

61.24% as 100ml

08.01.05 Ipilimumab 

Vial for preparing IV infusion: 50mg

03.01.02 Ipratropium 

Inhaler (MDI): 20mcg/puff
Nebules: 250mcg/1ml, 500mcg/2ml

It is recommended that nebulised ipratropium should be administered via a mouthpiece and NOT a facial mask due to the risk or precipitating glaucoma.

20mcg/puff inhaler is an alternative for chronic asthma.

12.02.02 Ipratropium Bromide 

Nasal spray: 21 micrograms/spray

02.05.05.02 Irbesartan  Tablets: 75mg, 150mg, 300mg
08.01.05 Irinotecan 

Injection: 40mg in 2ml & 100mg in 5ml

09.01.01.02 Iron Isomaltose 1000 Diafer

Solution for injection: 50mg/ml

09.01.01.02 Iron Isomaltoside 1000 Monofer®

Solution for injection: 100mg/1ml (1ml,5ml, 10ml vials)

15.01.02 Isoflurane 

250ml

05.01.09 Isoniazid 

Tablets: 50mg, 100mg

Liquid 50mg in 5ml . This is the nationally recommended standard strength.

Standardising strengths of high risk, unlicensed oral liquids formulations for anti-TB medicines.

 

05.01.09 Isoniazid  Injection: 50mg/2ml
06.01.01.02 Isophane Insulin - Insulatard 100 units/ml 

Cartridge: 3ml for NovoPen® Novopen penmate

Prefilled pen: 3ml Innolet®

Vial 10ml

Hospital notes - Humulin I® will remain on EP to allow patients to use own supplies. Message states : This is not available – use alternative.
Give patients who do not have own supply Human Insulatard® using vials and syringes as a temporary measure. 3ml pen not stocked but available on request.

02.07.01 Isoprenaline 

Injection for infusion:2.25mg/2ml vial


Used in critical care at City Hospitals Sunderland

02.06.01 Isosorbide Dinitrate 

Infusion: 25mg/50ml (0.05%), 50mg/50ml (0.1%)
Amps: 10 mg/10 mL (0.1%) 

23.01 Isosorbide dinitrate 

Injection: 0.05% (25 mg/50 mL) vial
Injection: 0.1% (10 mg/10 mL) vial


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

02.06.01 Isosorbide Mononitrate  Tablets: 10mg, 20mg, 40mg
SR tablets: 60mg
SR tablets are only to be used when the plain tablets are unsuitable
01.06.01 Ispaghula Husk  3.5g/sachet
05.02 Itraconazole  Capsules: 100mg
Oral solution: 50mg/5ml
02.06.03 Ivabradine  Tablets: 5mg, 7.5mg
08.01.05 Ixazomib Ninlaro®

Capsules: 4mg

04.07.02 Ketamine  Injection: 10 mg/1 mL, 50 mg/1 mL, 100 mg/1 mL
Oral solution: 50mg/5mL
15.01.01 Ketamine injection Ketalar®

Injection (vials): 50 mg/2 mL, 200 mg/20 mL, 500 mg/10 mL, 1000 mg/10 mL

06.07 Ketoconazole Ketoconazole HRA Tablets: 200mg

Indication: Cushing's Syndrome
11.08.02 Ketorolac 

Eye drops: 0.5%

15.01.04.02 Ketorolac 

Injection (amps): 30 mg/1 mL
For Hospice use only

01.06.05 Klean-Prep®  Oral powder (sachets)
02.04 Labetalol  Tablets: 50mg, 100mg, 200mg, 400mg
02.04 Labetalol  Injection: 100mg/20ml
04.08.01 Lacosamide   Tablets: 50 mg, 100 mg, 150 mg, 200 mg
Syrup (sugar-free): 50 mg/5 mL
01.06.04 Lactulose  Liquid
(Not recommended for first line use in primary care)
05.03.01 Lamivudine Epivir®, Zeffix®

Tablets: 100mg, 150mg, 300mg (brands include Epivir®, Zeffix®)
Oral solution: 50mg/5ml (Epivir®)

04.08.01 Lamotrigine  Tablets: 25 mg, 50 mg, 100 mg, 200 mg
Dispersible Tablets: 2 mg, 5 mg, 25 mg, 100 mg
08.03.04.03 Lanreotide 

Long acting Injection: 30mg
Autogel injections: 60mg, 90mg & 120mg

 

Green Plus for palliative care indications (leaflet in development)

08.03.04.03 Lanreotide 

Long acting Injection: 30mg
Autogel injections: 60mg, 90mg & 120mg

RED for acromegaly, neuroendocrine tumour and carcinoid

01.03.05 Lansoprazole  Capsules: 15mg, 30mg
Orodispersible tablets: 15mg, 30mg (with SALT input documented or pending)
09.05.02.02 Lanthanum Fosrenol ®

Tablets: 500 mg, 750 mg, 1 g (as carbonate hydrate)
Powder: 750 mg, 1 g

11.06 Latanoprost 

Eye drops: 50 micrograms/1 mL
Unit dose eye drops (preservative-free): 50 micrograms/1 mL

11.06 Latanoprost with Timolol 

Eye drops: latanoprost 50 micrograms/1 mL, timolol 5 mg/1 mL (Xalacom®)

20 Lecicarbon A  Suppository: Sodium hydrogen carbonate 0.500g, sodium dihydrogen phosphate 0.680g
05.03.03.02 Ledipasvir and Sofosbuvir Harvoni® Tablets: 400mg/90mg
10.01.03 Leflunomide  Tablets: 10 mg, 20 mg
08.02.04 Lenalidomide 

Capsules: 5mg, 10mg, 15mg, & 25mg

09.01.06 Lenograstim Granocyte®

(1st line for stem cell harvesting only)


Injection: 13.4 million-unit (105 micrograms), 33.6 million-unit (263 micrograms)

08.01.05 Lenvatinib Lenvima®

Capsules: 4mg and 10mg

02.06.02 Lercanidipine  Tablets: 10mg, 20mg
08.03.04.01 Letrozole 

Tablets: 2.5mg

06.04 Leuprorelin  Injection: 11.25mg
08.03.04.02 Leuprorelin Acetate 


Green+ Traffic Light OR Amber Traffic Light


Dependent on patient disease state


 


Prefilled syringes: 3.75mg, 11.25mg

07.03.01 Levest® 

Tablets: Ethinylestradiol 30micrograms/ norgestimate 150 micrograms

04.08.01 Levetiracetam  Tablets: 250 mg, 500 mg, 750 mg, 1 g
Oral solution: 100 mg/1 mL
Granules: 250 mg/sachet, 500 mg/sachet, 1 g/sachet

04.08.01 Levetiracetam  Vials: 500mg/5ml*
*Hospital use only

11.06 Levobunolol 

Eye drops: 0.5%
Unit dose eye drops: 0.5%

15.02 Levobupivacaine Chirocaine®

Injection (amps): 25 mg/10 mL, 50 mg/10 mL, 75 mg/10 mL 

05.01.12 Levofloxacin 

Tablets: 500mg (12 week prophylactic course in patients with myeloma)

11.03.01 Levofloxacin 

Eye drops: 0.5%
Unit dose eye drops: 0.5%

04.02.01 Levomepromazine  Tablets: 25mg
Injection: 25mg/1ml - for use in palliative care
04.02.01 Levomepromazine  Tablets: 6mg
07.03.05 Levonogrestrel 

Tablets: 1500 micrograms

As Upostelle® or Levonelle® - Upostelle® to be used in primary care

07.03.02.03 Levonorgestrel Mirena®

T-shaped intra-uterine system: 52mg


 


- For idiopathic menorrhagia. Especially in women requiring (reversible) contraception. Also used for protection with endometrial hyperplasia during oestrogen replacement therapy. Lasts for up to 5 years - for use in accordance with agreed guidelines.

07.03.02.03 Levonorgestrel Jaydess®

T-shaped intra-uterine progestogen only system: 13.5mg

 

Second line option when other methods are rejected or not appropriate

06.02.01 Levothyroxine  Tablets: 25 micrograms, 50 micrograms, 100 micrograms
Oral solutions are available
01.07.01 Lidocaine  Gel: 1%, 2%
Ointment: 5%
Prolonged use of lidocaine (more than 2 weeks) should be avoided. Can cause sensitivity reactions.
02.03.02 Lidocaine  Infusion: 0.2% (2 mg/1 mL) in dextrose 5%, 500 mL
02.03.02 Lidocaine  Injection: 1% (10 mg/1 mL), 2% (20 mg/1 mL)
Hospital use only
04.07.03 Lidocaine Versatis® Plasters: 5% (700mg/medicated plaster)
12.03.01 Lidocaine  

unlicensedunlicensed Lollies: 100mg

12.03.01 Lidocaine  

Spray: 10%

15.02 Lidocaine  topical

Gel: 2%, 10 g
Ointment: 5%, 15 g
Cream: 4%, 5 g (LMX4®)
Green+ Traffic Light   Spray: 10% (supplying 10 mg/dose), 50 mL (500 sprays) (Xylocaine®)

15.02 Lidocaine 

1% Injection: 5ml, 10ml
2% Injection: 5ml, 20ml

15.02 Lidocaine for dental use

Cartridges: lidocaine 1% with adrenaline 1 in 80,000, 2.2 mL

15.02 Lidocaine  Versatis®

Plasters: 5% (700 mg/plaster) (Versatis®)

Green Plus leaflet in development.

NHS England advise:

- not for initiation in primary care and should be reviewed for appropriateness.

- see links below for further information.

 

15.02 Lidocaine  topical

unlicensedunlicensed Topical: 4%, 50 mL

15.02 Lidocaine  

unlicensedunlicensed Lolly: 100 mg

11.07 Lidocaine with Fluorescein 

P/F unit dose eye drop: 4%/0.25%

12.02.03 Lidocaine and Phenylephrine 

unlicensedunlicensed Nasal spray: 2.5ml

15.02 Lidocaine with adrenaline (epinephrine) 

Injection: lidocaine 1% with adrenaline 1 in 200,000, 20 mL vials
Injection: lidocaine 2% with adrenaline 1 in 200,000, 20 mL vials

15.02 Lidocaine with adrenaline (epinephrine) and tetracaine 

unlicensedunlicensed Gel: Lidocaine 4% + Adrenaline 0.1% + Tetracaine 0.5% (LAT), 3 mL

15.02 Lidocaine with phenylephrine 

unlicensedunlicensed Nasal spray: Lidocaine 5% with phenylephrine 0.5%, 2.5 mL

15.02 Lidocaine2% with Chlorhexidine 0.25% Instillagel®

Gel: 11ml (Lidocaine 2% and chlorhexidine gluconate 0.25%)

01.06.07 Linaclotide  Capsules: 290 micrograms
For the symptomatic treatment of moderate-to-severe irritable bowel syndrome with constipation (IBS-C)
06.01.02.03 Linagliptin 

Tablets: 5mg

05.01.07 Linezolid  Tablets: 600mg
Oral solution: 100mg/5ml
05.01.07 Linezolid  IV infusion: 600mg/300ml
06.02.01 Liothyronine 

Tablets: 20 micrograms
Injection: 20 micrograms

11.08.01 Liquid Paraffin 

Eye ointment:  white soft paraffin 57.3%, liquid paraffin 42.5%, wool alcohols 0.2%. (Lacri-Lube®)

06.01.02.03 Liraglutide 

*Injection (pre-filled pen): 18mg/3ml (0.6mg/dose)

*Liraglutide is only approved on the Sunderland Joint Formulary for the treatment of diabetes. Its use for any other indication is considered non-formulary.

04.04 Lisdexamfetamine Elvanse®

Capsules: 20mg, 30mg, 40mg, 50mg, 60mg, 70mg (Elvanse®)
- For 3rd line use after an inadequate response to methylphenidate.
- For specialist initiation and only transferred to GPs after at least 6 month stable symptoms control.

02.05.05.01 Lisinopril  Tablets: 2.5mg, 5mg, 10mg, 20mg
04.02.03 Lithium Carbonate  Tablets: 250mg (6.8mmol Li+)
MR Tablets: 200mg & 400mg (5.4 & 10.8 mmol Li+)
- lithium should be prescribed by brand name
04.02.03 Lithium Citrate  Liquid: 509mg/5mL (5.4 mmol Li+/5mL), 1,018mg/5mL (10.8 mmol Li+/5mL)
M/R Tablets: 564mg (6 mmol Li+)
- lithium should be prescribed by brand name
06.01.02.03 Lixisenatide  Injection (pre-filled pen): 10 micrograms/dose, 20 micrograms/dose

Consider as 1st line G-L-P1 receptor agonist – lowest acquisition cost
07.03.01 Lizinna® 

Tablets: Ethinylestradiol 35micrograms/ norgestimate 250 micrograms

11.04.02 Lodoxamide 

Eye drops: 0.1%

07.03.01.04 Loestrin 20® 

Tablets: Ethinylestradiol 20 mcg / norethisterone 1.5mg

07.03.01 Loestrin 30® 

Tablets: Ethinylestradiol 30 micrograms / norethisterone 1.5mg

04.03.01 Lofepramine  Tablets: 70 mg
Sugar-free oral suspension: 70 mg/5 mL
- Safer than amitriptyline in overdosage, but not as effective.
04.10.03 Lofexidine  Tablets: 200 micrograms
07.03.01.03 Logynon® 

Tablets

07.03.01.03 Logynon® ED 

Tablets

08.01.01 Lomustine 

Capsules: 40mg
unlicensedunlicensed capsules: 10mg

01.04.02 Loperamide  Capsules: 2mg
Syrup: 1mg/5ml
Orodispersible tablets: 2mg*
* For high output stoma only
05.03.01 Lopinavir and ritonavir Kaletra®

Tablets: 100mg/25mg, 200mg/50mg
Oral solution: 400mg/100mg in 5ml

03.04.01 Loratadine  Tablets: 10mg
Oral solution: 5mg/5ml
04.01.02 Lorazepam  Tablets: 1mg, 2.5mg
Injection: 4mg/1ml
Oral solution: 1mg/5ml
04.08.02 Lorazepam  Injection: 4 mg/1 mL
23.01 Lorazepam  

Injection: 4 mg/1 mL ampoules


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

02.05.05.02 Losartan  Tablets: 12.5mg, 25mg, 50mg, 100mg
Oral suspension: 12.5mg/5ml
11.04.01 Loteprednol Lotemax®

Eye drops: 0.5%

01.06.07 Lubiprostone  Capsules: 24 micrograms
07.03.01 Lucette® 

Tablets: Ethinylestradiol 30 mcg / drospirenone 3 mg

05.01.03 Lymecycline  Capsules: 408mg (= tetracycline 300mg)
23.01 Macrogol ‘3350’ 

Sachet: Klean-Prep®


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

01.06.04 Macrogol oral powder  Prescribers should use the product with the lowest acquisition cost.
01.06.04 Macrogol paediatric sachet  Hospital use only
07.03.01 Maexeni ® 

Tablets: Ethinylestradiol 30 microgram/levonorgestrel 150 microgram

09.05.01.03 Magnesium Aspartate Magnaspartate®

Oral powder: 6.5g (10 mmol/sachet)

09.05.01.03 Magnesium Glycerophosphate 

Magnesium glycerophosphate tablets (Neomag)
Tablets: 4mmol (97mg)


unlicensed unlicensed 


Liquid: equivalent to magnesium 5 mmol; also contains phosphate 5 mmol /5 mL


 


Prescribers should prescribe the product with lowest acquisition cost

07.01.04 Magnesium Sulphate 

Ampoules: 20% in 10ml

09.05.01.03 Magnesium Sulphate 

10%, 1 g in 10 mL (equivalent to magnesium 4 mmol/10 mL
50%, 1 g in 2 mL (equivalent to magnesium 4 mmol/2 mL)
50%, 2.5 g in 5 mL (equivalent to magnesium 10 mmol/5 mL)
50%, 5 g in 10 mL (equivalent to magnesium 20 mmol/10 mL)

02.02.05 Mannitol  Intravenous infusion: 10%, 500ml; 20%, 250ml, 500ml
03.07 Mannitol  Inhalation powder, hard capsule (for use with disposable inhaler device): 40mg
Available through a managed pathway in line with NICE criteria
Only to be prescribed by secondary care from April 2016 in line with NHS England Clinical Commissioning Policy
05.03.01 Maraviroc Celsentri®

Tablets: 150mg, 300mg

07.03.01 Marvelon 30/150 ® 

Tablets: Ethinylestradiol 30mcg / desogestrel 150mcg

14.04 Measles, Mumps and Rubella Vaccine, Live (MMR) 

Measles, Mumps & Rubella vaccine (MMR)
Vial with solvent in a pre-filled syringe 0.5 mL (MMRVaxPro®)
Pre-filled syringe: 0.5 mL (Priorix®)
May contain traces of neomycin

05.05.01 Mebendazole  Tablets (chewable): 100mg
Oral suspension: 100mg/5ml
01.02 Mebeverine Hydrochloride  Tablets: 135mg
MR capsules: 200mg
06.04.01.02 Medroxyprogesterone Acetate  Tablets: 2.5 mg, 5 mg, 10 mg
07.03.02.02 Medroxyprogesterone Acetate 

Depot injection: 150mg in 1ml (Depo-Provera®)
S/C injection: 104mg/0.65ml (Sayana Press®)

07.05.04 Medroxyprogesterone acetate 

Tablets: 10mg


 

08.03.02 Medroxyprogesterone Acetate 

Tablets: 100mg & 200mg
Injections: 500mg in 2.5ml

10.01.01 Mefenamic Acid  Capsules: 250 mg
Tablets: 500 mg
Suspension: 50 mg/5 mL

Note: Obs & gynae use only
08.03.02 Megestrol Acetate 

Tablets: 160mg

04.01.01 Melatonin  Solution: 1mg/1ml

RAG status depends on indication:


Amber Traffic Light  For the management of sleep-wake disorders in children and young people


Green+ Traffic Light For the management of sleep-wake disorders in people over the age of 18 and over (note; check BNF for licensing information)


Green+ Traffic Light  Not currently approved by NTW for use in licensed indication, but approved for use in some other sleep disorders


Please refer to information sheet for up to date information regarding approved indications
04.01.01 Melatonin  MR tablets (Circadin ®): 2 mg – 1st line
MR tablets (Circadin ®): 2 mg (crushed) – 2nd line

RAG status depends on indication:


Amber Traffic Light  For the management of sleep-wake disorders in children and young people under the age of 18


Green+ Traffic Light For the management of sleep-wake disorders in people over the age of 18 and over (note; check BNF for licensing information)


Green+ Traffic Light  Not currently approved by NTW for use in licensed indication, but approved for use in some other sleep disorders


Please refer to information sheet for up to date information regarding approved indications
08.01.01 Melphalan 

Tablets: 2mg
Injection: 50mg

04.11 Memantine  Tablet: 10 mg, 20 mg
Oral solution: 5 mg/actuation (10 mg/1 mL)
09.06.06 Menadiol Sodium Phosphate 

Tablets: 10 mg

14.04 Meningococcal vaccine 

Meningococcal group A, C, W135 and Y conjugate vaccine (MenACWY)
Vial: 0.5 mL (Menveo®)
Pre-filled syringe: 0.5 mL (Nimenrix®)


Meningococcal group B (rDNA, component, adsorbed) vaccine (4CMenB)
Prefilled syringe: 0.5 mL (Bexsero®) 


Hib meningococcal group C combined vaccine (Hib/MenC)
Vial: 0.5 mL (Menitorix®)

15.02 Mepivacaine for dental use Scandonest Plain®

Injection: 3%, 2.2 mL cartridge

03.04.02 Mepolizumab Nucala

Powder for solution for injection: 100mg

01.05.03 Mercaptopurine  Tablets: 50mg
08.01.03 Mercaptopurine 

Tablets: 50mg
unlicensedunlicensed Suspension: 20mg in 1ml


 


Note, mercaptopurine is amber if used for inflammatory bowel disease

07.03.01.04 Mercilon® 

Tablets: Ethinylestradiol 20mcg / desogestrel 150mcg

05.01.02.02 Meropenem  Injection: 500mg, 1g
01.05.01 Mesalazine Octasa® Tablets: 400mg, 800mg
Octasa® is the first line brand in primary care
01.05.01 Mesalazine Asacol® Tablets: 400mg, 800mg (Asacol® is the second line brand in primary care)
Suppositories: 250mg, 500mg
Foam enema: 1g (preparation choice will depend on site of action required - choice between foam enema and retention enema depends on patient preference).
01.05.01 Mesalazine Pentasa®

SR Tablets: 500mg, 1g
SR Granules: 1g sachet, 2g sachet
Suppositories: 1g
Retention enema: 1g/100ml (preparation choice will depend on site of action required - choice between foam enema and retention enema depends on patient preference).

01.05.01 Mesalazine Salofalk® Tablets: 250mg, 500mg
01.05.01 Mesalazine  Mezavant® XL SR Tablets: 1.2g
01.05.01 Mesalazine Salofalk®

Granules GR MR: 500mg, 1g, 1.5g, 3g

08.01 Mesna 

Injection: 1g in 10ml
Tablets: 400mg

23.01 MESNA (sodium 2-mercapto-ethanesulphonate) 

Injection: 400 mg/4 mL ampoules
Tablets: 400 mg


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

02.07.02 Metaraminol  Ampoules: 10mg/1ml
06.01.02.02 Metformin  Tablets: 500mg, 850mg
MR Tablets: 500mg, 750mg, 1g
Oral solution (sugar-free): 500mg/5mL
N.B. The MR tablets are only to be prescribed where patients have failed to tolerate the conventional tablets despite careful dose titration
07.05.01.01 Metformin 

Tablets: 500mg
(For fertility indications)

04.07.02 Methadone 

Tablets: 5 mg
Linctus: 2 mg/5 mL
Oral Concentrate: 10mg/mL
Injection: 10 mg/1 mL

 

Specialist initiation only - consult pain team or palliative care before use as an analgesic.

(Red when used for addiction)

04.10.03 Methadone 

Oral solution (sugar-free available, must be specified): 1 mg/1 mL
Injection: 50 mg/2 mL, 50 mg/1 mL

 

(Red when used for addiction)

05.01.13 Methenamine Hippurate Hiprex®

Tablets 1g

BNF states this drug is "Less suitable for prescribing". 

Included on the Sunderland DROP list (Drugs to Review for Optimised Prescribing).

01.05.03 Methotrexate  Tablets: 2.5mg
08.01.03 Methotrexate 

Tablets: 2.5mg
unlicensedunlicensed Oral solution: 10mg in 5ml
unlicensedunlicensed Injections (various strengths) – including prefilled syringes
Intrathecal injection: 5mg in 2ml


Note, methotrexate is amber if used in chornic inglammarory conditions, e.g. Crohn's disease, rheumatoid arthritis

10.01.03 Methotrexate  Tablets: 2.5 mg
Prefilled pen (Metoject): 7.5mg, 10mg, 12.5mg, 15mg, 17.5mg, 20mg, 22.5mg, 25mg, 27.5mg, 30mg

Note: ONLY 2.5mg strength tablets to be prescribed. No other strengths to be prescribed
09.01.03 Methoxy Polyethylene Glycol-Epoetin Beta Mircera®

Injection (pre-filled syringe): 30 micrograms/0.3 mL, 50 micrograms/0.3 mL, 75 micrograms/0.3 mL, 100 micrograms/0.3 mL, 120 micrograms/0.3 mL, 150 micrograms/0.3 mL, 200 micrograms/0.3 mL, 250 micrograms/0.3 mL, 360 micrograms/0.6 Ml

02.05.02 Methyldopa  Tablets: 125mg, 250mg, 500mg
04.04 Methylphenidate 

Tablets: 5 mg, 10 mg,
MR Tablets: 18 mg, 27mg, 36 mg (Concerta XL®)
MR Capsules: 5mg, 10mg, 20mg, 30mg, 40mg (Medikinet XL®)
MR Capsules: 10mg, 20mg, 30mg (Equasym XL®)
- The effects of Equasym XL last for about 8 hours compared with about 12 hours for Concerta XL
- Also approved for the treatment of narcolepsy in paediatrics

06.03.02 Methylprednisolone  Tablets: 2mg, 4mg, 16mg, 100mg
06.03.02 Methylprednisolone  Injection: (as sodium succinate): 40mg, 125mg, 500mg, 1g, 2g
10.01.02.02 Methylprednisolone Acetate Depo-Medrone® Depot injection: 40 mg/mL (Depo-Medrone®)
10.01.02.02 Methylprednisolone Acetate Depo-Medrone® with Lidocaine Depot injection (with lidocaine): 40 mg (+ 10 mg)/1 mL, 80 mg (+ 20 mg)/2 mL (Depo-Medrone with Lidocaine®)
23.01 Methylthioninium chloride (methylene blue) 

Injection: 1 % (100 mg/10 mL) ampoules


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

01.02 Metoclopramide  Tablets: 10mg
Liquid: 5mg/5ml
04.06 Metoclopramide  Tablets: 10 mg
Liquid: 5 mg/5 mL
04.06 Metoclopramide  Injection: 10 mg/2 mL

RAG status is RED unless prescribing in end of life care
02.02.01 Metolazone  Tablets: 2.5mg, 5mg
02.04 Metoprolol  Tablets: 50mg, 100mg
SR Tablets: 200mg
02.04 Metoprolol   Oral solution: 50mg/5ml
02.04 Metoprolol  Injection: 5mg/5ml
05.01.11 Metronidazole  Tablets: 200mg, 400mg, 500mg
Suspension: 200/5ml
Suppositories: 500mg, 1g

05.01.11 Metronidazole 

IV infusion: 100mg/20ml, 500mg/100ml

07.02.02 Metronidazole 

Vaginal gel: 0.75%

06.07.03 Metyrapone  Capsules: 250mg
02.03.02 Mexiletine 

Capsules*: 50mg     *Hospital use only*

 Unlicensed  No licensed product available in the UK.  Available from special order manufacturers or specialist importing companies.

 

12.03.02 Miconazole 

Oral gel (sugar-free): 24 mg/1 mL (20 mg/1 g) (Daktarin)     

07.03.01 Microgynon 30® 

Tablets: Ethinylestradiol 30mcg / levonorgestrel 150mcg

07.03.01 Microgynon ED ® 

Tablets: Ethinylestradiol 30mcg / levonorgestrel 150mcg

07.03.02 Micronor® 

Tablets: 350 micrograms (Norethisterone)

04.08.02 Midazolam  Oromucosal solution (Buccolam®): 2.5 mg/0.5 mL, 5 mg/1 mL, 7.5 mg/1.5 mL, 10 mg/2 mL
15.01.04.01 Midazolam 

Injection (vials): 2 mg/2 mL, 5 mg/5 mL, 10 mg/2 mL ampoules; 50 mg/50 mL


note: 10mg/2ml is Green + if used in palliative medicine

02.07.02 Midodrine  Tablets: 2.5mg, 5mg
08.02.04 Mifamurtide 

Vial: 4mg

07.01.02 Mifepristone 

Tablets: 200mg

07.03.01.04 Millinette 20/75 ® 

Tablets: Ethinylestradiol 20mcg / gestodene 75 mcg

07.03.01 Millinette 30/75 ® 

Tablets: Ethinylestradiol 30mcg / gestodene 75 mcg

02.01.02 Milrinone 

Amps: 10mg/10ml


Used in critical care at City Hospitals Sunderland

07.03.01.07 Mini TT 380 Slimline® 

Intrauterine device - replacement every 5 years

05.01.03 Minocycline  Tablets: 50mg, 100mg
02.05.01 Minoxidil  Tablets: 2.5mg, 5mg, 10mg
07.04.02 Mirabegron 

M/R tablets: 25mg, 50mg


 

04.03.04 Mirtazapine  Tablets: 15mg, 30mg, 45mg
Orodispersible tablets: 15mg, 30mg, 45mg
- Orodispersible tablets should only be prescribed for use when other formulations are unsuitable
07.01.01 Misoprostol 

Tablets: 200 micrograms

08.01.02 Mitomycin 

Injection: 10mg, 20mg & 40mg
- Also approved for treatment in combination with 5-Fluorouracil for bladder cancer concurrent with radiotherapy.

08.01.02 Mitomycin 

unlicensedunlicensed Preservative free eye drop: 0.04% preservative free eye drops

08.01.05 Mitotane 

Tablets: 500mg

08.01.02 Mitoxantrone 

Injection: 20mg in 10ml

15.01.05 Mivacurium Chloride 

Injection (amps): 10 mg/5 mL, 20 mg/10 mL

04.03.02 Moclobemide 

Tablets: 150 mg, 300 mg

04.04 Modafinil  Tablets: 100 mg
- Only approved for limited use in the treatment of patients with narcolepsy
12.02.01 Mometasone Furoate 

Nasal spray: 50 micrograms/spray

03.03.02 Montelukast  Tablets: 10mg
Chewable tablets: 4mg, 5mg
Sachets: 4mg
04.07.02 Morphine Sulphate  IR tablets: 10 mg, 20 mg, 50 mg
MR capsules for twice daily administration (Zomorph®): 10 mg, 30 mg, 60 mg, 100 mg, 200 mg
MR tablets: 5 mg, 15 mg
MR suspension sachets: 20 mg, 30 mg, 60 mg, 100 mg, 200 mg
N.B. the MR suspension sachets are only for use when other formulations are unsuitable
Oral solution: 10 mg/5 mL, 20 mg/1 mL
Injection: 10 mg/1 mL, 15 mg/1 mL, 20 mg/1 mL, 30 mg/1 mL
Suppositories: 10 mg, 15 mg, 20 mg, 30 mg
01.06.05 Moviprep®  Oral powder (sachets)
05.01.12 Moxifloxacin  Tablets: 400mg
05.01.12 Moxifloxacin 

Injection for infusion: 400 mg/250mL

11.03.01 Moxifloxacin 

Eye drops: 0.5%

02.05.02 Moxonidine  Tablets: 200 micrograms, 300 micrograms, 400 micrograms
12.03.01 Mucogard® 

Oral rinse: 250ml

09.06.07 Multivitamin preparations Renavit ®

Tablets: contains ascorbic acid 60 mg, thiamine 1.5 mg, riboflavin 1.7 mg, nicotinamide 20 mg, pyridoxine hydrochloride 10 mg, folic acid 800 micrograms, cyanocobalamin 6 micrograms, D-biotin 300 micrograms, pantothenic acid 10 mg


For patients on dialysis

09.06.07 Multivitamin preparations Ketovite®

Tablets: contains Ascorbic acid, Riboflavin, Thiamine, Pyridoxine, Nicotinamide, Calcium pantothenate, Alpha tocopheryl acetate, Inositol, Biotin, Folic acid and Acetomenaphthone
Liquid (sugar-free 150mL): contains Vitamin A, Ergocalciferol, Choline chloride and Cyanocobalamin

09.06.07 Multivitamin preparations Abidec®

Abidec drops, 25mL
Contains Vitamins A (1,333 units as palmitate per 0.6mL dose), B group, C and D. Includes arachis (peanut) oil

09.06.07 Multivitamin preparations Dalivit®

Drops, 25mL
Contains Vitamins A (5,000 units as palmitate per 0.6mL dose), B group, C and D

12.02.03 Mupirocin 

Nasal ointment: 2% in white soft paraffin (Bactroban®)
2nd line for peanut allergy (in primary care)

09.06.07 Mutivitamin 

Capsules: Multivitamins BPC

10.01.03 Mycophenolate  Capsules: 250mg
Tablets: 500mg
08.02.01 Mycophenolate Mofetil 

Capsules: 250mg
Tablets: 500mg
Oral suspension: 1g in 5ml (200mg/ml)
Vial for preparing IV infusion: 500mg

08.02.01 Mycophenolate Sodium Myfortic®

E/C tablets: 180mg & 360mg
– 2nd line therapy in patients who do not tolerate mycophenolate mofetil

04.06 Nabilone  Capsules*: 1mg
*Hospital use and existing patients only. No new patients
03.07 N-Acetylcysteine  solution for nebulisation
02.06.04 Naftidrofuryl  Capsules: 100mg
04.10.01 Nalmefene  Tablets: 18mg
01.06.06 Naloxegol  Tablets: 12.5mg, 25mg
15.01.07 Naloxone 

Injection (amps): 400 micrograms/1 mL
Prefilled syringe: 2 mg/2 mL

23.01 Naloxone  

Injection: 400 micrograms/1 mL ampoules


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

04.10.03 Naltrexone  Tablets: 50 mg
04.07.04.01 Naproxen  Tablets: 250mg, 500mg
10.01.01 Naproxen  Tablets: 250mg, 500mg
10.01.04 Naproxen  Tablets: 250 mg, 500 mg
08.02.04 Natalizumab 

Vial for preparing infusions: 300mg in 15ml (20mg/ml)
- approved for rapidly evolving severe relapsing remitting multiple sclerosis in line with NICE

11.03.02 Natamycin 

unlicensed unlicensed Eye drops: 5%

11.04.02 Neodocromil 

Eye drops: 2%

10.02.01 Neostigmine  Tablets: 15 mg
Injection: 2.5 mg/1 mL
15.01.06 Neostigmine 

Injection (amps): 2.5 mg/1 mL

15.01.06 Neostigmine with Glycopyrronium 

Injection: Neostigmine metisulfate (methylsulphate) 2.5 mg with glycopyrronium 500 micrograms, 1 mL

11.08.02 Nepafenac  

Eye drops: 1 mg/1 mL

04.06 Netupitant and Palonosetron Akynzeo®

Capsules: 300mg/0.5mg

05.03.01 Nevirapine Viramune®

Oral suspension: 10mg/1ml
MR tablets: 100mg, 400mg
Tablets: 200mg

02.06.03 Nicorandil  Tablets: 10mg, 20mg
04.10.02 Nicotine  Nicorette®
Microtab (sublingual): 2 mg
Chewing gum: 2 mg, 4 mg
Patches (Invisi or non-Invisi): ‘5 mg' patch (releasing approx. 5 mg/16 hours), ‘10 mg' patch (releasing approx. 10 mg/16 hours), ‘15 mg' patch (releasing approx. 15 mg/16 hours)
Oral spray: 1 mg/metered dose
Nasal spray: 500 micrograms/metered spray
Inhalator: 10 mg/cartridge, 15 mg/cartridge

Nicotinell®
Lozenge: 1 mg, 2 mg
Patches: TTS 10 patch (releasing approx. 7 mg/24 hours), TTS 20 patch (releasing approx. 14 mg/24 hours), TTS 30 patch (releasing approx. 21 mg/24 hours)
02.06.02 Nifedipine  Capsules: 5mg, 10mg
Oral drops: 20mg/ml*
*Hospital use only
07.01.04 Nifedipine 

Capsules: 5mg, 10mg

02.06.02 Nifedipine modified release  Tablets: 10mg, 20mg, 30mg 60mg

Different versions of modified-release preparations may not have the same clinical effect. To avoid confusion between these different formulations of nifedipine, prescribers should specify the brand to be dispensed. Modified-release formulations may not be suitable for dose titration in hepatic disease
08.01.05 Nilotinib 

Capsules: 150mg, 200mg

02.06.02 Nimodipine  Tablets: 30mg
Infusion: 0.02%
08.01.05 Nintedanib Vargatef®

Soft capsules: 100mg, 150mg

15.01.02 Nitric oxide 
05.01.13 Nitrofurantoin  Tablets: 50mg, 100mg
MR capsules: 100mg
Oral suspension (sugar-free available): 25mg/5ml*

*Note: Liquid presentations of nitrofurantoin are very expensive compared to tablets and capsules. Current costs are £446.95 for 300ml (May 2017 drug tariff). Please consider whether capsules can be used. Macrodantin capsules can either be swallowed whole, or the capsules can be opened. DO NOT crush the tablets
15.01.02 Nitrous oxide 
08.02.04 Nivolumab 

Concentrate for IV infusion: 10mg in 1ml concentrate for IV infusion as (4ml & 10ml vials)


 


For the treatment of locally advanced or metastatic squamous nonsmall cell lung cancer (NSCLC) after prior chemotherapy in adults

07.03.03 Nonoxynol '9' Gygel®

Gel: 2%

02.07.02 Noradrenaline  

Injection for infusion amps: 4mg/4ml


Used in critical care at City Hospitals Sunderland

06.04.01.02 Norethisterone  Tablets: 5mg
07.05.04 Norethisterone 

Tablets: 5mg


Note: Anticipatory prescribing for postponement of menstruation while travelling should not be provided on NHS prescription in primary care. Supplies can be made on private prescription.

08.03.02 Norethisterone 

Tablets: 5mg

07.03.02 Norgeston® 

Tablets: 30 micrograms (Levonorgestrel)

07.03.02 Noriday® 

Tablets: 350 micrograms norethisterone

14.05.01 Normal immunoglobulin 

Human normal Immunoglobulin (HNIG)
Infusion: 100 mg/mL; 5 g/50 mL, 10 g/100 mL (Iqymune®) preferred product
Infusion: 100 mg/mL; 5 g/50 mL, 10 g/100 mL (Kiovig®)
For patients who cannot have Iqymune®

04.07.03 Nortriptyline   Tablets: 10 mg, 25 mg
For use after trialling other options as detailed above
07.03.01.07 Nova T 380® 

Intrauterine device - replacement every 5 years

07.03.01.06 NuvaRing® 

Vaginal ring releasing ethinylestradiol approximately 15 micrograms/24hours and etonogestrel approximately 120 micrograms/24hours

05.02 Nystatin  Oral suspension: 100,000 units/ml
12.03.02 Nystatin 

Oral suspension: 100,000 units/1 mL
1st line for oral candidiasis

01.09.01 Obeticholic acid Ocaliva

Tablets: 5mg and 10mg

08.02.03 Obinutuzumab Gazyvaro ®

Concentrate for IV infusion: 1000mg in 40ml


-for use in chronic lymphocytic leukaemia in combination with chlorambucil in patients who have co-morbitities that make fulldose fludarabinebased therapy unsuitable for them, only if bendamustinebased therapy is not suitable and the company provides obinutuzumab with the discount agreed in the patient access scheme in line with NICE (subject to NHS England funding)

11.08.02 Ocriplasmin 

Concentration for solution for intravitreal injection: 2.5mg/ml

08.03.04.03 Octreotide 

Injections: 50, 100 & 500 microg. in 1ml & 1mg in 5ml
Long-acting injections: 10mg, 20mg & 30mg

 

GREEN PLUS for palliative care indications (leaflet in development)

08.03.04.03 Octreotide 

Injections: 50, 100 & 500 microg. in 1ml & 1mg in 5ml
Long-acting injections: 10mg, 20mg & 30mg

RED for acromegaly, neuroendocrine tumour and carcinoid

23.01 Octreotide  

Injection: 50 micrograms/1 mL, 100 micrograms/1 mL ampoules


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

06.04.01.01 Oestrogen only HRT patch  Patches: Twice weekly matrix patches releasing approximately 25, 50, 75 and 100mcg/24 hours (e.g. Evorel®)

Patches: Once weekly matrix patches releasing approximately 50 and 100mcg estradiol/24 hours (Progynova TS®)
06.04.01.01 Oestrogen only HRT tablet Premarin Tablets: 625mcg, 1.25mg (Premarin)
06.04.01.01 Oestrogens for HRT Sandrena® Gel: 0.1% (Sandrena®)
06.04.01.01 Oestrogens for HRT Estradiol® Tablets: 1mg, 2mg
08.02.03 Ofatumumab Arzerra®

Concentrate for IV infusion: 100mg in 5ml


- for use in chronic lymphocytic leukaemia in combination with chlorambucil if the person is ineligible for fludarabinebased therapy and bendamustine is not suitable and the company provides ofatumumab with the discount agreed in the patient access scheme in line with NICE (subject to NHS England funding)

05.01.12 Ofloxacin  Tablets: 200mg, 400mg
05.01.12 Ofloxacin  IV infusion: 200mg/100ml
04.02.01 Olanzapine  Tablets: 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg
Orodispersible tablets: 5mg, 10mg, 15mg
N.B. The orodispersible tablets should only be used in situations where the plain tablets are unsuitable

10mg injection
- For rapid control of agitation and disturbed behaviours in patients with schizophrenia or manic episode, when oral therapy is not appropriate.
- The orodispersible tablets and injection are also approved for 2nd/3rd line use in the management of delirium in critical care patients – unlicensed indication.
08.01.05 Olaparib 

Capsules: 50mg
-approved for the maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based chemotherapy in line with NICE

08.01.05 Olaratumab 

Concentrate for solution for infusion: 10 mg/mL

12.01.03 Olive Oil 

Ear drops

11.04.02 Olopatadine 

Eye drops: 1 mg/1 mL

03.04.02 Omalizumab Xolair® Prefilled syringe: 75mg/0.5ml, 150mg/1ml

Review effectiveness after 16 weeks of commencing treatment
05.03.03.02 Ombitasvir/ paritaprevir/ ritonavir Viekirax® Tablets containing ombitasvir 12.5mg, paritaprevir 75mg and ritonavir 50mg
01.03.05 Omeprazole  Capsules: 10mg, 20mg,40mg
Tablets (MUPS): 20mg
Suspension: 10mg/5ml* (unlicensed)
*For use in paediatrics only
01.03.05 Omeprazole IV  Infusion vial: 40mg
04.06 Ondansetron  Tablets: 4 mg, 8 mg
Orodispersible films: 4 mg, 8 mg
Oral solution: 4 mg/5 mL
Suppositories: 16mg
04.06 Ondansetron  Injection: 4 mg/2 mL, 8 mg/4 mL

RAG status is RED unless prescribing in end of life care
12.03.01 Orabase 

Paste: 30 g

07.05.04 Oral contraceptives 

Co-cyprindol, Lucette (as per contraceptive section)

07.05.05 Oral contraceptives 

Co-cyprindol, Lucette - formulations as per contraceptives

09.02.01.02 Oral Rehydration Salts Dioralyte®

Oral powder: sachets containing sodium chloride 470 mg, potassium chloride 300 mg, disodium hydrogen citrate 530 mg, glucose 3.56 g/sachet (Dioralyte®)

01.04 Oral rehydration solution  Prescribers should choose the product with the lowest acquisition cost
04.05.01 Orlistat  Tablets: 120mg
04.09.02 Orphenadrine  Tablets: 50mg
Syrup: 50mg/5ml
12.03.05 Orthana® 
05.03.04 Oseltamivir Tamiflu® Capsules: 30mg, 45mg, 75mg
Oral suspension (sugar-free): 30mg/5ml
07.03.01 Ovranette® 

Tablets: 150 micrograms levonorgestrel and 30 micrograms ethinylestradiol

07.03.01 Ovysmen® 

Tablets: Ethinylestradiol 35 mcg / norethiserone 500mcg

08.01.05 Oxaliplatin 

Injections: 50mg, 100mg

04.07.03 Oxcarbazepine  Tablets: 150mg, 300mg, 600mg
Indicated in for trigeminal neuralgia and compression neuralgia after trialling carbamazepine
04.08.01 Oxcarbazepine  Tablets: 150 mg, 300 mg, 600 mg
Liquid (sugar-free): 300 mg/5 mL
11.07 Oxybuprocaine Hydrochloride 

Minims® eye drops (preservative free): 0.4%

07.04.02 Oxybutynin 

Tablets: 2.5mg, 5mg
Elixir: 2.5mg in 5ml
Self-adhesive patch: 36mg

04.07.02 Oxycodone  IR capsules: 5 mg, 10 mg, 20 mg
Liquid: 5 mg/5 mL, 10 mg/1 mL
Injection: 10 mg/1 mL, 20 mg/2 mL, 50 mg/1 mL
MR tablets: 5 mg, 10 mg, 20 mg, 40 mg, 80 mg
15.01.02 Oxygen 
05.01.03 Oxytetracycline  Tablets: 250mg
07.01.01 Oxytocin 

Injection: 5 units in 1 ml, 10 units in 1ml

08.01.05 Paclitaxel 

Concentrate for preparing IV infusion: 30mg in 5ml, 100mg in 16.7ml and 150mg in 25ml

22.01 Paediatric 

Red Adrenaline 1 mg/10 mL (1:10,000) prefilled syringe
Red Adrenaline Auto injector - 150 micrograms
Red Adrenaline Auto injector - 300 micrograms
Red Amiodarone 300 mg/10 mL prefilled syringe
Red Atropine 3 mg/10 mL prefilled syringe 
Red Calcium chloride 1000 mg/10 mL (10%) prefilled syringe
Red Dextrose 10%, 500 mL
Red Gelatin plasma substitute (Gelofusine or Volpex), 500 mL
Red Naloxone 400 micrograms/1 mL ampoules
Red Sodium bicarbonate 8.4%, 200 mL 
Red Sodium chloride 0.9% flush, 10 mL prefilled syringe
Red Sodium chloride 0.9% solution, 1000 mL


*These medications are red in the context of the paediatric resuscitation trolley. Please see other chapters for formulary status when used for other indications

08.03.04.01 Palbociclib 

Capsules: 125mg

04.02.02 Paliperidone  Pre-filled syringe: 50mg, 100mg, 150mg
-NTAG approved for the treatment of schizophrenia as per its licensed indication and as outlined in the Guidance on the Use of Antipsychotic Long-Acting Injections in the North of England
04.06 Palonosetron  Injection: 250 micrograms/5 mL
01.09.04 Pancreatin Creon® Capsules: Creon® 10,000, Creon® 25,000, Creon® 40,000
01.09.04 Pancreatin Pancrex® V Powder: 300G
01.09.04 Pancreatin Pancrease® HL Capsules
01.09.04 Pancreatin Nutrizym® 22 Capsules
15.01.05 Pancuronium Bromide 

Injection (amps): 4 mg/2 mL

08.01.05 Panobinostat Farydak®

Hard capsules: 10mg, 15mg, 20mg

15.01.05 Papaverine hydrochloride 

unlicensedunlicensed Injection: 30 mg/2 mL ampoules

04.07.01 Paracetamol  Tablets: 500 mg
Soluble Tablets: 500 mg
Suspension: 120 mg/5 mL, 250 mg/5 mL
Suppository: 60 mg, 125 mg, 250 mg, 500 mg
Injection: 500 mg/50 mL, 1g/100 mL
04.07.04.01 Paracetamol  Soluble Tablets: 500 mg
04.07.01 Paracetamol and codeine Co-codamol 8/500

Tablets: 8/500

11.08.01 Paraffin Yellow Soft 

Ointment: liquid paraffin 10%, wool fat 10% in yellow soft paraffin (Simple Eye Ointment)

04.08.02 Paraldehyde in olive oil  Injection: 50 mg/50 mL
15.01.04.02 Parecoxib 

Injection (vials): 40 mg 

09.06.04 Paricalcitol Zemplar®

Capsules: 1 microgram, 2 micrograms, 4 micrograms
Injection: 5 micrograms/1 mL

04.03.03 Paroxetine  Tablets: 10 mg, 20 mg, 30 mg
Liquid (sugar-free): 10 mg/5 mL
09.02.01.01 Patiromer calcium Veltassa ®

Oral powder sachetes 8.4g, 16.8g, 25.2g

08.01.05 Pazopanib 

Tablets: 200mg, 400mg

08.01 Pegasparagase 

Vial: 3750 international units

08.02.04 Peginterferon alfa-2a 

Injections in prefilled syringes 135 microgram, 180 microgram
Prefilled pens: 135 micrograms and 180 micrograms

08.02.04 Peginterferon alfa-2b 

Prefilled injection pens: 50, 80, 100, 120, 150 micrograms
-approved for chronic hepatitis C as peginterferon alffa 2a

08.02.04 Peginterferon beta-1a 

Prefilled pen: 125 microgram (Plegridy)

08.01.05 Pembrolizumab 

Vial for preparing IV infusion: 50mg

08.01.03 Pemetrexed 

Injection: 100mg & 500mg

10.01.03 Penicillamine  Tablets: 125 mg, 250 mg

Note: this is as an alternative after biologics
07.04.03 Pentosan polysulphate sodium 

Capsules: 50mg, 100mg

01.02 Peppermint Oil 

Capsules: 0.2ml

modified and instant release.

01.01.02 Peptac  Sugar-free suspension (sodium alginate 250mg, sodium bicarbonate 133.5mg, calcium carbonate 80mg in 5mL. Contains 3.1 mmol Na+/5mL)
04.08.01 Perampanel  Tablets: 2mg, 4mg, 8mg
02.05.05.01 Perindopril erbumine  Tablets: 2mg, 4mg, 8mg
04.02.01 Perphenazine  Tablets: 2mg, 4mg
08.01.05 Pertuzumab Perjeta®

Vial: 420mg

04.07.02 Pethidine 

Injection: 50 mg/1 mL, 100 mg/2 mL, 50 mg/5 mL, 100 mg/10 mL

 

Only for use by midwives or in palliative care.

04.03.02 Phenelzine 

Tablets: 15mg
- For use on advice from psychiatrists only

04.08.01 Phenobarbital  Tablets: 15 mg, 30 mg, 60 mg
Elixir: 15mg/5 mL

CHM advise brand specific prescribing
(Alcohol-free elixir available from Rosemont Pharmaceuticals - unlicensed)
04.08.01 Phenobarbital  Alcohol free Solution: 50mg/5ml* (Unlicensed from Rosemont)
*For paediatric use only
04.08.02 Phenobarbital  Injection: 15mg/1 mL, 30 mg/1 mL, 60 mg/1 mL, 200 mg/1 mL
02.05.04 Phenoxybenzamine Hydrochloride  Capsules: 10mg
05.01.01.01 Phenoxymethylpenicillin (Penicllin V)  Tablets: 250mg
Oral Solution (sugar-free available): 125/5ml, 250mg/5ml
23.01 Phentolamine 

Injection: 10 mg/1 mL ampoules


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

10.01.01 Phenylbutazone 

Tablets: 100mg

Indication: Ankylosing Spondylitis. Only be used by a specialist in severe cases where other treatments have been found unsuitable
This is to be used for existing patients only. No new patients should be commenced on phenylbutazone.

02.07.02 Phenylephrine 

Ampoules: 10mg/1ml
unlicensed unlicensed Prefilled syringe: 3 mg/ 30 mL

11.05 Phenylephrine Hydrochloride 

Minims® (preservative free): 2.5%, 10%
unlicensed unlicensed Eye drops: 2.5%

04.08.01 Phenytoin  Chewable Tablets (as Phenytoin base): (Infatabs®): 50 mg
Capsules (as phenytoin sodium): 25 mg, 50 mg, 100 mg, 300 mg
Suspension (as Phenytoin base) (Epanutin®): 30 mg/5 mL

CHM advise brand specific prescribing
04.08.02 Phenytoin  Injection: 250 mg/5 mL
03.09.01 Pholcodine Linctus, BP 

5mg/5ml,

09.05.02.01 Phosphate (oral supplements) 

Effervescent tablets: equivalent to phosphorus 500 mg, 16.1 mmol; sodium 468.8 mg, 20.4 mmol; potassium 123 mg, 3.1 mmol (Phosphate-Sandoz®)

09.05.02.01 Phosphate Polyfusor® 

Intravenous infusion: 500 mL

01.06.04 Phosphates (Rectal) Fleet® Ready to use Enema
09.06.06 Phytomenadione Konakion® MM

Capsules: 1 mg (in oily basis)
Injection: 10 mg/1 mL (Konakion® MM), 2 mg/0.2 mL (Konakion® MM Paediatric)
NB) Konakion® MM Paediatric can be given orally, by intramuscular injection or be intravenous injection. Oral dispensers are provided in each pack for safe administration.

23.01 Phytomenadione (vitamin K) 

Injection: 10 mg/1 mL ampoules


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

08.01.05 Picibanil 

unlicensedunlicensed Injection: 100microgram
Named patient supply only

01.06.05 Picolax®  Oral powder (sachets)
11.06 Pilocarpine 

Eye drops: 1%, 2%, 4%
Minims® (preservative free): 2%

12.03.05 Pilocarpine Hydrochloride 

Tablets: 5 mg

06.01.02.03 Pioglitazone  Tablets: 15mg, 30mg, 45mg
05.01.01.04 Piperacillin and Tazobactam  Injections: 2.25g (containing piperacillin 2g & tazobactam 250mg/2.25g vial) , 4.5g (containing piperacillin 4g & tazobactam 500mg/4.5g vial)
04.02.02 Pipotiazine Palmitate  Injection: 50 mg/1 mL, 100 mg/2 mL
- specialist initiation only
03.11 Pirfenidone Esbriet® Capsules: 267mg

Newcastle tertiary referral
10.03.02 Piroxicam  Gel: 0.5%
04.04 Pitolisant  Tablets: 20mg
- approved for use in patients with narcolepsy who experience psychomotor side effects with modafinil and dexamfetamine.
05.01.01.05 Pivmecillinam  Tablets: 200mg
08.01.02 Pixantrone 

Injection: 29mg powder for reconstitution injection
-approved as a possible treatment for adults with multiply relapsed or refractory aggressive non-Hodgkin's B cell lymphoma if they have previously been treated with rituximab and they are having third- or fourth-line treatment NICE

04.07.04.02 Pizotifen  Tablets: 500 micrograms, 1.5 mg
09.01.07 Plerixafor Mozobil®

(2nd line for stem cell harvesting – needs Cancer Drugs Fund application)


Injection: 24 mg/1.2 mL

14.04 Pneumococcal vaccine 

Pneumococcal conjugate (13 serotypes) vaccine (PCV13)
Prefilled syringe: 0.5 mL (Prevenar 13®)


Pneumococcal polysaccharide (23 serotypes) vaccine (PPV23)
Vial: 0.5 mL (MSD)

11.03.01 Polihexanide 

unlicensed unlicensed P/F eye drops: 0.02%
unlicensed unlicensed Eye drops: 0.06%

14.04 Poliomyelitis Vaccine Live (oral)  

Use combined vaccines

09.02.01.01 Polystyrene Sulphonate Resins Calcium Resonium®

Powder: 300g

11.08.01 Polyvinyl Alcohol 

Eye drops: 1.4% (Liquifilm Tears® and Sno Tears®)

08.02.04 Pomalidomide Imnovid®

Capsules: 1mg, 2mg, 3mg, 4mg

08.01.05 Ponatinib Iclusig®

Tablets: 15mg, 45mg

03.05.02 Poractant Alfa  Vials: 120mg, 240mg
05.02 Posaconazole (oral)  Oral solution: 200mg/5ml
09.05.02.01 Potassium acid phosphate 

unlicensed unlicensed Oral solution (for use in paediatrics): 1mmol/1ml, 100ml

11.03.01 Potassium ascorbate 

unlicensed unlicensed Eye drops: 10%
unlicensed unlicensed P/F eye drops: 10%

09.02.01.01 Potassium Chloride 

Modified-release tablets: equivalent to potassium 8 mmol per tablet (Slow-K®)

09.02.01.01 Potassium Chloride 

Effervescent tablets: equivalent to potassium 12 mmol per tablet (Sando-K®)
Syrup (sugar-free):  equivalent to potassium 1 mmol/mL (Kay-Cee-L®)

11.08.01 Povidone  

unlicensed unlicensed Single dose units (preservative-free): 5%

04.09.01 Pramipexole  Tablets: 88 micrograms, 180 micrograms, 350 micrograms, 700 micrograms
MR tablets: 260 micrograms, 520 micrograms, 1.05 mg, 1.57 mg, 2.1 mg, 2.62 mg, 3.15 mg
02.09 Prasugrel  Tablets: 5mg, 10mg
02.12 Pravastatin   Tablets: 10mg, 20mg, 40mg
01.05.02 Prednisolone  Tablets: 1mg, 5mg
Retention enema: 20mg/100ml (Predsol®)
Suppositories: 5mg
06.03.02 Prednisolone  Tablets: 1mg, 5mg
Tablets (soluble): 5mg
Oral solution: 5mg/5ml

NB. Oral solution or soluble tablets should only be used when the patient has swallowing difficulties where plain tablets are not suitable. The oral solution has a lower acquisition cost than soluble tablets in primary care.
06.03.02 Prednisolone  Tablets: 25mg*
*Specialist use only
10.01.04 Prednisolone  Injection: 25 mg/mL (Deltastab)

See section 6.3.2
Can be used as an alternative for those who cannot tolerate NSAIDs or who are resistant to other treatments

See section 6.3.2 for other preparations
11.04.01 Prednisolone 

Eye drops: 0.5%
Minims® (preservative free): 0.5%
unlicensed unlicensed Eye drops: 0.003%, 0.01%, 0.03%, 0.1% and 0.3%
unlicensed unlicensed Eye drops (preservative free): 0.01%, 0.03%, 0.1%, 0.3%, 0.5% and 1%

11.04.01 Prednisolone 

Eye drops: 1% (Pred Forte)

10.01.02.02 Prednisolone Acetate Deltastab® Depot injection: 25 mg/1 mL (Deltastab®)

See section 6.3.2 for other preparations
12.01.01 Prednisolone sodium phosphate 

Eye/ear drops: 0.5%

04.07.03 Pregabalin  Capsules: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg
Liquid: 20mg/mL

For use after trialling other options as detailed above
04.08.01 Pregabalin  Capsules: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg
Oral solution: 20 mg/1 mL
06.01.05 Pregabalin  See section 4.8 for preparations
09.02.02.01 Premixed potassium infusion bags 

Infusion: 0.15% (10 mmol) potassium chloride & 0.9% sodium chloride 500ml
Infusion: 0.15% (20 mmol) potassium chloride & 0.9% sodium chloride 1000ml
Infusion: 0.15% (10 mmol) potassium chloride & 5% glucose 500ml
Infusion: 0.15% (20 mmol) potassium chloride & 5% glucose 1000ml
Infusion: 0.15% (10 mmol) potassium chloride & 10% glucose 500ml
Infusion:  0.15% (10 mmol) potassium chloride, 0.18% sodium chloride & 4%  glucose 500ml
Infusion:  0.15% (20 mmol) potassium chloride, 0.18% sodium chloride & 4%  glucose 1000ml
Infusion:  0.15% (10 mmol) potassium chloride, 0.9% sodium chloride & 5%  glucose 500ml
Infusion:  0.2% (13.5 mmol) potassium chloride & 0.9% sodium chloride 500ml
Infusion: 0.2% (27 mmol) potassium chloride & 0.9% sodium chloride 1000ml
Infusion:  0.2% (13.5 mmol) potassium chloride & 5% glucose 500ml
Infusion:  0.2% (27 mmol) potassium chloride & 5% glucose 1000ml
Infusion:  0.2% (13.5 mmol) potassium chloride, 0.18% sodium chloride & 4% glucose 500ml
Infusion: 0.2% (27 mmol) potassium chloride, 0.18% sodium chloride & 4% glucose 1000ml
Infusion:  0.3% (20 mmol) potassium chloride & 0.9% sodium chloride 500ml
Infusion: 0.3% (40 mmol) potassium chloride & 0.9% sodium chloride 1000ml
Infusion: 0.3% (20 mmol) potassium chloride & 5% glucose 500ml
Infusion:  0.3% (40 mmol) potassium chloride & 5% glucose 1000ml
Infusion: 0.3% (20 mmol) potassium chloride & 10% glucose 500ml
Infusion:  0.3% (20 mmol) potassium chloride & 20% glucose 500ml
Infusion:  0.3% (20 mmol) potassium chloride, 0.18% sodium chloride & 4% glucose 500ml
Infusion: 0.3% (40 mmol) potassium chloride, 0.18% sodium chloride & 4% glucose 1000ml
Infusion:  0.3% (20 mmol) potassium chloride, 0.45% sodium chloride & 5% glucose 500ml
Infusion:  0.3% (20 mmol) potassium chloride, 0.9% sodium chloride & 5% glucose 500ml
Infusion:  0.6% (40 mmol) potassium chloride & 0.9% sodium chloride 500ml
Infusion:  0.6% (40 mmol) potassium chloride & 5% glucose 500ml

15.02 Prilocaine Hydrochloride Citanest®

Injection (vials): 500 mg/50 mL (1%) 

15.02 Prilocaine Hydrochloride Prilotekal®

Injection (amps): 100 mg/5 mL (2%)

15.02 Prilocaine hyperbaric solution 

2% hyperbaric solution, 5ml amp: Prilocaine hydrochloride 20mg/ml and glucose 60mg/ml

04.08.01 Primidone  Suspension: 50 mg/5 mL, 250 mg/5 mL (available from Rosemont Pharmaceuticals)

CHM advise brand specific prescribing
04.08.01 Primidone 

Tablets: 50mg, 250 mg

CHM advise brand specific prescribing

10.01.04 Probenecid 

Tablets: 500mg


unlicensedunlicensed



Note: This drug has been discontinued (community supplies may not be possible)

08.01.05 Procarbazine 

Capsules: 50mg

04.06 Prochlorperazine  Tablets: 5 mg
Syrup: 5 mg/5 mL
Injection: 12.5 mg/1 mL
Buccal tablets: 3 mg – for the treatment of nausea associated with migraine when the oral route cannot be used due to vomiting
04.09.02 Procyclidine  Tablets: 5 mg
Syrup (sugar-free): 2.5 mg/5 mL, 5 mg/5 mL
04.09.02 Procyclidine  Injection: 10 mg/2 mL
23.01 Procyclidine 

Injection: 10 mg/2 mL ampoules


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

06.04.01.02 Progesterone  Pessaries: 200mg, 400mg
Injection: 50mg/1mL
04.01.01 Promethazine Hydrochloride  Tablets: 10mg, 25mg
Elixir: 5mg/5ml
Injection: 25mg/1ml
04.06 Promethazine Hydrochloride  Tablets: 10 mg, 25 mg
Liquid: 5 mg/5 mL
Injection: 25 mg/1 mL
07.04.02 Propiverine 

Tablets: 15mg

15.01.01 Propofol 

Injection (emulsion): 0.5% (100 mg/20 mL) vials (Lipuro®)
Injection (emulsion): 1% (200 mg/20 mL) and (1 g/100 mL) vials (Lipuro®)

02.04 Propranolol  Ampoule*: 1mg/1ml (unlicensed)
*Hospital use only
02.04 Propranolol  M/R Capsule: 80mg, 160mg
04.07.04.02 Propranolol  Tablets: 10mg*, 40 mg, 80 mg
Solution: 10mg/5ml**, 40 mg/5 mL

*10mg tablets may also be used for anxiety
**Hospital use for paediatrics only
06.02.02 Propylthiouracil  Tablets: 50mg
02.08.03 Protamine Sulphate  Injection: 50mg/5ml
23.01 Protamine sulphate  

Injection: 50 mg/5 mL ampoules


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

06.05.01 Protirelin TRH Injection: 200 micrograms/1 mL
11.07 Proxymetacaine Hydrochloride Minims®

Minims® eye drops (preservative free): 0.5%

01.06.07 Prucalopride  Tablets: 1mg, 2mg
05.01.09 Pyrazinamide 

Tablets: 500mg

Liquid: 500mg/5ml. This is the nationally recommended strength:

Standardising strengths of high risk, unlicensed oral liquids formulations for anti-TB medicines.

10.02.01 Pyridostigmine Bromide Mestinon® Tablets: 60 mg
Used as the standard initial symptomatic treatment for MG. Maximum beneficial dose is usually 360mg daily. Steroids and other immunosuppressant drugs are used to obtain remission those with more severe disease who do not respond sufficiently well to pyridostigmine.
23.01 Pyridoxine (high dose) 

Injection: 100 mg/2 mL ampoules
Injection: 300 mg/2 mL ampoules


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

09.06.02 Pyridoxine Hydrochloride 

Tablets: 10 mg, 20 mg, 50mg

09.06.02 Pyridoxine Hydrochloride 

unlicensed unlicensed Injection: 50 mg/2 mL
Paediatric use only

04.02.01 Quetiapine 

Tablets: 25mg, 100mg, 150mg, 200mg, 300mg
Prolonged release tablets: 50mg, 150mg, 200mg, 300mg, 400mg
– this formulation is only approved for use in patients who require an outside carer to administer their medicines, and for short term use when rapid dose titration is considered important e.g. where its use might avoid the need to admit the patient to hospital


 


(note: preferred brand of quetiapine XL in primary care is Biquelle XL)

06.07.01 Quinagolide  Tablets: 75micrograms, starter pack of 3 x 25microgram tablets and 3 x 50microgram tablets
10.02.02 Quinine 

Tablets: 300mg

The MHRA advises:

  • Quinine should not be used routinely for nocturnal leg cramps
  • Only consider use when cramps cause regular disruption of sleep.
  • Trial for 4 weeks and discontinue if no benefit.
  • Reassess after 3 months. 
08.01.05 Radium-223 dichloride 
05.03.01 Raltegravir Isentress ®

Tablets: 400mg

02.05.05.01 Ramipril  Capsules: 1.25mg, 2.5mg, 5mg, 10mg
11.08.02 Ranibizumab 

Intravitreal injection: 10mg in 1ml as a 0.23ml vial (dose 0.5mg/0.05ml)

01.03.01 Ranitidine  Tablets: 150mg, 300mg
Liquid: 75mg/5ml

DotLiquid may contain alcohol; up to 405mg per 5ml spoonful, which is equivalent to about 11ml of beer or 5ml of wine

Injection: 50mg/2ml
02.06.03 Ranolazine  MR Tablets: 375mg, 500mg
04.09.01 Rasagiline  Tablets: 1 mg
10.01.04 Rasburicase Fastertec® Solution for infusion: 1.5 mg/mL
Commissioned by NHS England
04.03.04 Reboxetine  Tablets: 4mg
- not licensed for use in the elderly
08.01.05 Regorafenib Stivarga®

Tablets: 40mg

15.01.04.03 Remifentanil 

Injection (vials): 1 mg, 2 mg, 5 mg

06.01.02.03 Repaglinide  Tablets: 500 micrograms, 1mg, 2mg
03.04.02 Reslizumab 

Vials: 25mg, 100mg

04.08.01 Retigabine  Tablets: 50 mg, 100 mg, 200mg, 300 mg, 400 mg
Starter pack available
05.03.05 Ribavirin  Capsules: 200mg
Tablets: 200mg
Oral solution: 200mg/5ml
08.03.04.01 Ribociclib 

Tablets: 200mg

05.01.09 Rifampicin  IV infusion: 600mg vials for IV infusion
05.01.09 Rifampicin  Capsules: 150mg, 300mg
Oral syrup: 100mg/5ml

N.B. these formulations are GREEN+ when used in the treatment of tuberculosis
05.01.09 Rifampicin and Isoniazid 

Tablets: Rifinah® 150 tablets - rifampicin 150mg & isoniazid 100mg, Rifinah® 300 tablets - rifampicin 300mg & isoniazid 150mg

05.01.09 Rifampicin and Isoniazid and Pyrazinamide Rifater® Tablets: Rifater® tablets- rifampicin 120mg, isoniazid 50mg & pyrazinamide 300mg
05.01.07 Rifaximin  Tablets: 550mg
07.03.01 Rigevidon® 

Tablets: Ethinylestradiol 30mcg / levonorgestrel 150mcg

05.03.01 Rilpivirine hydrochloride Edurant®

Tablets: 25mg

04.09.03 Riluzole  Tablets: 50 mg
06.06.02 Risedronate   Tablets: 5mg, 30mg, 35mg
04.02.01 Risperidone  Tablets: 500 microgram, 1mg, 2mg, 3mg, 4mg, 6mg
Oral liquid: 1mg/1ml
Orodispersible tablets: 500 microgram, 1mg, 2mg (Quicklets ®)
N.B. The dispersible tablets should only be used in situations where the plain tablets are unsuitable
04.02.02 Risperidone  Long acting injection: 25 mg, 37.5 mg, 50 mg
05.03.01 Ritonavir Norvir®

Tablets: 100mg

08.02.03 Rituximab 

Concentrate for IV infusion: 100mg in 10ml & 500mg in 50ml


-for musculoskeletal indications see chapter 10
-approved for first line use in NHL in combination with CHOP in line with NICE
-approved for maintenance therapy in follicular NHL that has responded to first line induction therapy with rituximab in combination with chemotherapy in line with NICE
-approved for stage III and IV follicular lymphoma in previously untreated people in line with NICE
-approved for replased or refractory follicular NHL in line with NICE
-approved for Post-transplant lymphoproliferative disease
- approved for first line use in CLL in combination with fludarabine and cyclophosphamide in line with  NICE
-approved for combination with fludarabine and cyclophosphamide for relapsed or refractory CLL in line with NICE
-approved for autoimmune haematological conditions (where conventional treatments have failed)
– Autoimmune haemolytic anaemia
(AIHA), Evans syndrome, pure red cell aplasia (PRCA), acquired haemophilia A & thrombocytopenia purpura (TTP).
- Combination with bendamustine for first line use in CLL (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate.
- a
pproved for vasculitis (including Wegener’s granulomatosis in adults and children) that has not responded adequately to conventional treatment (e.g. corticosteroids, cyclophosphamide) NICE and additional NHS England criteria
-NECDAG approved for the treatment of NLPHL
-NECDAG approved for newly diagnosed mantle cell NHL in patients aged <60 years old approved in combination with bendamustine for first line use in CLL (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate NICE
-NECDAG approved in combination with bendamustine for patients with CLL not fit for FCR chemotherapy or for patients who relapse within 2 years of FCR chemotherapy and not fit for alemtuzumab.
-NECDAG approved with salvage chemotherapy for patients relapsing > 12 months post 1st line -therapy with R-CHOP
-NECDAG approved with a standard NHL induction regimen in patients who cannot be given an anthracycline. Rituximab with other chemotherapy regimens is an alternative treatment option e.g. DECC, CVP for this group of patients, as part of their first line therapy. Also in addition to the MACOP-B regimen for the small number of young patients with DLBCL, subtype Primary Mediastinal B cell Lymphoma
-NECDAG approved for the treatment of hairy Cell Leukaemia (HCL) or Hairy cell Leukaemia varian (HCL-v) who:


        -relapse early after purine analogue therapy (< 2 years post treatment)
        -are refractory to purine analogues.
-NTAG approved for the treatment of immune (idiopathic) thrombocytopenic purpura (ITP) in adults and children NTAG
-approved for the treatment of immunobullous disease in line with NHS England Commissioning Policy



SC injection: 1.4g solution


-approved for use as maintenance single agent therapy in FL, mantle cell lymphoma, marginal zone lymphoma and lymphoplasmacytic lymphoma in line with NHS ENGLAND SSC1434

09.01.04 Rituximab 

(1st line for ITP -Intravenous with oral Prednisolone or Dexamethasone)
Injection: 100mg, 500mg

10.01.03 Rituximab 

Concentrate for solution for infusion: 100 mg/10 mL, 500 mg/50 mL

Note: 2nd line with MTX on failure after 6 months of 1st line; or monotherapy if MTX contraindicated due to pulmonary fibrosis)


NTAG approved in combination with methotrexate as first-line biological therapy in cases where there is an absolute contraindication to tumour necrosis factor inhibitors


NTAG approved for combination with other (non-methotrexate) disease modifying antirheumatic drugs and as monotherapy in cases in which conventional treatment with tumour necrosis factor inhibitors or methotrexate is deemed unsafe

02.08.02 Rivaroxaban  Tablets: 10mg, 15mg, 20mg
04.11 Rivastigmine  Capsules: 1.5 mg, 3 mg, 4.5 mg, 6 mg
Oral solution: 2 mg/1 mL
Patches: 4.6 mg/24 hours, 9.5 mg/24 hours, 13.3mg/24hours
15.01.05 Rocuronium Bromide Esmeron®

Injection (vials): 50 mg/5 mL

03.03.03 Roflumilast Daxas®

Tablets: 500 micrograms

09.01.04 Romiplostim Nplate®

(3rd line for severe, refractory ITP – choice according to patient preference)
Injection: 250 micrograms

04.09.01 Ropinirole 

Tablets: 250 micrograms, 500 micrograms, 1 mg, 2 mg, 5 mg
MR tablets: 2 mg, 4 mg, 8 mg


(preferred brand in primary care is Repinex XL)

15.02 Ropivacaine Hydrochloride Naropin®

Injection: 20 mg/10 mL, 75 mg/10 mL, 100 mg/10 mL ampoules (Naropin®)
Infusion: 400 mg/200 mL infusion bag (Naropin®)
unlicensedunlicensed Infusor: 0.2%, 230 mL

02.12 Rosuvastatin  Tablets: 5mg, 10mg, 20mg, 40mg
14.04 Rotavirus vaccine 

Rotavirus vaccine, live
Oral suspension: 1.5 mL (Rotarix®)

04.09.01 Rotigotine  Transdermal patches: 2 mg/24 hrs, 4 mg/24 hrs, 6 mg/24 hrs, 8 mg/24 hrs
14.04 Rubella vaccine 

Use combined vaccines

08.01.05 Ruxolitinib 

Tablets: 5mg, 15mg, 20mg

02.05.05 Sacubitril and valsartan Entresto® Tablets:
24mg/26mg (containing 24.3mg sacubitril and 25.7mg valsartan as sacubitril valsartan sodium salt complex)

49mg/51mg (containing 48.6mg sacubitril and 51.4mg valsartan as sacubitril valsartan sodium salt complex)

97mg/103mg (containing 97.2mg sacubitril and 102.8mg valsartan as sacubitril valsartan sodium salt complex)
04.09.01 Safinamide Xadago

Tablets: 50mg, 100mg.

Green Plus information leaflet: Click here.

03.01.01.01 Salbutamol  Metered dose inhaler (MDI): 100mcg/puff
Breath actuated MDI: 100mcg/puff
Breath actuated dry powder inhaler (DPI): 100mcg/puff, 200mcg/puff
Nebules: 2.5mg/2.5ml, 5mg/2.5ml
Injection: 500mcg/1ml, 5mg/5ml
12.03.05 Saliveze® 
12.03.05 Salivix® 
03.01.01.01 Salmeterol  Inhaler (MDI): 25mcg/puff
Breath actuated inhaler (Accuhaler): 50mcg/puff
05.03.01 Saquinavir Invirase®

Tablets: 500mg

10.01.03 Sarilumab 

Pre-filled pen: 150mg, 200mg
Syringe: 150mg, 200mg

06.01.02.03 Saxagliptin 

Tablets: 2.5mg, 5mg

10.01.03 Secukinumab Consentyx ® Injection: 150 mg/mL,
Pre-filled pen or pre-filled syringe: 150-mg
04.09.01 Selegiline Hydrochloride  Tablets: 5 mg
09.05.05 Selenium 

Tablets: 200 micrograms
Oral solution available

09.05.05 Selenium 

Injection: 100micrograms in 2ml

01.06.02 Senna  Tablets: 7.5mg
Syrup: 7.5mg/5ml
04.03.03 Sertraline  Tablets: 50 mg, 100 mg
Liquid: 50mg/5ml
09.05.02.02 Sevelamer Carbonate Renvela®

Powder for oral suspension: 2.4 g

09.05.02.02 Sevelamer Hydrochloride  Renagel®

Tablets: 800 mg

15.01.02 Sevoflurane 

250ml

02.05.01 Sildenafil  Liquid: 1mg/1ml*
*Hospital use for paediatric patients
02.05.01 Sildenafil  Tablets: 20mg, 25mg
Oral suspension: 10mg/1ml
07.04.05 Sildenafil 

Tablets: 25mg, 50mg, 100mg

05.03.03.02 Simeprevir  Capsules: 150mg
01.01.01 Simeticone  Liquid: 40mg/1ml*
*Hospital use only
03.09.02 Simple Linctus, BP 
03.09.02 Simple Linctus, Paediatric BP  *Hospital use only
02.12 Simvastatin  Tablets: 10mg, 20mg, 40mg
08.02.02 Sirolimus 

Tablets: 1mg & 2mg
Oral solution: 1mg per ml

06.01.02.03 Sitagliptin 

Tablets: 25mg, 50mg, 100mg

10.01.03 Sodium Aurothiomalate 

Injection: 10 mg/0.5 mL, 50 mg/0.5 mL

Note: this is as an alternative after biologics

09.02.01.03 Sodium Bicarbonate 

(to provide around 6-7 mmol)


Tablets: 600 mg
Capsules: 500 mg


Prescribers should prescribe the product with lowest acquisition cost

09.02.01.03 Sodium Bicarbonate 

unlicensed unlicensed Oral solution (For use in paediatrics): 1mmol/1ml (100ml)

09.02.02.01 Sodium Bicarbonate 

Infusion: 1.26% 500ml
Infusion: 4.2% 500ml
Infusion: 8.4% 500ml

12.01.03 Sodium Bicarbonate 

Ear drops: 5%

23.01 Sodium bicarbonate 

Injection: 1.26 % Polyfusor® infusion 500 mL
Injection: 8.4 % (840 mg/10 mL) ampoules, Polyfusor® infusion 200 mL


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

07.04.04 Sodium chloride 

100ml sachets: 0.9% solution

07.04.04 Sodium chloride 

0.9% solutions (up to 3 litres)

09.02.01.02 Sodium Chloride Slow Sodium®

SR tablets: 600mg (equivalent to approximately 10mmol sodium)

09.02.02.01 Sodium Chloride 

Sodium Chloride 0.9%(normal saline)
Injection: 5ml, 10ml & 20ml
IV infusion: 100ml, 250ml, 500ml & 1000ml
Irrigation: 1000ml & 3000ml



Sodium Chloride 0.18%
IV infusion: 500ml


Sodium Chloride 0.45%
IV infusion: 500ml


Sodium Chloride1.8%
IV infusion: 500ml


Sodium Chloride 2.7%
IV infusion: 500ml


Sodium Chloride 5%
IV infusion: 500ml


Sodium Chloride 30%
Injection: 10ml

11.99.99.99 Sodium chloride 

Unit dose eye drops: 0.9%
Eye drops: 5%
Eye ointment: 5%
P/F eye drops: 5%

12.02.02 Sodium chloride 

Nasal drops: 0.9%

03.07 Sodium chloride 0.9%  Nebuliser solution: 10ml
03.07 Sodium chloride 7% (Hypertonic) Nebusal® Nebuliser solution: 4ml
09.02.02.01 Sodium Chloride and Glucose Intravenous Infusion 

IV infusion: 0.9%/5% 500ml
IV infusion: 0.18%/4% 500ml & 1000ml
IV infusion: 0.18%/10% 500ml
Infusion: 0.45%/5% 500ml

09.02.01.02 Sodium Chloride Oral solution  

unlicensed unlicensed Oral solution (for use in paediatrics): 1mmol/1ml, 100ml

11.99.99.99 Sodium Citrate 

P/F eye drops: 10.11%

15.03 Sodium Citrate 

Oral solution: 0.3 molar, 30 mL

01.06.04 Sodium citrate micro-enema 
06.06.02 Sodium Clodronate  Capsules: 400mg*
*For breast pain/breast cancer/myeloma patients only
11.04.02 Sodium Cromoglicate 

Eye drops: 2%

11.04.02 Sodium Cromoglicate 

unlicensed unlicensed Eye drops (preservative free): 2%

09.01.01.01 Sodium Feredetate Sytron®

Sugar-free elixir: 190mg/5ml (27.5mg elemental iron/5ml)

05.01.07 Sodium fusidate  Tablets: 250mg
Oral suspension: 250mg/5ml (as fusidic acid)
07.04.03 Sodium hyaluronate Hyacyst 120

Prefilled syringe: 120mg/50ml

11.08.01 Sodium Hyaluronate 

Eye drops (preservative-free): 0.1% (Hylo-Tear®)
Eye drops (preservative-free): 0.2% (Hylo-Forte®)


Brands in primary care may vary

11.99.99.99 Sodium Hyaluronate  

Prefilled syringe (Microvisc): 14mg/ml
Prefilled siringe (Provisc): 10mg/ml
Healon GV: 14mg/ml

01.06.02 Sodium hydrogen carbonate / sodium dihydrogen phosphate Lecicarbon A® Suppository: Sodium hydrogen carbonate 0.500g, sodium dihydrogen phosphate 0.680g

Only for pre-operative use for patients undergoing rectal surgery or diagnostic procedure.
23.01 Sodium nitrite 

Injection: 3% (300 mg/10 mL) ampoules


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

02.05.01 Sodium Nitroprusside 

Injection for infusion: 50mg vial


Used in critical care at City Hospitals Sunderland

01.06.02 Sodium Picosulfate  Elixir: 5mg/5ml*
*For use in paedatrics only
09.02.01.01 Sodium polystyrene sulfonate Resonium A®

Powder: 454g

02.13 Sodium Tetradecyl Sulphate  Injection: 0.2%, 5ml ampoule
Injection: 0.5%, 2ml ampoule
Injection: 1%, 2ml ampoule
Injection: 3%, 2ml, 5ml ampoule
23.01 Sodium thiosulphate 

Injection: 50% (10 g/20 mL) ampoules


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

04.02.03 Sodium valproate  M/R Tablets: 200mg, 300mg & 500mg
- used for the prevention and treatment of manic episodes associated with bipolar disorder (unlicensed indication). May be useful in patients unresponsive to lithium. See section 4.8.1 for other sodium valproate formulations.
04.08.01 Sodium Valproate 

Tablets, crushable: 100 mg
Tablets (e/c): 200 mg, 500 mg
MR Tablets: 200 mg, 300 mg, 500 mg
MR Granules: 50 mg, 100 mg, 250 mg, 500 mg, 750 mg, 1g
Liquid (sugar-free available): 200 mg/5 mL

04.08.01 Sodium Valproate  Injection: 400mg
04.08.01 Sodium Valproate  Suppositories: 300 mg (unlicensed in the UK)
05.03.03.02 Sofosbuvir  Tablets: 400mg
05.03.03.02 Sofosbuvir/velpatasvir/voxilaprevir Vosevi

Tablets: 400mg/100mg/100mg

07.04.02 Solifenacin 

Tablets: 5mg, 10mg

06.05.01 Somatropin 
08.01.05 Sorafenib 

Tablets: 200mg

02.04 Sotalol  Tablets: 40mg, 80mg, 160mg
02.02.03 Spironolactone  Tablets: 25mg, 50mg, 100mg
02.02.03 Spironolactone  Suspension: 25mg/5ml*
*Specialist initiation/paediatric use only
06.04 Spironolactone  Tablets: 25mg & 100mg
07.05.05 Spironolactone 

Tablets: 50mg

05.03.01 Stavudine Zerit®

Capsules: 20mg, 30mg, 40mg
Oral solution: 1mg/ml

02.10.02 Streptokinase  Vials: 250,000 unit, 1.5 million-unit (MU)
05.01.09 Streptomycin  Injection: 1g
08.01.05 Streptozocin 

unlicensedunlicensed Injection: 1g (only available on a named patient basis)

06.06.02 Strontium Ranelate 

Granules (Protelos®): 2 g/sachet

Possible alternative treatment if patient cannot take alendronic acid and risedronate, in line with NICE


 


Although previously in the joint formulary and still recommended in some guidelines, strontium ranelate (Protelos) is being withdrawn from the market during 2017 and will become unavailable for use. For existing patients receiving strontium, prescribers are asked to discontinue the drug and:



  • Clarify whether ongoing treatment is indicated

  • Trial an oral bisphosphonate in patients where it has not been tried before and where it is not contra-indicated

  • Consider bone-clinic referral if ongoing high risk of future fractures (FRAX risk assessment) and intolerant to oral agents.


Further information can be found here: https://www.sps.nhs.uk/articles/discontinuation-of-protelos-strontium-ranelate-2g-granules-for-oral-suspension/

01.03.03 Sucralfate  Tablets: 1g
Suspension: 1g/5ml
15.01.06 Sugammadex Bridion®

Injection: 500 mg/5 mL ampoules

01.05.01 Sulfasalazine  Tablets: 500mg
10.01.03 Sulfasalazine  EC Tablets: 500 mg
Oral suspension (sugar-free): 250 mg/5 mL
10.01.04 Sulfinpyrazone 

Tablets: 100mg, 200mg


 


unlicensedunlicensed

17 Sulphur hexafluoride SonoVue®

Microbubbles 8 microlitres/mL

04.02.01 Sulpiride  Tablets: 200mg, 400mg
Oral solution (sugar-free): 200mg/5ml
04.07.04.01 Sumatriptan  Tablets: 50 mg, 100 mg
Nasal spray: 10 mg/0.1 mL actuation, 20 mg/0.1 mL actuation
Injection (pre-filled syringe): 6 mg/0.5 mL
08.01.05 Sunitinib 

Capsules: 50mg 100mg, 400mg

06.04 Sustanon 250®   Injection: 1ml injection (testosterone propionate 30mg, testosterone
phenylpropionate 60mg, testosterone isocaproate 60mg & testosterone
decanoate 100mg)
15.01.05 Suxamethonium Chloride 

Injection (amps): 100 mg/2 mL

11.08.01 Systane (Contains hydroxypropyl guar, polyethylene glycol 400, propylene glycol (and other ingredients) 

Eye drops: 10ml Multidose bottles
Eye drops: 0.8ml Preservative free vials

08.02.02 Tacrolimus 

500 microgram Capsules: 1mg & 5mg (Prograf & Adoport)
unlicensedunlicensed Oral suspension: 1mg in 1ml  
RED - Concentrate for preparing IV infusion: 5mg in 1 ml
- approved for renal transplantation in children and adolescents in line with NICE

 

MR Capsules (Advagraf): 500microgram, 1mg, 3mg & 5mg
- only approved for use for prophylaxis of organ rejection in kidney and liver transplantation. Advagraf® is approved for use in patients who are currently prescribed Prograf, and de novo patients should be prescribed Adoport®.

 

MR tablets (Envarsus): 750microgram, 1mg, 4mg
- approved for the treatment of renal and liver transplant patients who are suffering from neurotoxicity with other formulations or for patients requiring large doses of tacrolimus.

07.04.01.02 Tadalafil 

Tablets: 5mg
(Green plus for indications involving urinary retention or benign prostatic hyperplasia)

07.04.05 Tadalafil 

*Tablets: 10mg, 20mg 
(*For post radical prostatectomy)

08.01.05 Talimogene laherparepvec Imlygic®

Solution for injection: 106 plaque forming units/1ml & 108 plaque forming units/1ml


-approved for the treatment of unresectable metastatic melanoma in line with NICE and NHS England Commissioning Policy

07.05.01.01 Tamoxifen 

Tablets: 20mg

08.03.04.01 Tamoxifen 

Tablets: 10mg & 20mg
Sugar-free oral solution: 10mg in 5ml

07.04.01 Tamsulosin Hydrochloride 

M/R capsules: 400 micrograms

04.07.02 Tapentadol Palexia®

Palexia® MR Tablets: 50 mg, 100 mg, 150 mg, 200 mg, 250 mg
Use only after trial with other strong opiates

Specialist initiation only - consult pain team or palliative care before use.

08.01.03 Tegafur with Uracil Uftoral®

Capsules:  containing tegafur 100mg & uracil 224mg

05.01.07 Teicoplanin  Injection (for IV infusion): 200mg, 400mg
05.03.03.02 Telaprevir  Tablets: 375mg
04.01.01 Temazepam  Tablets: 10mg, 20mg
Oral solution: 10mg/5ml
05.01.01.02 Temocillin  Vials: 1g*
*Hospital use only
08.01.05 Temozolomide 

Capsules: 5mg, 20mg, 100mg, 250mg

02.10.02 Tenecteplase  Vials: 40mg, 50mg
05.03.01 Tenofovir and emtricitabine Truvada®

Tablets containing: 200mg of emtricitabine and 245mg of tenofovir disoproxil (equivalent to 300mg of tenofovir disoproxil fumarate or 136mg of tenofovir)

05.03.01 Tenofovir disoproxil Viread®

Tablets: 123mg, 163mg, 204mg, 245mg (as tenofovir disoproxil fumarate)

05.03.01 Tenofovir Disproxil  Tablets: 245mg
Granules (sugar-free): 33mg/1g (7.5g contains approximately 245mg tenofovir disoproxil)
05.03.01 Tenofovir, cobicistat, elvitegravir and emtricitabine Stribild®

Tablets: 150mg/150mg/200mg/245mg

05.03.01 Tenofovir, efavirenz and emtricitabine Atripla®

Tablets: 600mg/200mg/245mg

05.02 Terbinafine  Tablets: 250mg
03.01.01.01 Terbutaline  Breath actuated DPI (Turbohaler): 500mcg/puff
07.01.04 Terbutaline 

Ampoules: 500micrograms/ml

08.02.04 Teriflunomide 

Film coated tablets: 14mg

06.06.01 Teriparatide  Pre-filled pen: 250mcg/1mL
06.05.02 Terlipressin  Injection: 1mg vial, 1 mg/8.5mL
06.04 Testosterone   Gel: 50mg/5g (1%) sachets (Testogel®)
06.04.02 Testosterone - transdermal Tostran® Testosterone 2% gel (10 mg/5mL) metered application from pump
06.04.02 Testosterone - transdermal Testogel® Testosterone gel 1% (50mg/5g)
06.04.02 Testosterone esters - intramuscular Sustanon 250® Depot injection: 250 mg (testosterone propionate 30mg, testosterone phenylpropionate 60mg, testosterone isocaproate 60mg & testosterone decanoate 100mg)
06.04.02 Testosterone oral Restandol Testocaps® Capsules: 40 mg
06.04 Testosterone Undecanoate  

Injection: 1g in 4ml (250mg/ml) oily injection (Nebido®)


The medication is only green plus when used for treatment of gender dysphoria. For indications other than gender dysphoria please see 'Male sex hormones and antagonists - 06.04.02'

06.04.02 Testosterone undecanoate Intramuscular Nebido®

Injection: 1g/4 mL (250mg/mL)


 


Please note, if this medication is used for gender dysphoria please see 'Sex hormones - 06.04'. If used for gender dysphoria the status is green plus.

14.04 Tetanus vaccine 

Use combined vaccines

04.09.03 Tetrabenazine  Tablets: 25 mg
11.07 Tetracaine Hydrochloride 

Minims® eye drops (preservative free): 0.5%, 1%

06.05.01 Tetracosactide  Injection: 250 micrograms/1mL
Depot injection: 1mg/1mL
08.02.04 Thalidomide 

Capsules: 50mg


- approved in combination with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma in line with NICE
- approved for the treatment of bleeding from bowel angiodysplasia in patients with an inherited/acquired bleeding disorder on specialist advice only.
-approved for the treatment of severe epistaxis as a result of hereditary haemorrhagic telangiectasia (HHT) who have failed all other treatments.

03.01.03 Theophylline 

Theophylline SR
Nuelin SA® tablets: 175mg, 250mg
Slo-Phyllin® capsules: 60mg, 125mg, 250mg
Uniphyllin® tablets: 200mg, 300mg, 400mg

N.B. Modified release preparations must be prescribed by brand name

09.06.02 Thiamine 

Tablets: 50 mg, 100 mg

15.01.01 Thiopental (thiopentone) sodium 

Injection (vials): 500 mg 

08.01.01 Thiotepa 

Injection: 15mg

06.04.01.01 Tibolone  Tablets: 2.5mg
02.09 Ticagrelor 

Tablets: 60mg, 90mg
Ticagrelor in combination with low-dose aspirin is recommended for up to 12 months as a treatment option in adults with acute coronary syndromes. However, selected patients at high risk may be offered ticagrelor 60mg bd for up to a maximum of three years by the initiating specialist in secondary care. This will be communicated to practices in the patients discharge letter.

05.01.03 Tigecycline  Injection: 50mg
11.06 Timolol 

Eye drops: 0.25%, 0.5%
Unit dose eye drops (preservative-free): 0.25%, 0.5%
Eye drops gel forming solution (once daily): 0.25%, 0.5%
Eye drops (unit dose) (once daily, preservative-free): 0.1%
Preservative free eye drops (Eysano PF): 0.25%, 0.5%

05.01.11 Tinidazole  Tablets: 500mg*
*After consultation with microbiology only
03.01.02 Tiotropium 

HandiHaler® Dry powder inhaler device and refill: 18mcg
Refill: 18mcg
Respimat®: 2.5mcg

Braltus Zonda Dry powder inhaler : 10mcg (first choice option if tiotropium dry powder inhaler is required).

Tiotropium Respimat is a step 4 option for chronic asthma and may be useful for patients with COPD who can not use a dry powder inhaler.

 

03.01.04 Tiotropium & olodaterol® Spiolto Respimat

Inhalation solution via respimat device: 2.5 microgram/2.5 microgram

05.03.01 Tipranavir Aptivus®

Oral solution: 100mg/ml
Capsules: 250mg

02.09 Tirofiban  Infusion: 12.5mg/250ml
08.01.05 Tivozanib Fotivda®

1340mg hard capsules

Tivozanib for treating advanced renal cell carcinoma (TA512) 21.3.18

10.02.02 Tizanidine  Tablets: 2 mg, 4 mg
05.01.04 Tobramycin inhaler TOBI Podhaler® TOBI Podhaler: 28mg

Approved in line with NHS England specialised commissioning criteria for the treatment of chronic pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Only to be prescribed by secondary care from April 2016 in line with NHS England Clinical Commissioning Policy.
10.01.03 Tocilizumab 

Concentrate for intravenous infusion: 80 mg/4 mL, 200 mg/10 mL, 400 mg/20 mL
Subcutaneous injection: 162mg/0.9mL (for rheumatoid arthritis only)

Note: 3rd line with MTX on failure after 6 months of 2nd line; or monotherapy if MTX contraindicated due to pulmonary fibrosis

10.01.03 Tofacitinib 

Tablets: 5mg

06.01.02.01 Tolbutamide  Tablets: 500mg
04.09.01 Tolcapone  Tablets: 100mg
07.04.02 Tolterodine 

Tablets: 1mg, 2mg

06.05.02 Tolvaptan Jinarc® Tablets: 15mg, 30mg
Tablets (combination packs): 45mg/15mg, 60/30mg, 90/30mg
06.05.02 Tolvaptan Samsca® Tablets: 15mg, 30mg
04.08.01 Topiramate  Tablets: 25 mg, 50 mg, 100 mg, 200 mg
Capsules: 15 mg, 25 mg, 50 mg
08.01.05 Topotecan 

Capsules: 0.25mg, 1mg capsules
Vials: 1mg, 4mg

08.01.05 Trabectedin Yondelis®

Injection: 250microgram

04.07.02 Tramadol  Capsules: 50 mg
Soluble Tablets: 50 mg

04.07.02 Tramadol 

MR: 50mg, 100mg, 150mg, 200mg, 300mg, 400mg
MR formulation only to be used on advice of pain specialists

06.01.05 Tramadol  see section 4.7 for preparations
08.01.05 Trametinib Mekinist®

Film coated tablets: 500microgram, 2mg

02.11 Tranexamic Acid  Tablets: 500mg
Injection: 500mg/5ml

For mouthwash: dissolve tablets in water as per hospital instruction
12.03.04 Tranexamic Acid Mouthwash 

Tablets: 500mg
For mouthwash: dissolve tablets in water as per hospital instruction

08.01.05 Trastuzumab Herceptin®

Vial for preparing IV infusion: 150mg
Injection: 600mg s/c injection

08.01.05 Trastuzumab emtansine Kadcyla®
11.06 Travoprost 

Eye drops: 40 micrograms/1 mL

11.06 Travoprost with Timolol 

Eye drops: travoprost 40 micrograms/1 mL, timolol 5 mg/1 mL (DuoTrav®)

04.03.01 Trazodone  Capsules: 50 mg, 100 mg
Tablets: 150 mg
Liquid (sugar-free): 50 mg/5 mL
- Trazodone is widely used off-licence for night sedation and behavioural symptoms of dementia – see section 4.1
08.01.01 Treosulfan 

Infusion: 5g

08.01.05 Tretinoin 

Capsules: 10mg

10.01.02.02 Triamcinolone Acetonide Adcortyl® Intra-articular injection: 10 mg/1 mL, 50 mg/5 mL (Adcortyl®)
10.01.02.02 Triamcinolone Acetonide Kenalog® Intra-articular injection: 40 mg/1 mL, 80mg/2 mL (Kenalog®)
12.01.01 Triamcinolone with neomycin, gramicidin and nystatin Kenacomb Otic®

unlicensedunlicensed Ointment: 1 mg triamcinolone acetonide, 2.5 mg neomycin sulphate, 0.25mg gramicidin, 100,000 units nystatin per 5 g

04.02.01 Trifluoperazine  Tablets: 1mg, 5mg
Syrup: 1mg/5ml
Oral sugar-free solution: 5mg/5ml
11.03.03 Trifluorothymidine 

unlicensed unlicensed Preservative free eye drops: 1%

08.01.05 Trifluridine and tipiracil  

Tablets: 15mg/6.14mg, 20mg/8.19mg -approved for previously treated metastatic colorectal cancer in adults in line with NICE and NHS England Commissioning Policy

05.01.08 Trimethoprim  Tablets: 100mg, 200mg
Oral suspension: 50mg/5ml
08.03.04.02 Triptorelin Gonapeptyl Depot®


Green+ Traffic Light OR Amber Traffic Light


Dependent on patient disease state


IM injection: 3mg, 11.25mg and 22.5mg

06.07.02 Triptorelin (as acetate) 

Injection (pre-filled syringe): 3.75mg (Gonapeptyl Depot®)
Injection (vial): 3mg, 11.25mg, 22.5mg (Decapeptyl SR®)



Green+ Traffic Light  N.B. Green+ for precocious puberty indication

07.03.01.03 Tri-regol® 

Tablets

11.05 Tropicamide 

Eye drops: 0.5%, 1%
Minims® (preservative free): 0.5%, 1%

07.04.02 Trospium 

Tablets: 20mg

07.03.01.07 T-Safe® Cu 380 A 

Intrauterine device - replacement every 10 years

07.03.01.07 TT 380 Slimline® 

Intrauterine device - replacement every 10 years

14.04 Typhoid vaccine 

Typhoid Polysaccharide vaccine
Prefilled syringe: 0.5 mL (TYPHIM Vi®)
Prefilled syringe: 0.5 mL (Typherix®)
Gastro-resistant capsules: three capsules (Vivotif®)

07.03.05 Ulipristal EllaOne®

Tablet: 30mg


Recommended by NETAG as the preferred drug treatemnt option for post-coital contraception for patients who present between 72 hours and 120 hours following unprotected intercourse.

17 Urografin 150® 

Ampoules: 10ml


For infusion: 250ml

02.10.02 Urokinase  Vials: 10,000 units, 25,000 units, 50,000 units, 100,000 units, 250,000 units, 500,000 units
01.09.01 Ursodeoxycholic acid 

Tablets: 150mg, 250mg, 300mg, 500mg
Capsules: 250mg
Suspension: 250mg/5ml (Ursofalk®) - for use in bariatric patients

01.05.03 Ustekinumab Stelara

Concentrate for solution for infusion: 130mg

10.01.03 Ustenkinumab  Solution for injection: 45mg
05.03.02.01 Valaciclovir Valtrex® Tablets: 500mg
05.03.02.02 Valganciclovir  Tablets: 450mg
04.02.03 Valproic Acid (as semisodium valproate)  Tablets: 250 mg, 500 mg
- licensed alternative to sodium valproate m/r tablets
02.05.05.02 Valsartan  Capsules: 40mg, 80mg, 160mg
09.06.07 Valupak multivitamins and minerals 

Tablets

05.01.07 Vancomycin  Capsules: 125mg
05.01.07 Vancomycin  Injection (for IV infusion): 500mg, 1g
11.03.01 Vancomycin  

unlicensed unlicensed Eye drops: 1.4%

04.10.02 Varenicline  Tablets: 500 micrograms, 1 mg
Starter pack available
14.04 Varicella-Zoster vaccine (VZ) 

Varicella-zoster virus Oka strain (live, attenuated)
Vial with solvent in a pre-filled syringe 0.5 mL strain) (Varilrix®)
May contain traces of neomycin


Varicella virus Oka/Merck strain (live, attenuated)
Vial with solvent in a pre-filled syringe 0.5 mL (VARIVAX®)
May contain traces of gelatin and neomycin


For adult shingles vaccination programme


Varicella-zoster virus Oka/Merck strain (live, attenuated)
Vial with solvent in a pre-filled syringe 0.65 mL (Zostavax®)
May contain traces of gelatin and neomycin

06.05.02 Vasopressin (Argipressin)  Injection: 20 units/1mL
15.01.05 Vecuronium Bromide Norcuron®

Injection (vials): 10 mg

01.05.03 Vedolizumab 
08.01.05 Vemurafenib 

Tablets: 240mg

08.01.05 Venetoclax 

Tablets: 10mg, 50mg & 100mg
-approved for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutations, and who are unsuitable for or have failed a B-cell receptor pathway inhibitor; and for the treatment of adult patients with CLL in the absence of 17p deletion ot TP53 mutation, and who are unsuitable for or have failed both chemo-immunotherapy and a B-cell receptor pathway inhibitor in line Early Access to Medicines Scientific Opinion

04.03.04 Venlafaxine 

Tablets: 37.5 mg, 75 mg
Solution: 75mg/5ml*
MR tablets: 75 mg, 150 mg
- Patients who are deemed stable on doses of up to 225mg daily of MR Venlafaxine should be switched to the equivalent dose of immediate-release venlafaxine
- MR preparations are only to be used in patients currently prescribed doses of 300mg and over and for whom there is no suitable alternative, those who have experienced discontinuation reactions (at any dose), and for patients who need to take the once daily formulation in order to facilitate care visits.
(preferred brand of Venlafaxine XL in primary care is Vencarm XL)
*Hospital use only

02.06.02 Verapamil  Tablets: 40mg, 80mg, 120mg
SR Tablets: 120mg, 240mg
Oral solution: 40mg/5ml
MR Capsules: 180mg
02.06.02 Verapamil  Injection: 5mg/2ml (2.5mg/1ml)
11.08.02 Verteporfin 

Injection: 15 mg

04.08.01 Vigabatrin  Tablets: 500 mg
Powder: (sugar-free): 500 mg/sachet

08.01.04 Vinblastine 

Injection: 10mg

08.01.04 Vincristine 

Injection: 2mg in 2ml
Prefilled syringe: 2mg in 20ml
Infusion bags: 2mg in 50ml

08.01.04 Vindesine Sulphate 

Injection: 5mg

08.01.04 Vinorelbine 

Capsules: 20mg, 30mg
Injections: 10mg in 1ml & 50mg in 5ml

23.01 Viper venom antiserum 

Injection: 1g vials


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

09.06.01 Vitamins A and D 

Capsules: containing vitamin A 4,000 units, vitamin D 400 units (10 micrograms)

09.06.02 Vitamins B+C (Pabrinex® High Potency IV and IM) 

IM High Potency Injection: 7 mL
IV High Potency Injection: 10 mL

11.08.01 VitaPOS Ointment 

Eye ointment (containing retinol palmitate (vitamin A) 250iu/g, white soft paraffin, light liquid paraffin, liquid paraffin and wool fat)

05.02 Voriconazole  Tablets: 50mg, 200mg
Injection (for IV infusion): 200mg

To be used for:
-Prophylaxis of fungal infection in haematological malignancy
-Treatment of invasive aspergillosis
-Treatment of candida infections resistant to narrower-spectrum azoles
-Treatment of scedosporium and fusarium infections
11.03.02 Voriconazole 

unlicensed unlicensed Eye drops: 1%

04.03.03 Vortioxetine  Tablets: 5mg, 10mg, 20mg

- approved for the treatment of major depressive episodes in adults whose condition has responded inadequately to 2 antidepressants within the current episode in line with NICE
02.08.02 Warfarin  Tablets: 500mcg, 1mg, 3mg, 5mg
07.04.04 Water 

Volumes (up to 3 litres)

09.02.02.01 Water for Injection 

Injection: 2ml, 5ml, 10ml, 20ml, 100ml & 500ml
Irrigation: 1000ml
Oral: 100ml

12.03.05 Xerotin 

Spray (sugar-free):100 mL

12.02.02 Xylometazoline 

Nasal drops: 0.05%, 0.1%
Nasal spray: 0.1%

01.07.02 Xyloproct® ointment  Ointment containing lidocaine 5%, hydrocortisone acetate 0.275%, aluminium acetate 3.5% and zinc oxide 18%.

Recommended for short-term use only
07.03.01 Yasmin® 

Tablets: ethinylestradiol 30 microgram/drospirenone 3mg

14.04 Yellow fever vaccine 

Only available from a designated Yellow Fever Vaccination Centre (YFVC) A listing of approved YFVCs in England, Wales, and Northern Ireland (EWNI) can be found at: https://nathnacyfzone.org.uk/search-centres

05.03.04 Zanamivir inhalation  Dry powder for inhalation: 5mg/blister (via Diskhaler®)
05.03.01 Zidovudine Retrovir®

Capsules: 100mg, 250mg
Oral solution: 50mg/5ml
Solution for infusion: 200mg/20ml

05.03.01 Zidovudine and lamivudine Combivir®

Tablets: 150mg/300mg

09.05.04 Zinc acetate 

Capsules: 25mg

09.05.04 Zinc Sulphate 

Effervescent tablets: 125 mg (Solvazinc)

06.06.02 Zoledronic Acid Aclasta® Infusion: 50mcg/1mL (Aclasta®)

For the treatment of postmenopausal osteoporosis, osteoporosis in men and Paget’s disease

N.B. prescribe by brand name (Aclasta®) to avoid confusion with a different strength product used to treat hypercalcaemia of malignancy and the prevention of skeletal events in patients with metastatic breast cancer.
06.06.02 Zoledronic Acid Zometa Concentrate for intravenous infusion, vial: 4mg

Indication:prevention of treatment associated osteoporosis and to reduce the risk of recurrence in post-menopausal patients with early breast cancer (note: unlicensed for this indication)
08.03.04.01 Zoledronic acid (Zometa) 

Concentrate for intravenous infusion (vial): 4mg


Indication: prevention of treatment associated osteoporosis and to reduce the risk of recurrence in post-menopausal patients with early breast cancer (note: unlicensed for this indication)

04.08.01 Zonisamide  Capsules: 25 mg, 50 mg, 100 mg
04.01.01 Zopiclone  Tablets: 3.75mg, 7.5mg
04.02.02 Zuclopenthixol acetate  Injection: 50 mg/1 mL
- For short-term use by NTW specialists only
04.02.02 Zuclopenthixol Decanoate  Injection: 200mg/1ml, 500mg/1ml
Sunderland Joint Formulary